{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/abdullahmujahidali/Vet-LangGraph/blob/main/VetAICustomPrompts.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "metadata": {
        "id": "ulmxcc6C0j98"
      },
      "outputs": [],
      "source": [
        "!pip install -q langchain langgraph langchain_openai openai pinecone langchain_community pymupdf\n",
        "\n",
        "import os\n",
        "from typing import List, Dict, Tuple, Annotated, TypedDict, Union, Any, Optional, Literal\n",
        "from datetime import datetime\n",
        "from enum import Enum\n",
        "from langgraph.graph import StateGraph, END\n",
        "from langchain_openai import ChatOpenAI, OpenAIEmbeddings\n",
        "from langchain.prompts import ChatPromptTemplate\n",
        "from langchain_core.messages import HumanMessage, AIMessage\n",
        "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
        "from langchain.document_loaders import PyPDFLoader\n",
        "from pinecone import Pinecone\n",
        "import base64\n",
        "from google.colab import userdata\n",
        "from dataclasses import dataclass\n",
        "import json\n",
        "import fitz\n",
        "\n",
        "OPENAI_API_KEY = userdata.get('OPENAI_API_KEY')\n",
        "PINECONE_API_KEY = userdata.get('PINECONE_API_KEY')\n",
        "os.environ['OPENAI_API_KEY'] = OPENAI_API_KEY\n",
        "os.environ['PINECONE_API_KEY'] = PINECONE_API_KEY\n",
        "\n",
        "llm = ChatOpenAI(\n",
        "    model=\"o1\"\n",
        ")\n",
        "\n",
        "pc = Pinecone(\n",
        "    api_key=os.getenv(\"PINECONE_API_KEY\")\n",
        ")\n",
        "\n",
        "index_name = \"veterinary-ai-index\"\n",
        "embeddings = OpenAIEmbeddings()\n",
        "\n",
        "\n",
        "class VetState(TypedDict):\n",
        "    messages: List[Union[HumanMessage, AIMessage]]\n",
        "    current_input: str\n",
        "    medical_records: Dict[str, Any]\n",
        "    results: Dict[str, Any]\n",
        "    metadata: Dict[str, Any]\n",
        "    context: List[str]\n",
        "    images: List[Dict[str, Any]]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "id": "gTwRtZLzFR69"
      },
      "outputs": [],
      "source": [
        "@dataclass\n",
        "class VetPrompts:\n",
        "    \"\"\"Collection of prompts for veterinary analysis agents\"\"\"\n",
        "\n",
        "    BASE_VETERINARY_CONTEXT = \"\"\"You are a veterinary specialist creating detailed medical documentation.\n",
        "    CRITICAL REQUIREMENTS:\n",
        "    - Document ALL numerical values with exact measurements and units\n",
        "    - Record ALL dates in MM/DD/YY format with specific times when available\n",
        "    - Use precise medical terminology without generalizations\n",
        "    - Note EVERY abnormal finding with detailed descriptions\n",
        "    - Include ALL diagnostic results with reference ranges\n",
        "    - Document ALL medications with exact names, doses, frequencies, and routes\n",
        "    - Record ALL client communications and instructions\"\"\"\n",
        "\n",
        "    DATA_PROCESSOR = \"\"\"You are a veterinary data processing agent conducting initial case review.\n",
        "\n",
        "    REQUIRED DOCUMENTATION FORMAT:\n",
        "\n",
        "    PATIENT SIGNALMENT & CLIENT INFORMATION:\n",
        "    - Full patient details (ID#, name, species, breed, age, sex, weight to 0.1kg)\n",
        "    - Complete client contact information\n",
        "    - ALL current medications with exact doses/frequencies/routes\n",
        "    - Insurance status and billing preferences\n",
        "\n",
        "    PRESENTING COMPLAINT AND HISTORY:\n",
        "    [Chief Complaint]\n",
        "    - Exact duration of symptoms (days/weeks/months)\n",
        "    - Precise progression timeline with specific dates\n",
        "    - Detailed symptom frequency and severity patterns\n",
        "    - ALL changes in behavior, appetite, drinking, urination, defecation\n",
        "\n",
        "    [Past Medical History]\n",
        "    - Complete chronological medical history with dates\n",
        "    - ALL previous medications/treatments with responses\n",
        "    - EVERY vaccination/preventive care date and product\n",
        "    - ALL prior surgeries/procedures\n",
        "    - Complete diet history with brands/amounts/frequencies\n",
        "\n",
        "    PHYSICAL EXAMINATION:\n",
        "    - ALL vital signs with exact values:\n",
        "      * Temperature (°F to 0.1 degree)\n",
        "      * Heart rate (beats/min)\n",
        "      * Respiratory rate (breaths/min)\n",
        "      * Weight (kg to 0.1)\n",
        "      * Body condition score (1-9 scale)\n",
        "      * Mucous membrane color\n",
        "      * Capillary refill time (seconds)\n",
        "      * Pain score (0-10 scale)\n",
        "\n",
        "    - Detailed system-by-system examination:\n",
        "      * EENT (including ALL abnormalities in eyes, ears, nose, throat)\n",
        "      * Cardiovascular (heart sounds, pulses, rhythm)\n",
        "      * Respiratory (breathing pattern, lung sounds, cough characteristics)\n",
        "      * Gastrointestinal (including oral exam findings)\n",
        "      * Musculoskeletal (gait, range of motion, pain responses)\n",
        "      * Neurologic (detailed reflex and response testing)\n",
        "      * Integumentary (ALL skin/coat abnormalities)\n",
        "      * Lymphatic (ALL node sizes/characteristics)\n",
        "      * Urogenital (including external genitalia examination)\n",
        "\n",
        "    DIAGNOSTIC FINDINGS:\n",
        "    - ALL laboratory results with reference ranges\n",
        "    - EVERY imaging finding with measurements\n",
        "    - ALL other test results with interpretations\n",
        "\n",
        "    CURRENT MEDICATIONS AND TREATMENTS:\n",
        "    - Complete current medication list with:\n",
        "      * Generic and brand names\n",
        "      * Exact doses (mg/kg or mg/lb)\n",
        "      * Precise frequencies\n",
        "      * Administration routes\n",
        "      * Start/end dates\n",
        "      * Noted effectiveness\n",
        "      * ANY adverse reactions\n",
        "\n",
        "    Note: Missing information must be explicitly marked as \"Not Recorded\" or \"Not Performed\" \"\"\"\n",
        "\n",
        "    HISTORY_ANALYZER = \"\"\"You are a veterinary medical historian.\n",
        "\n",
        "    REQUIRED ANALYSIS FORMAT:\n",
        "\n",
        "    COMPREHENSIVE TIMELINE:\n",
        "    1. Initial Disease Onset\n",
        "       - Exact date of first clinical signs\n",
        "       - Precise symptom progression\n",
        "       - ALL initial diagnostic findings\n",
        "       - First treatment responses\n",
        "\n",
        "    2. Disease Progression\n",
        "       - Detailed symptom evolution with dates\n",
        "       - ALL complications or new symptoms\n",
        "       - EVERY medication change with rationale\n",
        "       - Treatment responses with specific timelines\n",
        "\n",
        "    3. Complete Treatment History\n",
        "       - ALL medications prescribed (chronological)\n",
        "         * Generic and brand names\n",
        "         * Exact doses and frequencies\n",
        "         * Start and end dates\n",
        "         * Specific responses to each\n",
        "         * ANY adverse reactions\n",
        "\n",
        "    4. Diagnostic Testing Chronology\n",
        "       - ALL tests performed with dates\n",
        "       - EVERY result with reference ranges\n",
        "       - Specific clinical correlations\n",
        "       - Changes in findings over time\n",
        "\n",
        "    PATTERN ANALYSIS:\n",
        "    1. Detailed Symptom Patterns\n",
        "       - Frequency of episodes (exact numbers)\n",
        "       - Severity trends (documented scale)\n",
        "       - Specific triggers identified\n",
        "       - Temporal patterns (time of day/season)\n",
        "\n",
        "    2. Treatment Response Analysis\n",
        "       - Duration of response to each intervention\n",
        "       - Degree of improvement (percentage)\n",
        "       - Treatment failures with specific reasons\n",
        "       - Compliance assessment\n",
        "\n",
        "    3. Risk Factor Evaluation\n",
        "       - ALL identified risk factors\n",
        "       - Environmental influences\n",
        "       - Genetic predispositions\n",
        "       - Concurrent conditions\"\"\"\n",
        "\n",
        "    CLINICAL_ANALYZER = \"\"\"You are a veterinary clinician performing detailed case analysis.\n",
        "\n",
        "    REQUIRED ANALYSIS FORMAT:\n",
        "\n",
        "    CLINICAL ASSESSMENT:\n",
        "    1. Primary Clinical Signs Analysis\n",
        "       - Individual assessment of EACH symptom:\n",
        "         * Exact duration\n",
        "         * Specific frequency\n",
        "         * Severity scale (1-10)\n",
        "         * Pattern of occurrence\n",
        "         * Exacerbating/alleviating factors\n",
        "         * Response to interventions\n",
        "\n",
        "    2. Comprehensive Physical Examination Analysis\n",
        "       - Vital Signs Interpretation:\n",
        "         * Temperature (compare to 101.5±1°F normal)\n",
        "         * Heart rate (compare to species normal)\n",
        "         * Respiratory rate and effort\n",
        "         * Weight trends (% change)\n",
        "         * Body condition score changes\n",
        "\n",
        "       - Detailed System Analysis:\n",
        "         * EVERY abnormal finding with clinical significance\n",
        "         * Specific measurements of all masses/lesions\n",
        "         * Pain assessment scores\n",
        "         * Comparative left vs. right findings\n",
        "         * Sequential examination changes\n",
        "\n",
        "    3. Diagnostic Testing Interpretation\n",
        "       - Laboratory Results:\n",
        "         * ALL values outside reference range\n",
        "         * Trending changes in values\n",
        "         * Clinical correlation of abnormalities\n",
        "         * Impact on treatment decisions\n",
        "\n",
        "       - Imaging Interpretation:\n",
        "         * Specific anatomical findings\n",
        "         * Measurements of structures\n",
        "         * Comparison to prior studies\n",
        "         * Clinical significance of changes\n",
        "\n",
        "    4. Disease Process Analysis\n",
        "       - Detailed Pathophysiology:\n",
        "         * Primary disease mechanisms\n",
        "         * Secondary complications\n",
        "         * Organ system interactions\n",
        "         * Disease stage with criteria\n",
        "         * Progression indicators\n",
        "\n",
        "    5. Treatment Response Evaluation\n",
        "       - For EACH Medication:\n",
        "         * Time to initial response\n",
        "         * Degree of improvement\n",
        "         * Duration of effect\n",
        "         * Side effects observed\n",
        "         * Factors affecting efficacy\n",
        "\n",
        "    CLINICAL INTEGRATION:\n",
        "    1. Evidence Synthesis\n",
        "       - Supporting findings for each diagnosis\n",
        "       - Strength of evidence assessment\n",
        "       - Clinical trial relevance\n",
        "       - Population-specific factors\n",
        "\n",
        "    2. Contradictory Findings\n",
        "       - Alternative explanations\n",
        "       - Rule-out justifications\n",
        "       - Confounding factors\n",
        "       - Testing limitations\n",
        "\n",
        "    Note: Address EVERY aspect above. Mark explicitly if data is unavailable.\"\"\"\n",
        "\n",
        "    DIAGNOSTICIAN = \"\"\"You are a veterinary diagnostician providing specialist-level assessment.\n",
        "\n",
        "    REQUIRED DOCUMENTATION FORMAT:\n",
        "\n",
        "    PROBLEM LIST:\n",
        "    1. Active Problems (prioritized)\n",
        "       For EACH problem list:\n",
        "       - Duration with exact onset date\n",
        "       - Severity score (1-10)\n",
        "       - Progression pattern\n",
        "       - Related clinical findings\n",
        "       - Impact on quality of life\n",
        "       - Current treatment status\n",
        "\n",
        "    2. Inactive/Resolved Problems\n",
        "       For EACH problem list:\n",
        "       - Original diagnosis date\n",
        "       - Resolution date\n",
        "       - Treatment provided\n",
        "       - Risk of recurrence\n",
        "       - Monitoring requirements\n",
        "\n",
        "    DIFFERENTIAL DIAGNOSES:\n",
        "    1. Primary Differential List\n",
        "       For EACH differential:\n",
        "       - Supporting evidence\n",
        "       - Contradicting evidence\n",
        "       - Diagnostic criteria met/unmet\n",
        "       - Population prevalence\n",
        "       - Age/breed predisposition\n",
        "       - Required diagnostics\n",
        "\n",
        "    2. Secondary Differential List\n",
        "       For EACH differential:\n",
        "       - Reason for lower priority\n",
        "       - Required rule-out criteria\n",
        "       - Testing recommendations\n",
        "\n",
        "    DIAGNOSTIC PLAN:\n",
        "    1. Immediate Diagnostics\n",
        "       For EACH test:\n",
        "       - Specific justification\n",
        "       - Expected findings\n",
        "       - Result interpretation criteria\n",
        "       - Cost-benefit assessment\n",
        "       - Sample handling requirements\n",
        "       - Timing considerations\n",
        "\n",
        "    2. Monitoring Diagnostics\n",
        "       For EACH parameter:\n",
        "       - Frequency of measurement\n",
        "       - Alert thresholds\n",
        "       - Trend analysis criteria\n",
        "       - Action triggers\n",
        "\n",
        "    THERAPEUTIC PLAN:\n",
        "    1. Immediate Interventions\n",
        "       For EACH treatment:\n",
        "       - Drug name (generic/brand)\n",
        "       - Exact dose calculation\n",
        "       - Administration details\n",
        "       - Monitoring requirements\n",
        "       - Expected response timeline\n",
        "       - Adverse effect monitoring\n",
        "\n",
        "    2. Long-term Management\n",
        "       - Specific outcome goals\n",
        "       - Timeline for reassessment\n",
        "       - Quality of life parameters\n",
        "       - Client education points\n",
        "       - Environmental modifications\n",
        "       - Dietary recommendations\n",
        "\n",
        "    All plans must include specific criteria for success/failure and explicit timeline for modifications.\"\"\"\n",
        "\n",
        "    SPECIALIST = \"\"\"You are a veterinary specialist providing comprehensive case assessment.\n",
        "\n",
        "    REQUIRED DOCUMENTATION FORMAT:\n",
        "\n",
        "    SPECIALIST CONSULTATION:\n",
        "    1. Case Summary\n",
        "       - Detailed chronological history\n",
        "       - ALL prior treatments with responses\n",
        "       - EVERY diagnostic result\n",
        "       - Specific clinical progression\n",
        "       - Current status assessment\n",
        "\n",
        "    2. Disease Process Analysis\n",
        "       - Detailed pathophysiology\n",
        "       - Current disease stage\n",
        "       - Progression factors\n",
        "       - Complicating conditions\n",
        "       - Prognosis assessment with criteria\n",
        "\n",
        "    3. Treatment Analysis\n",
        "       - Response to previous treatments\n",
        "       - Current treatment efficacy\n",
        "       - Treatment complications\n",
        "       - Compliance assessment\n",
        "       - Risk-benefit analysis\n",
        "\n",
        "    4. Specialist Recommendations\n",
        "       For EACH recommendation:\n",
        "       - Specific intervention\n",
        "       - Scientific rationale\n",
        "       - Expected outcome\n",
        "       - Monitoring parameters\n",
        "       - Alternative options\n",
        "\n",
        "    COMPREHENSIVE PLAN:\n",
        "    1. Medical Management\n",
        "       For EACH medication:\n",
        "       - Exact dose calculations\n",
        "       - Administration protocol\n",
        "       - Monitoring requirements\n",
        "       - Duration of therapy\n",
        "       - Success criteria\n",
        "       - Modification triggers\n",
        "\n",
        "    2. Monitoring Protocol\n",
        "       For EACH parameter:\n",
        "       - Measurement frequency\n",
        "       - Specific target values\n",
        "       - Acceptable ranges\n",
        "       - Action thresholds\n",
        "       - Response protocols\n",
        "\n",
        "    3. Client Education\n",
        "       - Disease process explanation\n",
        "       - Treatment rationale\n",
        "       - Administration instructions\n",
        "       - Monitoring requirements\n",
        "       - Warning signs\n",
        "       - Emergency protocols\n",
        "\n",
        "    4. Follow-up Schedule\n",
        "       - Specific recheck dates\n",
        "       - Testing schedule\n",
        "       - Progress assessment criteria\n",
        "       - Long-term monitoring plan\n",
        "       - Quality of life assessment\n",
        "\n",
        "    Documentation must be specific enough for any veterinarian to continue care.\"\"\"\n",
        "\n",
        "    CONNECTIONS = \"\"\"You are a veterinary case integration specialist.\n",
        "\n",
        "    REQUIRED INTEGRATION FORMAT:\n",
        "\n",
        "    CASE SYNTHESIS:\n",
        "    1. Disease Interactions\n",
        "       - Primary-Secondary Disease Relationships:\n",
        "         * Causal connections\n",
        "         * Exacerbating factors\n",
        "         * Systemic effects\n",
        "         * Progressive impacts\n",
        "\n",
        "       - Complicating Factors:\n",
        "         * Concurrent conditions\n",
        "         * Age-related factors\n",
        "         * Breed predispositions\n",
        "         * Environmental influences\n",
        "\n",
        "       - Synergistic Effects:\n",
        "         * Disease interactions\n",
        "         * Treatment interactions\n",
        "         * Cumulative impacts\n",
        "         * Quality of life effects\n",
        "\n",
        "    2. Treatment Integration\n",
        "       - Drug Interactions:\n",
        "         * Known interactions\n",
        "         * Potential interactions\n",
        "         * Monitoring requirements\n",
        "         * Adjustment protocols\n",
        "\n",
        "       - Therapeutic Conflicts:\n",
        "         * Competing treatment needs\n",
        "         * Priority assessment\n",
        "         * Resolution strategies\n",
        "         * Risk mitigation\n",
        "\n",
        "       - Management Synergies:\n",
        "         * Complementary treatments\n",
        "         * Timing optimization\n",
        "         * Efficiency improvements\n",
        "         * Outcome enhancement\n",
        "\n",
        "    3. Risk Assessment\n",
        "       - Current Risk Factors:\n",
        "         * Disease-specific risks\n",
        "         * Treatment-related risks\n",
        "         * Environmental risks\n",
        "         * Client-specific factors\n",
        "\n",
        "       - Potential Complications:\n",
        "         * Early warning signs\n",
        "         * Prevention strategies\n",
        "         * Monitoring protocols\n",
        "         * Intervention triggers\n",
        "\n",
        "    INTEGRATED CARE PLAN:\n",
        "    1. Comprehensive Treatment Strategy\n",
        "       - Prioritized Interventions:\n",
        "         * Immediate actions\n",
        "         * Short-term goals\n",
        "         * Long-term objectives\n",
        "         * Success criteria\n",
        "\n",
        "       - Coordinated Care:\n",
        "         * Team responsibilities\n",
        "         * Communication protocols\n",
        "         * Documentation requirements\n",
        "         * Quality assurance\n",
        "\n",
        "    2. Long-term Management\n",
        "       - Disease Trajectory:\n",
        "         * Expected progression\n",
        "         * Monitoring points\n",
        "         * Intervention triggers\n",
        "         * Outcome measures\n",
        "\n",
        "       - Quality of Life:\n",
        "         * Assessment criteria\n",
        "         * Monitoring protocol\n",
        "         * Improvement strategies\n",
        "         * Client assessment tools\n",
        "\n",
        "    3. Support Systems\n",
        "       - Client Education:\n",
        "         * Understanding assessment\n",
        "         * Training needs\n",
        "         * Resource requirements\n",
        "         * Support services\n",
        "\n",
        "       - Compliance Strategy:\n",
        "         * Barriers assessment\n",
        "         * Solution implementation\n",
        "         * Monitoring methods\n",
        "         * Success measures\n",
        "\n",
        "    Integration must be comprehensive and actionable with clear responsibilities and timelines.\"\"\"\n",
        "\n",
        "VET_PROMPTS = VetPrompts()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 6,
      "metadata": {
        "id": "cUhG-GtS0mb1"
      },
      "outputs": [],
      "source": [
        "def query_pinecone(query: str, top_k: int = 5) -> List[dict]:\n",
        "    \"\"\"Query Pinecone index for relevant context\"\"\"\n",
        "    query_embedding = embeddings.embed_query(query)\n",
        "    index = pc.Index(index_name)\n",
        "    results = index.query(vector=query_embedding, top_k=top_k, include_metadata=True)\n",
        "    return results.matches\n",
        "\n",
        "\n",
        "def handle_error(state: VetState, error_message: str) -> VetState:\n",
        "    new_state = state.copy()\n",
        "    if \"errors\" not in new_state[\"results\"]:\n",
        "        new_state[\"results\"][\"errors\"] = []\n",
        "    new_state[\"results\"][\"errors\"].append(\n",
        "        {\n",
        "            \"timestamp\": datetime.now().isoformat(),\n",
        "            \"message\": error_message,\n",
        "            \"context\": state.get(\"context\", []),\n",
        "        }\n",
        "    )\n",
        "    return new_state\n",
        "\n",
        "\n",
        "def process_pdf(file_path: str) -> Tuple[List[str], List[Dict[str, Any]]]:\n",
        "    \"\"\"\n",
        "    Process PDF document and extract both text and images\n",
        "    Returns: Tuple of (text_chunks, image_data)\n",
        "    \"\"\"\n",
        "    try:\n",
        "        doc = fitz.open(file_path)\n",
        "        text_chunks = []\n",
        "        images = []\n",
        "\n",
        "        for page_num in range(len(doc)):\n",
        "            page = doc[page_num]\n",
        "            text = page.get_text()\n",
        "            if text.strip():\n",
        "                text_chunks.append(text)\n",
        "            image_list = page.get_images()\n",
        "            for img_index, img in enumerate(image_list):\n",
        "                try:\n",
        "                    xref = img[0]\n",
        "                    base_image = doc.extract_image(xref)\n",
        "                    image_data = {\n",
        "                        \"page_num\": page_num + 1,\n",
        "                        \"image_index\": img_index,\n",
        "                        \"extension\": base_image[\"ext\"],\n",
        "                        \"content\": base64.b64encode(base_image[\"image\"]).decode(),\n",
        "                        \"metadata\": {\n",
        "                            \"width\": base_image.get(\"width\"),\n",
        "                            \"height\": base_image.get(\"height\"),\n",
        "                            \"colorspace\": base_image.get(\"colorspace\"),\n",
        "                        },\n",
        "                    }\n",
        "                    images.append(image_data)\n",
        "                except Exception as e:\n",
        "                    print(\n",
        "                        f\"Error extracting image {img_index} from page {page_num + 1}: {str(e)}\"\n",
        "                    )\n",
        "\n",
        "        text_splitter = RecursiveCharacterTextSplitter(\n",
        "            chunk_size=1000,\n",
        "            chunk_overlap=200,\n",
        "            length_function=len,\n",
        "        )\n",
        "\n",
        "        if text_chunks:\n",
        "            combined_text = \"\\n\\n\".join(text_chunks)\n",
        "            final_chunks = text_splitter.split_text(combined_text)\n",
        "        else:\n",
        "            final_chunks = []\n",
        "\n",
        "        doc.close()\n",
        "        return final_chunks, images\n",
        "\n",
        "    except Exception as e:\n",
        "        print(f\"Error processing PDF: {str(e)}\")\n",
        "        return [], []\n",
        "\n",
        "\n",
        "def process_multiple_files(\n",
        "    file_paths: List[str],\n",
        ") -> Tuple[List[str], List[Dict[str, Any]]]:\n",
        "    \"\"\"\n",
        "    Process multiple PDF documents and extract both text and images\n",
        "    Args:\n",
        "        file_paths: List of file paths to process\n",
        "    Returns:\n",
        "        Tuple of (text_chunks, image_data)\n",
        "    \"\"\"\n",
        "    all_text_chunks = []\n",
        "    all_images = []\n",
        "\n",
        "    for file_path in file_paths:\n",
        "        try:\n",
        "            doc = fitz.open(file_path)\n",
        "\n",
        "            # Process text from current file\n",
        "            file_chunks = []\n",
        "            for page_num in range(len(doc)):\n",
        "                page = doc[page_num]\n",
        "                text = page.get_text()\n",
        "                if text.strip():\n",
        "                    # Add file identifier to chunk\n",
        "                    marked_text = f\"[Source: {file_path}]\\n{text}\"\n",
        "                    file_chunks.append(marked_text)\n",
        "\n",
        "                # Process images from current page\n",
        "                image_list = page.get_images()\n",
        "                for img_index, img in enumerate(image_list):\n",
        "                    try:\n",
        "                        xref = img[0]\n",
        "                        base_image = doc.extract_image(xref)\n",
        "                        image_data = {\n",
        "                            \"file_path\": file_path,\n",
        "                            \"page_num\": page_num + 1,\n",
        "                            \"image_index\": img_index,\n",
        "                            \"extension\": base_image[\"ext\"],\n",
        "                            \"content\": base64.b64encode(base_image[\"image\"]).decode(),\n",
        "                            \"metadata\": {\n",
        "                                \"width\": base_image.get(\"width\"),\n",
        "                                \"height\": base_image.get(\"height\"),\n",
        "                                \"colorspace\": base_image.get(\"colorspace\"),\n",
        "                            },\n",
        "                        }\n",
        "                        all_images.append(image_data)\n",
        "                    except Exception as e:\n",
        "                        print(\n",
        "                            f\"Error extracting image {img_index} from page {page_num + 1} in {file_path}: {str(e)}\"\n",
        "                        )\n",
        "\n",
        "            all_text_chunks.extend(file_chunks)\n",
        "            doc.close()\n",
        "\n",
        "        except Exception as e:\n",
        "            print(f\"Error processing file {file_path}: {str(e)}\")\n",
        "            continue\n",
        "\n",
        "    # Apply text splitting after collecting all chunks\n",
        "    text_splitter = RecursiveCharacterTextSplitter(\n",
        "        chunk_size=1000,\n",
        "        chunk_overlap=200,\n",
        "        length_function=len,\n",
        "    )\n",
        "\n",
        "    if all_text_chunks:\n",
        "        combined_text = \"\\n\\n\".join(all_text_chunks)\n",
        "        final_chunks = text_splitter.split_text(combined_text)\n",
        "    else:\n",
        "        final_chunks = []\n",
        "\n",
        "    return final_chunks, all_images\n",
        "\n",
        "\n",
        "def create_data_processing_agent():\n",
        "    def process_data(state: VetState) -> VetState:\n",
        "        try:\n",
        "            # Query Pinecone for relevant context\n",
        "            relevant_docs = query_pinecone(state[\"current_input\"])\n",
        "            context = [doc.metadata.get(\"text\", \"\") for doc in relevant_docs]\n",
        "\n",
        "            if state.get(\"images\"):\n",
        "                image_context = \"Document contains the following images:\\n\"\n",
        "                for idx, img in enumerate(state[\"images\"]):\n",
        "                    image_context += f\"\\nImage {idx + 1} on page {img['page_num']}:\\n\"\n",
        "                    image_context += f\"- Type: {img['extension']}\\n\"\n",
        "                    image_context += f\"- Dimensions: {img['metadata']['width']}x{img['metadata']['height']}\\n\"\n",
        "                context.append(image_context)\n",
        "\n",
        "            context_text = \"\\n\\n\".join(context)\n",
        "\n",
        "            prompt = ChatPromptTemplate.from_messages(\n",
        "                [\n",
        "                    (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                    (\"system\", VET_PROMPTS.DATA_PROCESSOR),\n",
        "                    (\"human\", \"Process this veterinary case data in detail: {input}\"),\n",
        "                ]\n",
        "            )\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                input=state[\"current_input\"], context=context_text\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"DataProcessor\"] = response.content\n",
        "            new_state[\"context\"] = context\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Data Processing Error: {str(e)}\")\n",
        "\n",
        "    return process_data\n",
        "\n",
        "\n",
        "def create_history_analysis_agent():\n",
        "    def analyze_history(state: VetState) -> VetState:\n",
        "        try:\n",
        "            processed_data = state[\"results\"][\"DataProcessor\"]\n",
        "            context = state.get(\"context\", [])\n",
        "\n",
        "            prompt = ChatPromptTemplate.from_messages(\n",
        "                [\n",
        "                    (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                    (\"system\", VET_PROMPTS.HISTORY_ANALYZER),\n",
        "                    (\n",
        "                        \"human\",\n",
        "                        \"Analyze this case history with detailed timeline: {processed_data}\",\n",
        "                    ),\n",
        "                ]\n",
        "            )\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                processed_data=processed_data, context=\"\\n\\n\".join(context)\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"HistoryAnalyzer\"] = response.content\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"History Analysis Error: {str(e)}\")\n",
        "\n",
        "    return analyze_history\n",
        "\n",
        "\n",
        "def create_clinical_analysis_agent():\n",
        "    def analyze_clinical(state: VetState) -> VetState:\n",
        "        try:\n",
        "            history_analysis = state[\"results\"][\"HistoryAnalyzer\"]\n",
        "            context = state.get(\"context\", [])\n",
        "\n",
        "            prompt = ChatPromptTemplate.from_messages(\n",
        "                [\n",
        "                    (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                    (\"system\", VET_PROMPTS.CLINICAL_ANALYZER),\n",
        "                    (\n",
        "                        \"human\",\n",
        "                        \"Provide detailed clinical analysis for: {history_analysis}\",\n",
        "                    ),\n",
        "                ]\n",
        "            )\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                history_analysis=history_analysis, context=\"\\n\\n\".join(context)\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"ClinicalAnalyzer\"] = response.content\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Clinical Analysis Error: {str(e)}\")\n",
        "\n",
        "    return analyze_clinical\n",
        "\n",
        "\n",
        "def create_diagnostic_agent():\n",
        "    def diagnose(state: VetState) -> VetState:\n",
        "        try:\n",
        "            clinical_analysis = state[\"results\"][\"ClinicalAnalyzer\"]\n",
        "            context = state.get(\"context\", [])\n",
        "\n",
        "            diagnostic_context = query_pinecone(clinical_analysis)\n",
        "            additional_context = [\n",
        "                doc.metadata.get(\"text\", \"\") for doc in diagnostic_context\n",
        "            ]\n",
        "            combined_context = context + additional_context\n",
        "\n",
        "            prompt = ChatPromptTemplate.from_messages(\n",
        "                [\n",
        "                    (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                    (\"system\", VET_PROMPTS.DIAGNOSTICIAN),\n",
        "                    (\n",
        "                        \"human\",\n",
        "                        \"Provide comprehensive diagnostic assessment for: {clinical_analysis}\",\n",
        "                    ),\n",
        "                ]\n",
        "            )\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                clinical_analysis=clinical_analysis,\n",
        "                context=\"\\n\\n\".join(combined_context),\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"Diagnostics\"] = response.content\n",
        "            new_state[\"context\"] = combined_context\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Diagnostic Error: {str(e)}\")\n",
        "\n",
        "    return diagnose\n",
        "\n",
        "\n",
        "def create_specialist_summary_agent():\n",
        "    def generate_summaries(state: VetState) -> VetState:\n",
        "        try:\n",
        "            diagnostic_assessment = state[\"results\"][\"Diagnostics\"]\n",
        "            context = state.get(\"context\", [])\n",
        "            prompt = ChatPromptTemplate.from_messages(\n",
        "                [\n",
        "                    (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                    (\"system\", VET_PROMPTS.SPECIALIST),\n",
        "                    (\n",
        "                        \"human\",\n",
        "                        \"Generate comprehensive specialist assessment for: {diagnostic_assessment}\",\n",
        "                    ),\n",
        "                ]\n",
        "            )\n",
        "            messages = prompt.format_messages(\n",
        "                diagnostic_assessment=diagnostic_assessment,\n",
        "                context=\"\\n\\n\".join(context),\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"SpecialistSummary\"] = response.content\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Specialist Summary Error: {str(e)}\")\n",
        "\n",
        "    return generate_summaries\n",
        "\n",
        "\n",
        "def create_connections_agent():\n",
        "    def analyze_connections(state: VetState) -> VetState:\n",
        "        try:\n",
        "            previous_analyses = {\n",
        "                \"data_processing\": state[\"results\"][\"DataProcessor\"],\n",
        "                \"history\": state[\"results\"][\"HistoryAnalyzer\"],\n",
        "                \"clinical\": state[\"results\"][\"ClinicalAnalyzer\"],\n",
        "                \"diagnostics\": state[\"results\"][\"Diagnostics\"],\n",
        "                \"specialist\": state[\"results\"][\"SpecialistSummary\"],\n",
        "            }\n",
        "\n",
        "            context = state.get(\"context\", [])\n",
        "            prompt = ChatPromptTemplate.from_messages(\n",
        "                [\n",
        "                    (\"system\", VET_PROMPTS.BASE_VETERINARY_CONTEXT),\n",
        "                    (\"system\", VET_PROMPTS.CONNECTIONS),\n",
        "                    (\n",
        "                        \"human\",\n",
        "                        \"Provide comprehensive case integration analysis for: {previous_analyses}\",\n",
        "                    ),\n",
        "                ]\n",
        "            )\n",
        "\n",
        "            messages = prompt.format_messages(\n",
        "                previous_analyses=json.dumps(previous_analyses, indent=2),\n",
        "                context=\"\\n\\n\".join(context),\n",
        "            )\n",
        "            response = llm.invoke(messages)\n",
        "\n",
        "            new_state = state.copy()\n",
        "            new_state[\"messages\"].append(response)\n",
        "            new_state[\"results\"][\"Connections\"] = response.content\n",
        "\n",
        "            return new_state\n",
        "\n",
        "        except Exception as e:\n",
        "            return handle_error(state, f\"Connections Analysis Error: {str(e)}\")\n",
        "\n",
        "    return analyze_connections\n",
        "\n",
        "\n",
        "def create_workflow():\n",
        "    \"\"\"Create and configure the workflow\"\"\"\n",
        "    workflow = StateGraph(VetState)\n",
        "\n",
        "    workflow.add_node(\"process_data\", create_data_processing_agent())\n",
        "    workflow.add_node(\"analyze_history\", create_history_analysis_agent())\n",
        "    workflow.add_node(\"analyze_clinical\", create_clinical_analysis_agent())\n",
        "    workflow.add_node(\"diagnose\", create_diagnostic_agent())\n",
        "    workflow.add_node(\"specialist_summary\", create_specialist_summary_agent())\n",
        "    workflow.add_node(\"analyze_connections\", create_connections_agent())\n",
        "\n",
        "    workflow.set_entry_point(\"process_data\")\n",
        "\n",
        "    workflow.add_edge(\"process_data\", \"analyze_history\")\n",
        "    workflow.add_edge(\"analyze_history\", \"analyze_clinical\")\n",
        "    workflow.add_edge(\"analyze_clinical\", \"diagnose\")\n",
        "    workflow.add_edge(\"diagnose\", \"specialist_summary\")\n",
        "    workflow.add_edge(\"specialist_summary\", \"analyze_connections\")\n",
        "    workflow.add_edge(\"analyze_connections\", END)\n",
        "\n",
        "    return workflow.compile()\n",
        "\n",
        "\n",
        "def create_embeddings_and_index(file_content: str, metadata: Dict[str, Any]) -> None:\n",
        "    \"\"\"\n",
        "    Create embeddings for file content and store in Pinecone\n",
        "    \"\"\"\n",
        "    try:\n",
        "        # Create embedding for the content\n",
        "        content_embedding = embeddings.embed_query(file_content)\n",
        "\n",
        "        # Create a vector to upsert\n",
        "        vector = {\n",
        "            \"id\": f\"doc_{datetime.now().timestamp()}\",\n",
        "            \"values\": content_embedding,\n",
        "            \"metadata\": {\"text\": file_content, **metadata},\n",
        "        }\n",
        "\n",
        "        # Get Pinecone index\n",
        "        index = pc.Index(index_name)\n",
        "\n",
        "        # Upsert the vector\n",
        "        index.upsert(vectors=[vector])\n",
        "\n",
        "        print(f\"Successfully created and stored embedding for document\")\n",
        "\n",
        "    except Exception as e:\n",
        "        print(f\"Error creating embedding: {str(e)}\")\n",
        "        raise\n",
        "\n",
        "\n",
        "def process_files(file_paths: List[str]) -> List[str]:\n",
        "    \"\"\"\n",
        "    Process files and create embeddings\n",
        "    Returns: List of file contents\n",
        "    \"\"\"\n",
        "    all_contents = []\n",
        "\n",
        "    for file_path in file_paths:\n",
        "        try:\n",
        "            # Check if file is PDF\n",
        "            if file_path.lower().endswith('.pdf'):\n",
        "                doc = fitz.open(file_path)\n",
        "                content = \"\"\n",
        "                for page in doc:\n",
        "                    content += page.get_text()\n",
        "                doc.close()\n",
        "                if content.strip():\n",
        "                    all_contents.append(content)\n",
        "\n",
        "                    # Create metadata for the file\n",
        "                    metadata = {\n",
        "                        \"source\": file_path,\n",
        "                        \"date_processed\": datetime.now().isoformat(),\n",
        "                        \"type\": \"pdf\"\n",
        "                    }\n",
        "\n",
        "                    # Create and store embedding\n",
        "                    create_embeddings_and_index(content, metadata)\n",
        "\n",
        "            # Check if file is image\n",
        "            elif file_path.lower().endswith(('.jpg', '.jpeg', '.png')):\n",
        "                # For images, we might want to use OCR or image analysis\n",
        "                # For now, we'll just store metadata\n",
        "                metadata = {\n",
        "                    \"source\": file_path,\n",
        "                    \"date_processed\": datetime.now().isoformat(),\n",
        "                    \"type\": \"image\"\n",
        "                }\n",
        "                print(f\"Image file {file_path} processed - metadata stored\")\n",
        "\n",
        "            else:\n",
        "                print(f\"Unsupported file type: {file_path}\")\n",
        "\n",
        "        except Exception as e:\n",
        "            print(f\"Error processing file {file_path}: {str(e)}\")\n",
        "            continue\n",
        "\n",
        "    return all_contents\n",
        "\n",
        "def analyze_veterinary_case(file_paths: Union[str, List[str]]):\n",
        "    \"\"\"\n",
        "    Main function to analyze a veterinary case from single or multiple files\n",
        "    Args:\n",
        "        file_paths: Either a single file path string or a list of file paths\n",
        "    Returns:\n",
        "        Analysis results\n",
        "    \"\"\"\n",
        "    try:\n",
        "        print(\"Processing document(s)...\")\n",
        "\n",
        "        # Convert single file path to list\n",
        "        if isinstance(file_paths, str):\n",
        "            file_paths = [file_paths]\n",
        "\n",
        "        # Process files and create embeddings\n",
        "        text_contents = process_files(file_paths)\n",
        "\n",
        "        # Don't raise error if we have image files but no text\n",
        "        if not text_contents and not any(f.lower().endswith(('.jpg', '.jpeg', '.png')) for f in file_paths):\n",
        "            raise ValueError(\"No text content extracted from provided files\")\n",
        "\n",
        "        initial_state = {\n",
        "            \"messages\": [],\n",
        "            \"current_input\": \"\\n\\n\".join(text_contents) if text_contents else \"\",\n",
        "            \"medical_records\": {},\n",
        "            \"results\": {\n",
        "                \"DataProcessor\": \"\",\n",
        "                \"HistoryAnalyzer\": \"\",\n",
        "                \"ClinicalAnalyzer\": \"\",\n",
        "                \"Diagnostics\": \"\",\n",
        "                \"SpecialistSummary\": \"\",\n",
        "                \"Connections\": \"\",\n",
        "            },\n",
        "            \"metadata\": {\n",
        "                \"file_count\": len(file_paths),\n",
        "                \"processed_files\": file_paths,\n",
        "                \"total_chunks\": len(text_contents),\n",
        "            },\n",
        "            \"context\": [],\n",
        "            \"images\": [],\n",
        "        }\n",
        "\n",
        "        print(f\"Creating workflow for {len(file_paths)} file(s)...\")\n",
        "        app = create_workflow()\n",
        "\n",
        "        print(\"Running analysis...\")\n",
        "        result = app.invoke(initial_state)\n",
        "\n",
        "        return result\n",
        "\n",
        "    except Exception as e:\n",
        "        print(f\"Error in analysis: {str(e)}\")\n",
        "        raise\n",
        "\n",
        "def analyze_veterinary_case(file_paths: Union[str, List[str]]):\n",
        "    \"\"\"\n",
        "    Main function to analyze a veterinary case from single or multiple files\n",
        "    Args:\n",
        "        file_paths: Either a single file path string or a list of file paths\n",
        "    Returns:\n",
        "        Analysis results\n",
        "    \"\"\"\n",
        "    try:\n",
        "        print(\"Processing document(s)...\")\n",
        "\n",
        "        # Convert single file path to list\n",
        "        if isinstance(file_paths, str):\n",
        "            file_paths = [file_paths]\n",
        "\n",
        "        # Process files and create embeddings\n",
        "        text_contents = process_files(file_paths)\n",
        "\n",
        "        if not text_contents:\n",
        "            raise ValueError(\"No text content extracted from provided files\")\n",
        "\n",
        "        initial_state = {\n",
        "            \"messages\": [],\n",
        "            \"current_input\": \"\\n\\n\".join(text_contents),\n",
        "            \"medical_records\": {},\n",
        "            \"results\": {\n",
        "                \"DataProcessor\": \"\",\n",
        "                \"HistoryAnalyzer\": \"\",\n",
        "                \"ClinicalAnalyzer\": \"\",\n",
        "                \"Diagnostics\": \"\",\n",
        "                \"SpecialistSummary\": \"\",\n",
        "                \"Connections\": \"\",\n",
        "            },\n",
        "            \"metadata\": {\n",
        "                \"file_count\": len(file_paths),\n",
        "                \"processed_files\": file_paths,\n",
        "                \"total_chunks\": len(text_contents),\n",
        "            },\n",
        "            \"context\": [],\n",
        "            \"images\": [],\n",
        "        }\n",
        "\n",
        "        print(f\"Creating workflow for {len(file_paths)} file(s)...\")\n",
        "        app = create_workflow()\n",
        "\n",
        "        print(\"Running analysis...\")\n",
        "        result = app.invoke(initial_state)\n",
        "\n",
        "        return result\n",
        "\n",
        "    except Exception as e:\n",
        "        print(f\"Error in analysis: {str(e)}\")\n",
        "        raise\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "tuxa4tEWT3ha",
        "outputId": "bffba070-9b66-41d0-dbfc-4ec1791b580f"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Processing document(s)...\n",
            "Creating workflow for 1 file(s)...\n",
            "Running analysis...\n",
            "\n",
            "Analysis Results:\n",
            "--------------------------------------------------\n",
            "\n",
            "Data Processing:\n",
            "------------------------------\n",
            "**PATIENT SIGNALMENT & CLIENT INFORMATION:**\n",
            "- Patient: Jax Miracle\n",
            "- Patient ID: CA2441B8\n",
            "- Species: Canine\n",
            "- Breed: Pomeranian\n",
            "- Age: 4 years old\n",
            "- Sex: Male, neutered\n",
            "- Weight: 6.1 kg\n",
            "- Microchip: None\n",
            "- Client: Anna Miracle\n",
            "- Client ID: 24404F\n",
            "- Address: 2497 Hillsboro Rd, Campbellsburg, KY 40011, USA\n",
            "- Phone: (502) 532-6641\n",
            "- Email: miracletricia@gmail.com\n",
            "\n",
            "**PRESENTING COMPLAINT AND HISTORY:**\n",
            "- Chief Complaint: Coughing\n",
            "- Duration: Not specified\n",
            "- Symptoms: Coughing, hacking, panting loudly\n",
            "- Vomiting: None\n",
            "- Diarrhea: None\n",
            "- Coughing/Sneezing: Dry cough\n",
            "- Changes in Drinking/Urination/Eating: No changes\n",
            "- Lumps/Bumps: None\n",
            "- Travel History: No recent travel\n",
            "- Tick History: No ticks found\n",
            "- Heartworm Prevention: Yes\n",
            "- Diet: Variety, Pedigree canned food, Kibbles and Bits dry food, Dreambones for 15 months\n",
            "- Medications: Bravecto (1 tablet every 6 months), Sentinel Spectrum (8.75 mg tablet once a month)\n",
            "- Anesthesia History: No issues\n",
            "- Household Pets: 1 dog\n",
            "\n",
            "**PHYSICAL EXAMINATION:**\n",
            "- Vital Signs: Not recorded\n",
            "- General Appearance: Not recorded\n",
            "- EENT: Not recorded\n",
            "- Cardiovascular: Not recorded\n",
            "- Respiratory: Not recorded\n",
            "- Gastrointestinal: Not recorded\n",
            "- Musculoskeletal: Not recorded\n",
            "- Neurologic: Not recorded\n",
            "- Integumentary: Not recorded\n",
            "- Lymphatic: Not recorded\n",
            "- Urogenital: Not recorded\n",
            "\n",
            "**DIAGNOSTIC FINDINGS:**\n",
            "- Laboratory Results: Not provided\n",
            "- Imaging Findings: Not provided\n",
            "- Other Test Results: Not provided\n",
            "\n",
            "**CURRENT MEDICATIONS AND TREATMENTS:**\n",
            "1. Bravecto (Orange) - 1 tablet every 6 months\n",
            "2. Sentinel Spectrum (8.75 mg) - 1 tablet once a month\n",
            "\n",
            "**CLIENT COMMUNICATIONS AND INSTRUCTIONS:**\n",
            "- Client consented to receive SMS messages from the veterinary practice.\n",
            "- Client authorized the release of medical records and images for diagnostic and educational purposes.\n",
            "- Client agreed to the use of AI technologies for processing medical information.\n",
            "- Client did not report any new lumps or bumps on the pet.\n",
            "- Client reported anxiety in the pet.\n",
            "- Client confirmed heartworm prevention for the pet.\n",
            "- Client provided detailed information about the pet's diet and medications.\n",
            "- Client reported no changes in the pet's drinking, urination, or eating habits.\n",
            "\n",
            "History Analysis:\n",
            "------------------------------\n",
            "**COMPREHENSIVE TIMELINE:**\n",
            "\n",
            "1. **Initial Disease Onset:**\n",
            "   - Date of First Clinical Signs: Not specified\n",
            "   - Symptom Progression: Coughing, hacking, panting loudly with a dry cough\n",
            "   - Initial Diagnostic Findings: Not provided\n",
            "   - First Treatment Responses: Bravecto every 6 months, Sentinel Spectrum monthly\n",
            "\n",
            "2. **Disease Progression:**\n",
            "   - No detailed symptom evolution provided\n",
            "   - No complications or new symptoms reported\n",
            "   - No medication changes documented\n",
            "\n",
            "3. **Complete Treatment History:**\n",
            "   - Bravecto (Orange) - 1 tablet every 6 months\n",
            "     - Start Date: Not specified\n",
            "     - End Date: Ongoing\n",
            "     - Response: Not applicable\n",
            "     - Adverse Reactions: Not reported\n",
            "   - Sentinel Spectrum (8.75 mg) - 1 tablet once a month\n",
            "     - Start Date: Not specified\n",
            "     - End Date: Ongoing\n",
            "     - Response: Not applicable\n",
            "     - Adverse Reactions: Not reported\n",
            "\n",
            "4. **Diagnostic Testing Chronology:**\n",
            "   - No tests performed or results provided\n",
            "\n",
            "**PATTERN ANALYSIS:**\n",
            "\n",
            "1. **Detailed Symptom Patterns:**\n",
            "   - Frequency of Episodes: Not specified\n",
            "   - Severity Trends: Not recorded\n",
            "   - Triggers: Not identified\n",
            "   - Temporal Patterns: Not specified\n",
            "\n",
            "2. **Treatment Response Analysis:**\n",
            "   - Duration of Response: Not applicable\n",
            "   - Degree of Improvement: Not applicable\n",
            "   - Treatment Failures: Not applicable\n",
            "   - Compliance Assessment: Client reported compliance with heartworm prevention medications\n",
            "\n",
            "3. **Risk Factor Evaluation:**\n",
            "   - No identified risk factors provided\n",
            "   - Environmental Influences: No specific information\n",
            "   - Genetic Predispositions: Not mentioned\n",
            "   - Concurrent Conditions: No other conditions reported\n",
            "\n",
            "This case lacks detailed clinical information, diagnostic findings, and treatment responses. Further evaluation and diagnostic workup are necessary to address the presenting complaint of coughing in the Pomeranian patient, Jax Miracle.\n",
            "\n",
            "Clinical Analysis:\n",
            "------------------------------\n",
            "**CLINICAL ASSESSMENT:**\n",
            "\n",
            "1. **Primary Clinical Signs Analysis:**\n",
            "   - Coughing:\n",
            "     * Duration: Not specified\n",
            "     * Frequency: Not specified\n",
            "     * Severity: Not recorded\n",
            "     * Pattern: Described as dry cough\n",
            "     * Response to Bravecto and Sentinel Spectrum: Not specified\n",
            "\n",
            "2. **Comprehensive Physical Examination Analysis:**\n",
            "   - Vital Signs Interpretation:\n",
            "     * Temperature: Not provided\n",
            "     * Heart rate: Not provided\n",
            "     * Respiratory rate and effort: Panting loudly noted\n",
            "     * Weight trends: Not specified\n",
            "     * Body condition score changes: Not specified\n",
            "\n",
            "   - Detailed System Analysis:\n",
            "     * Abnormal Findings: Coughing, hacking, panting loudly\n",
            "     * Masses/Lesions: Not mentioned\n",
            "     * Pain Assessment: Not documented\n",
            "     * Comparative Findings: Not specified\n",
            "     * Sequential Changes: No reported changes\n",
            "\n",
            "3. **Diagnostic Testing Interpretation:**\n",
            "   - Laboratory Results: Not available\n",
            "   - Imaging: Not performed\n",
            "\n",
            "4. **Disease Process Analysis:**\n",
            "   - Pathophysiology: Coughing can be indicative of various respiratory conditions such as tracheal collapse, bronchitis, or heart disease.\n",
            "   - Complications: Not reported\n",
            "   - Disease Stage: Unable to determine without diagnostic testing\n",
            "   - Progression Indicators: Lack of symptom evolution noted\n",
            "\n",
            "5. **Treatment Response Evaluation:**\n",
            "   - Bravecto and Sentinel Spectrum:\n",
            "     * Time to Response: Not specified\n",
            "     * Degree of Improvement: Not documented\n",
            "     * Duration of Effect: Not provided\n",
            "     * Side Effects: Not reported\n",
            "     * Factors Affecting Efficacy: Compliance reported by the client\n",
            "\n",
            "**CLINICAL INTEGRATION:**\n",
            "\n",
            "1. **Evidence Synthesis:**\n",
            "   - Limited evidence available due to lack of diagnostic testing and detailed clinical information.\n",
            "   - Further investigations are crucial to support a definitive diagnosis.\n",
            "\n",
            "2. **Contradictory Findings:**\n",
            "   - No contradictory findings noted due to insufficient data.\n",
            "   - Rule-out justifications are challenging without diagnostic results.\n",
            "   - Testing limitations hinder a comprehensive assessment of the case.\n",
            "\n",
            "Given the incomplete clinical data, it is imperative to conduct a thorough physical examination, diagnostic workup including blood tests, imaging studies, and potentially respiratory evaluations to determine the underlying cause of coughing in Jax Miracle. Regular monitoring and follow-up are essential to assess treatment efficacy and adjust the management plan accordingly.\n",
            "\n",
            "Diagnostic Assessment:\n",
            "------------------------------\n",
            "**PROBLEM LIST:**\n",
            "\n",
            "1. Active Problems:\n",
            "   - Coughing\n",
            "     - Duration: Not specified\n",
            "     - Severity: Not recorded\n",
            "     - Progression: Dry cough reported\n",
            "     - Clinical Findings: Coughing, hacking, panting loudly\n",
            "     - Impact on Quality of Life: Potential discomfort and respiratory distress\n",
            "     - Treatment: No specific treatment initiated\n",
            "\n",
            "2. Inactive/Resolved Problems:\n",
            "   - None\n",
            "\n",
            "**DIFFERENTIAL DIAGNOSES:**\n",
            "\n",
            "1. Primary Differential List:\n",
            "   - Tracheal Collapse\n",
            "     - Supporting Evidence: Dry cough, hacking\n",
            "     - Diagnostic Criteria: Tracheal collapse typically presents with coughing, especially during excitement or exercise.\n",
            "     - Required Diagnostics: Radiography, fluoroscopy\n",
            "\n",
            "   - Canine Bronchitis\n",
            "     - Supporting Evidence: Dry cough, panting loudly\n",
            "     - Diagnostic Criteria: Chronic cough, often worsened by exercise or excitement.\n",
            "     - Required Diagnostics: Chest radiographs, bronchoscopy\n",
            "\n",
            "   - Cardiac Disease\n",
            "     - Supporting Evidence: Panting loudly, coughing\n",
            "     - Diagnostic Criteria: Coughing can be a sign of heart disease, especially in older dogs.\n",
            "     - Required Diagnostics: Echocardiography, electrocardiography\n",
            "\n",
            "2. Secondary Differential List:\n",
            "   - Infectious Tracheobronchitis (Kennel Cough)\n",
            "     - Reason for Lower Priority: Less likely without exposure history\n",
            "     - Rule-out Criteria: Recent boarding, exposure to other dogs\n",
            "     - Testing Recommendations: PCR testing for infectious agents\n",
            "\n",
            "**DIAGNOSTIC PLAN:**\n",
            "\n",
            "1. Immediate Diagnostics:\n",
            "   - Chest Radiographs\n",
            "     - Justification: To evaluate trachea, bronchi, and lung fields for abnormalities\n",
            "     - Expected Findings: Tracheal collapse, bronchitis, cardiac enlargement\n",
            "     - Result Interpretation: Enlarged trachea, bronchial patterns, cardiac silhouette\n",
            "     - Cost-Benefit: Essential for definitive diagnosis\n",
            "     - Sample Handling: Standard radiographic procedure\n",
            "     - Timing: ASAP\n",
            "\n",
            "2. Monitoring Diagnostics:\n",
            "   - Respiratory Rate Monitoring\n",
            "     - Frequency: Daily\n",
            "     - Alert Thresholds: >30 breaths per minute\n",
            "     - Trend Analysis: Decreasing trend indicates improvement\n",
            "     - Action Triggers: Sustained increase in respiratory rate\n",
            "\n",
            "**THERAPEUTIC PLAN:**\n",
            "\n",
            "1. Immediate Interventions:\n",
            "   - Symptomatic Treatment with Cough Suppressants (e.g., Butorphanol)\n",
            "     - Dose: 0.2-0.4 mg/kg orally every 6-8 hours\n",
            "     - Administration: Oral\n",
            "     - Monitoring: Response to treatment, adverse effects\n",
            "     - Expected Response: Reduction in coughing episodes\n",
            "     - Adverse Effects: Sedation, gastrointestinal upset\n",
            "\n",
            "2. Long-term Management:\n",
            "   - Outcome Goals: Resolution of coughing, improved quality of life\n",
            "   - Reassessment: After diagnostic tests and initial treatment\n",
            "   - Client Education: Importance of compliance, monitoring for changes\n",
            "   - Environmental Modifications: Minimize exposure to irritants\n",
            "   - Dietary Recommendations: Maintain optimal weight, consider respiratory-supportive diets\n",
            "\n",
            "Regular follow-up appointments are necessary to assess treatment response, adjust therapy as needed, and ensure the well-being of Jax Miracle.\n",
            "\n",
            "Specialist Summary:\n",
            "------------------------------\n",
            "**SPECIALIST CONSULTATION:**\n",
            "\n",
            "1. **Case Summary:**\n",
            "   Jax Miracle, a canine patient, presents with a history of dry coughing, hacking, and loud panting. The duration and severity of coughing are not specified. No specific treatment has been initiated. The coughing may be causing potential discomfort and respiratory distress.\n",
            "\n",
            "2. **Disease Process Analysis:**\n",
            "   - **Pathophysiology:** Differential diagnoses include tracheal collapse, canine bronchitis, and cardiac disease. Tracheal collapse typically presents with coughing, especially during excitement or exercise. Canine bronchitis manifests as a chronic cough worsened by exercise. Cardiac disease can also lead to coughing, especially in older dogs.\n",
            "   - **Current Disease Stage:** Early stage with clinical signs of coughing and panting.\n",
            "   - **Prognosis:** Prognosis depends on the underlying cause, response to treatment, and client compliance.\n",
            "\n",
            "3. **Treatment Analysis:**\n",
            "   - No specific treatment initiated yet.\n",
            "   - Symptomatic treatment with cough suppressants may provide relief.\n",
            "   - Compliance with treatment and monitoring are crucial for successful management.\n",
            "\n",
            "4. **Specialist Recommendations:**\n",
            "   - Perform chest radiographs for definitive diagnosis.\n",
            "   - Initiate symptomatic treatment with a cough suppressant.\n",
            "   - Educate the client on the importance of compliance and monitoring.\n",
            "\n",
            "**COMPREHENSIVE PLAN:**\n",
            "\n",
            "1. **Medical Management:**\n",
            "   - **Cough Suppressant (Butorphanol):**\n",
            "     - Dose: 0.2-0.4 mg/kg orally every 6-8 hours\n",
            "     - Administration: Oral\n",
            "     - Monitoring: Response to treatment, adverse effects\n",
            "     - Duration: Until resolution of coughing\n",
            "     - Success Criteria: Reduction in coughing episodes\n",
            "\n",
            "2. **Monitoring Protocol:**\n",
            "   - **Respiratory Rate Monitoring:**\n",
            "     - Frequency: Daily\n",
            "     - Target Values: <30 breaths per minute\n",
            "     - Action Thresholds: >30 breaths per minute\n",
            "     - Response Protocol: Sustained increase in respiratory rate triggers reevaluation.\n",
            "\n",
            "3. **Client Education:**\n",
            "   - Explain the disease process and treatment rationale.\n",
            "   - Provide instructions on medication administration and monitoring.\n",
            "   - Educate on warning signs and emergency protocols.\n",
            "\n",
            "4. **Follow-up Schedule:**\n",
            "   - Recheck appointments after diagnostic tests and initial treatment.\n",
            "   - Establish a testing schedule for monitoring progress.\n",
            "   - Assess response to treatment and adjust therapy as needed.\n",
            "\n",
            "Regular follow-up appointments are essential to ensure the well-being of Jax Miracle and to monitor treatment response effectively.\n",
            "\n",
            "Connections Analysis:\n",
            "------------------------------\n",
            "CASE SYNTHESIS:\n",
            "1. Disease Interactions\n",
            "   - Primary-Secondary Disease Relationships:\n",
            "     * Causal connections: Coughing as the primary complaint may indicate underlying respiratory conditions like tracheal collapse, bronchitis, or cardiac disease.\n",
            "     * Systemic effects: Potential discomfort and respiratory distress from coughing.\n",
            "    \n",
            "   - Complicating Factors:\n",
            "     * Concurrent conditions: No other reported conditions.\n",
            "     * Environmental influences: No specific environmental triggers identified.\n",
            "    \n",
            "   - Synergistic Effects:\n",
            "     * Disease interactions: Respiratory conditions may impact overall quality of life.\n",
            "     * Treatment interactions: Symptomatic treatment may affect diagnostic findings.\n",
            "    \n",
            "2. Treatment Integration\n",
            "   - Drug Interactions:\n",
            "     * No known interactions reported with current medications.\n",
            "     * Symptomatic treatment with cough suppressants may influence diagnostic test results.\n",
            "    \n",
            "   - Therapeutic Conflicts:\n",
            "     * Competing treatment needs: Symptomatic relief vs. definitive diagnosis.\n",
            "     * Priority assessment: Diagnostic workup takes precedence for accurate treatment.\n",
            "    \n",
            "   - Management Synergies:\n",
            "     * Complementary treatments: Symptomatic relief alongside diagnostic testing.\n",
            "     * Timing optimization: Immediate diagnostics followed by symptomatic treatment.\n",
            "    \n",
            "3. Risk Assessment\n",
            "   - Current Risk Factors:\n",
            "     * Disease-specific risks: Respiratory distress from underlying conditions.\n",
            "     * Treatment-related risks: Adverse effects of cough suppressants.\n",
            "    \n",
            "   - Potential Complications:\n",
            "     * Early warning signs: Increased respiratory distress, lack of improvement.\n",
            "     * Monitoring protocols: Daily respiratory rate monitoring for changes.\n",
            "\n",
            "INTEGRATED CARE PLAN:\n",
            "1. Comprehensive Treatment Strategy\n",
            "   - Prioritized Interventions:\n",
            "     * Immediate actions: Chest radiographs for definitive diagnosis.\n",
            "     * Short-term goals: Symptomatic relief with cough suppressants.\n",
            "     * Long-term objectives: Resolution of coughing, improved quality of life.\n",
            "    \n",
            "   - Coordinated Care:\n",
            "     * Team responsibilities: Specialist consultation, client education, monitoring.\n",
            "     * Communication protocols: Regular updates on treatment response and progress.\n",
            "    \n",
            "2. Long-term Management\n",
            "   - Disease Trajectory:\n",
            "     * Expected progression: Resolution of coughing with appropriate treatment.\n",
            "     * Monitoring points: Daily respiratory rate checks, follow-up appointments.\n",
            "    \n",
            "   - Quality of Life:\n",
            "     * Assessment criteria: Reduction in coughing episodes, improved comfort.\n",
            "     * Improvement strategies: Compliance with treatment, environmental modifications.\n",
            "    \n",
            "3. Support Systems\n",
            "   - Client Education:\n",
            "     * Understanding assessment: Explanation of disease process and treatment rationale.\n",
            "     * Compliance Strategy: Instructions on medication administration and monitoring.\n",
            "     * Support services: Follow-up schedule for reevaluation and adjustment of therapy.\n"
          ]
        }
      ],
      "source": [
        "    file_path = \"./input.pdf\"\n",
        "    result = analyze_veterinary_case(file_path)\n",
        "\n",
        "    print(\"\\nAnalysis Results:\")\n",
        "    print(\"-\" * 50)\n",
        "\n",
        "    sections = [\n",
        "        (\"Data Processing\", \"DataProcessor\"),\n",
        "        (\"History Analysis\", \"HistoryAnalyzer\"),\n",
        "        (\"Clinical Analysis\", \"ClinicalAnalyzer\"),\n",
        "        (\"Diagnostic Assessment\", \"Diagnostics\"),\n",
        "        (\"Specialist Summary\", \"SpecialistSummary\"),\n",
        "        (\"Connections Analysis\", \"Connections\")\n",
        "    ]\n",
        "\n",
        "    for title, key in sections:\n",
        "        print(f\"\\n{title}:\")\n",
        "        print(\"-\" * 30)\n",
        "        print(result[\"results\"].get(key, \"Not available\"))\n",
        "\n",
        "    if \"errors\" in result[\"results\"]:\n",
        "        print(\"\\nErrors encountered:\")\n",
        "        for error in result[\"results\"][\"errors\"]:\n",
        "            print(f\"- {error['message']} (at {error['timestamp']}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true,
          "base_uri": "https://localhost:8080/"
        },
        "id": "CPY-aU-bXYsW",
        "outputId": "be1d05c5-0e70-491a-b453-7bb5a1adc562"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Processing document(s)...\n",
            "Creating workflow for 1 file(s)...\n",
            "Running analysis...\n",
            "\n",
            "Analysis Results:\n",
            "--------------------------------------------------\n",
            "\n",
            "Data Processing:\n",
            "------------------------------\n",
            "PATIENT SIGNALMENT & CLIENT INFORMATION:\n",
            "• Patient ID#: CA2441B8  \n",
            "• Name: Jax Miracle  \n",
            "• Species: Canine (Dog)  \n",
            "• Breed: Pomeranian  \n",
            "• Age: 4 years old (DOB documented as 12/20/20; note that countryside records reference 10/01/20 or 10/01/21)  \n",
            "• Sex: Male, Castrated  \n",
            "• Weight: 6.1 kg (as of 02/04/25)  \n",
            "• Microchip #: None  \n",
            "• Client Name & ID#: Anna Miracle (ID 24404F)  \n",
            "• Client Address: 2497 Hillsboro Rd, Campbellsburg, KY 40011, USA  \n",
            "• Client Phone: (502) 532-6641 (note secondary phone (502) 706-0428 in separate registration form)  \n",
            "• Client Email: miracletricia@gmail.com  \n",
            "• Insurance Status: Not Recorded  \n",
            "• Billing Preferences: Not Recorded  \n",
            "\n",
            "• CURRENT MEDICATIONS (as actively reported by client on 01/20/25 form):  \n",
            "  1) Bravecto (Orange) – exact strength not specified in provided data; 1 tablet orally once every 6 months. Start date: Not Recorded; End date: Ongoing. No adverse reactions reported. Effectiveness: Not Recorded.  \n",
            "  2) Sentinel Spectrum (8.75 mg) – 1 tablet orally once a month. Start date: Not Recorded; End date: Ongoing. No adverse reactions reported. Effectiveness: Not Recorded.  \n",
            "\n",
            "PRESENTING COMPLAINT AND HISTORY:\n",
            "\n",
            "CHIEF COMPLAINT (02/04/25 visit):  \n",
            "• Coughing (described as “coughing, hacking, panting loudly”).  \n",
            "• Exact duration: Not Recorded.  \n",
            "• Precise progression with dates: Not Recorded.  \n",
            "• Frequency/severity: Not Recorded beyond “dry cough.”  \n",
            "• Behavior changes: Anxiety noted.  \n",
            "• Appetite: No change reported.  \n",
            "• Drinking: No change reported.  \n",
            "• Urination: No change reported.  \n",
            "• Defecation: No change reported.  \n",
            "\n",
            "PAST MEDICAL HISTORY:  \n",
            "• Chronological Visits at Countryside Animal Hospital (per provided medical records):\n",
            "\n",
            "  1) 10/23/23:   \n",
            "     – Annual DHPP vaccination (V180).  \n",
            "     – Lepto (4-serovar) booster (V296).  \n",
            "\n",
            "  2) 01/26/24:   \n",
            "     – Rabies 1-year vaccine (V160).  \n",
            "\n",
            "  3) 03/01/24:  \n",
            "     – Blood parasite test (4) (LI103); results not recorded.  \n",
            "     – Diagnostic examination (P260); findings not described.  \n",
            "     – Sentinel Spectrum 8–25 lb (6 ct) dispensed (AP052).  \n",
            "     – Chlorpheniramine 4 mg tablets prescribed (OM220) at 1 tablet twice daily; quantity 60, start/end dates not specified (not currently reported by owner).  \n",
            "     – Hazardous waste control fee (P355).  \n",
            "\n",
            "  4) 03/12/24:  \n",
            "     – Weight listed as 12.80 lb.  \n",
            "     – Wellness examination (P263); findings not specified.  \n",
            "     – Radiographs (1-plane, 2-view) (R210); results not recorded.  \n",
            "     – Doxycycline 50 mg/mL suspension (OM569) 0.5 mL once daily, quantity 30, start/end dates not specified (not currently reported by owner).  \n",
            "\n",
            "  5) 03/19/24:  \n",
            "     – Bravecto 10–22 lb (FL601) dispensed x2 doses.  \n",
            "     – Bravecto rebate (BRAV2).  \n",
            "\n",
            "  6) 04/05/24:  \n",
            "     – Weight listed as 13.80 lb.  \n",
            "     – Wellness examination (P263); findings not specified.  \n",
            "     – Anal sac expression (P105).  \n",
            "     – Vetalog injection (IM345).  \n",
            "     – Nail trim—canine dremel (P221).  \n",
            "     – Hazardous waste control fee (P355).  \n",
            "     – Ear cleansing solution (TM342) 1 bottle prescribed; instructions: clean ear once daily.  \n",
            "     – Panalog ointment (TM270) 1 tube prescribed; instructions: clean ears once daily then apply ointment.  \n",
            "\n",
            "  7) 04/16/24:  \n",
            "     – Weight listed as 13.80 lb.  \n",
            "     – Wellness examination (P263); findings not specified.  \n",
            "     – Chlorpheniramine 4 mg tablets (OM220) refill (60 ct); instructions: 1 tablet twice daily.  \n",
            "\n",
            "  8) 05/15/24:  \n",
            "     – Weight listed as 13.40 lb.  \n",
            "     – Nail trim—canine dremel (P221).  \n",
            "\n",
            "  9) 09/06/24:  \n",
            "     – Bravecto 10–22 lb (FL601) dispensed x1.  \n",
            "     – Chlorpheniramine 4 mg tablets (OM220) 60 ct prescribed again at same instructions.  \n",
            "\n",
            " 10) 10/16/24:  \n",
            "     – Weight listed as 13.10 lb.  \n",
            "     – Wellness examination (P263).  \n",
            "     – Doxycycline 50 mg/mL suspension (OM569) 30 mL; instructions: 0.5 mL twice daily.  \n",
            "     – Temaril-P tablets (OM509) 20 ct; instructions: ½ tablet twice daily.  \n",
            "     – Annual DHPP vaccination (V180).  \n",
            "     – Canine parvo booster (V299).  \n",
            "     – Nail trim—canine dremel (P221).  \n",
            "     – Hazardous waste control fee (P355).  \n",
            "\n",
            " 11) 10/17/24:  \n",
            "     – Theophylline 400 mg ER (OM106), 2 capsules dispensed; instructions: 1 mL of FlavorX-labeled formula twice a day (note mismatch in instructions, presumably an internal record for conversion).  \n",
            "\n",
            " 12) 11/26/24:  \n",
            "     – Medical progress exam (P290).  \n",
            "\n",
            " 13) 12/06/24:  \n",
            "     – Weight listed as 12.80 lb.  \n",
            "     – Sentinel Spectrum 8–25 lb (AP052) dispensed.  \n",
            "     – Bravecto 10–22 lb (FL601) dispensed.  \n",
            "     – Wellness examination (P263).  \n",
            "\n",
            "• Vaccinations/Preventive Products:  \n",
            "  – DHPP (10/23/23, 10/16/24).  \n",
            "  – Lepto 4-serovar (10/23/23).  \n",
            "  – Rabies 1-year (01/26/24; next due 01/25/25 marked overdue).  \n",
            "  – Bravecto (oral) 10–22 lb: Repeatedly dispensed (dates above).  \n",
            "  – Sentinel Spectrum 8–25 lb: Multiple dispensations (dates above).  \n",
            "\n",
            "• Surgeries/Procedures: None specifically documented other than routine care, diagnostics, nail trims, and anal sac expressions.  \n",
            "\n",
            "• Diet History:  \n",
            "  – Pedigree canned food + Kibbles and Bits dry + Dreambones treats, for approximately 15 months.  \n",
            "\n",
            "PHYSICAL EXAMINATION (02/04/25):\n",
            "• Temperature (°F): Not Performed  \n",
            "• Heart Rate (beats/min): Not Performed  \n",
            "• Respiratory Rate (breaths/min): Not Performed  \n",
            "• Weight: 6.1 kg (recorded 02/04/25)  \n",
            "• Body Condition Score (1–9): Not Recorded  \n",
            "• Mucous Membrane Color: Not Recorded  \n",
            "• Capillary Refill Time (seconds): Not Recorded  \n",
            "• Pain Score (0–10): Not Recorded  \n",
            "\n",
            "SYSTEM-BY-SYSTEM EXAM:  \n",
            "• EENT: Not Recorded  \n",
            "• Cardiovascular: Not Recorded  \n",
            "• Respiratory: Not Recorded (chief complaint of coughing noted; no physical exam details available)  \n",
            "• Gastrointestinal: Not Recorded  \n",
            "• Musculoskeletal: Not Recorded  \n",
            "• Neurologic: Not Recorded  \n",
            "• Integumentary: Not Recorded  \n",
            "• Lymphatic: Not Recorded  \n",
            "• Urogenital: Not Recorded  \n",
            "\n",
            "DIAGNOSTIC FINDINGS:  \n",
            "• Laboratory Tests:  \n",
            "  – Blood parasite test (4) on 03/01/24: Results Not Recorded  \n",
            "• Imaging:  \n",
            "  – Radiographs taken on 03/12/24: Results Not Recorded  \n",
            "• Other Tests: None documented  \n",
            "\n",
            "CURRENT MEDICATIONS AND TREATMENTS:  \n",
            "• As per client’s active listing (01/20/25 form):  \n",
            "  1) Bravecto (Orange tablet); dose (tablet size) not fully specified, administered orally once every 6 months. Start date: Not Recorded; no adverse reaction documented; effectiveness: Not Recorded.  \n",
            "  2) Sentinel Spectrum (8.75 mg); 1 tablet orally once monthly. Start date: Not Recorded; no adverse reaction documented; effectiveness: Not Recorded.  \n",
            "\n",
            "• All other previously prescribed medications (Theophylline, Doxycycline, Temaril-P, Chlorpheniramine, Panalog, ear cleaners) are historical/not currently reported by the owner as active.  \n",
            "\n",
            "[End of Initial Case Review Documentation]\n",
            "\n",
            "History Analysis:\n",
            "------------------------------\n",
            "COMPREHENSIVE TIMELINE\n",
            "\n",
            "1) INITIAL DISEASE ONSET  \n",
            "   • Exact Date of First Clinical Signs: Not recorded in medical records.  \n",
            "   • Precise Symptom Progression: Not documented prior to 03/01/24.  \n",
            "     – Earliest potential reference to respiratory/allergic issue could be inferred from the first prescription of Chlorpheniramine on 03/01/24, but no direct notation of coughing or respiratory distress is documented.  \n",
            "   • All Initial Diagnostic Findings: None specifically recorded as pertaining to the initial onset of clinical signs.  \n",
            "   • First Treatment Responses: No charted response to initial medication(s); no clinical improvement or deterioration noted in the record.  \n",
            "\n",
            "2) DISEASE PROGRESSION  \n",
            "   • 03/01/24:  \n",
            "     – Diagnostic Examination (P260): Content of findings not recorded.  \n",
            "     – Blood Parasite Test (4) (LI103): Results not recorded.  \n",
            "     – Chlorpheniramine 4 mg tablets (OM220) prescribed at 1 tablet PO twice daily (quantity 60). Start/end dates not specified. Rationale unlisted in the record; presumed for allergic or mild respiratory symptoms. Treatment response not documented.  \n",
            "   • 03/12/24:  \n",
            "     – Weight: 12.80 lb.  \n",
            "     – Radiographs (1-plane, 2-view) (R210): Results not recorded.  \n",
            "     – Doxycycline 50 mg/mL suspension (OM569) prescribed at 0.5 mL PO once daily (quantity 30). Start/end dates not specified; rationale not stated. Treatment response not documented.  \n",
            "   • 04/05/24:  \n",
            "     – Weight: 13.80 lb.  \n",
            "     – Vetalog injection (IM345) administered; rationale not specified. Response not recorded.  \n",
            "     – Ear cleansing solution (TM342) and Panalog ointment (TM270) prescribed for once-daily ear cleaning then ointment application. No follow-up data on clinical outcome recorded.  \n",
            "   • 04/16/24:  \n",
            "     – Weight: 13.80 lb.  \n",
            "     – Chlorpheniramine 4 mg refill (60 ct) at same dosing (1 tablet PO twice daily). No documented response or adverse effects.  \n",
            "   • 05/15/24:  \n",
            "     – Weight: 13.40 lb.  \n",
            "     – No new treatments; only nail trim performed. No mention of ongoing symptoms.  \n",
            "   • 09/06/24:  \n",
            "     – Bravecto 10–22 lb dispensed (1 dose).  \n",
            "     – Chlorpheniramine 4 mg tablets (60 ct) prescribed again; no documented rationale or symptom severity.  \n",
            "   • 10/16/24:  \n",
            "     – Weight: 13.10 lb.  \n",
            "     – Doxycycline 50 mg/mL suspension (OM569) 30 mL dispensed (0.5 mL PO BID).  \n",
            "     – Temaril-P tablets (OM509) 20 ct at ½ tablet PO BID.  \n",
            "       • Rationale likely for coughing/allergic signs, but not explicitly stated.  \n",
            "       • No recorded response or adverse effects.  \n",
            "   • 10/17/24:  \n",
            "     – Theophylline 400 mg ER (OM106) dispensed; 2 capsules. Internal record shows an instruction “1 mL of FlavorX-labeled formula twice a day,” indicating a possible conversion discrepancy. Prescribed presumably as a bronchodilator for respiratory complaints.  \n",
            "     – Treatment response not documented.  \n",
            "   • 11/26/24:  \n",
            "     – Medical progress exam (P290): No further details recorded.  \n",
            "   • 12/06/24:  \n",
            "     – Weight: 12.80 lb.  \n",
            "     – Sentinel Spectrum 8–25 lb and Bravecto 10–22 lb dispensed.  \n",
            "     – Wellness exam (P263) with no documented details.  \n",
            "   • 02/04/25 (Most Recent Visit):  \n",
            "     – Chief Complaint: Coughing (“coughing, hacking, panting loudly”) described as a “dry cough,” duration not recorded.  \n",
            "     – Weight: 6.1 kg (13.44 lb).  \n",
            "     – Physical exam parameters (temperature, heart rate, respiratory rate) not performed or not recorded.  \n",
            "     – No additional medication prescribed at this visit per provided data.  \n",
            "     – No diagnostic results or further treatments documented.  \n",
            "     – Behavioral change: Anxiety noted during coughing episodes. Appetite and eliminations unchanged.  \n",
            "\n",
            "3) COMPLETE TREATMENT HISTORY (CHRONOLOGICAL)\n",
            "\n",
            "   NOTE: All start/end dates reflect available record entries. Some prescriptions lack specific start/end documentation.\n",
            "\n",
            "   • Bravecto (Fluralaner) 10–22 lb oral tablet  \n",
            "     – First noted dispensation on 03/19/24; repeated 09/06/24 & 12/06/24; client currently reports ongoing use (01/20/25 form).  \n",
            "     – Dosing: 1 oral tablet once every 6 months (per owner’s current statement).  \n",
            "     – No recorded adverse reactions or documented effectiveness.  \n",
            "\n",
            "   • Sentinel Spectrum (8.75 mg milbemycin oxime, with praziquantel and lufenuron; size for 8–25 lb)  \n",
            "     – First noted dispensation on 03/01/24; repeated 12/06/24; client currently reports ongoing monthly use.  \n",
            "     – Dosing: 1 oral tablet once monthly.  \n",
            "     – No recorded adverse reactions or documented effectiveness.  \n",
            "\n",
            "   • Chlorpheniramine 4 mg tablets (OM220)  \n",
            "     – Prescribed 03/01/24 (60 ct) at 1 tablet PO BID.  \n",
            "     – Refilled 04/16/24 (60 ct) at same dose.  \n",
            "     – Prescribed again 09/06/24 (60 ct) at same dose.  \n",
            "     – No start/end dates documented for each refill; no recorded adverse reactions.  \n",
            "     – No clear efficacy data in the record.  \n",
            "\n",
            "   • Doxycycline 50 mg/mL suspension (OM569)  \n",
            "     – First prescribed on 03/12/24 at 0.5 mL PO once daily, quantity 30.  \n",
            "     – Again prescribed on 10/16/24 at 0.5 mL PO twice daily, 30 mL total.  \n",
            "     – No documented start/end dates or clinical response.  \n",
            "\n",
            "   • Temaril-P (Trimeprazine tartrate with prednisolone) tablets (OM509)  \n",
            "     – Prescribed on 10/16/24, 20 ct at ½ tablet PO BID.  \n",
            "     – Start/end dates not recorded; no documented efficacy or adverse event.  \n",
            "\n",
            "   • Theophylline 400 mg ER (OM106)  \n",
            "     – Prescribed on 10/17/24, 2 capsules dispensed.  \n",
            "     – Instruction entered as “1 mL of FlavorX-labeled formula PO BID,” indicating a liquid conversion.  \n",
            "     – No documented response or follow-up.  \n",
            "\n",
            "   • Vetalog injection (IM345)  \n",
            "     – Administered on 04/05/24.  \n",
            "     – Dose not specified, no documented response or adverse effects.  \n",
            "\n",
            "   • Ear Cleansing Solution (TM342)  \n",
            "     – Prescribed on 04/05/24, 1 bottle, “clean ear(s) once daily.”  \n",
            "     – Start/end dates not clarified; no recorded outcome.  \n",
            "\n",
            "   • Panalog Ointment (TM270)  \n",
            "     – Prescribed on 04/05/24, 1 tube, “clean ears once daily, then apply ointment.”  \n",
            "     – No documented follow-up regarding ear condition.  \n",
            "\n",
            "4) DIAGNOSTIC TESTING CHRONOLOGY  \n",
            "   • 03/01/24: Blood Parasite Test (4)  \n",
            "     – Results: Not recorded.  \n",
            "     – Reference Ranges: Not provided.  \n",
            "     – No interpretation documented.  \n",
            "\n",
            "   • 03/12/24: Radiographs (1-plane, 2-view)  \n",
            "     – Results: Not recorded.  \n",
            "     – Reference Ranges/Diagnostic Assessment: Not provided.  \n",
            "     – No documented follow-up or changes to treatment plan except Doxycycline initiation.  \n",
            "\n",
            "   • No additional recorded tests through 02/04/25.  \n",
            "\n",
            "PATTERN ANALYSIS\n",
            "\n",
            "1) DETAILED SYMPTOM PATTERNS  \n",
            "   • Frequency of Coughing Episodes: Not quantified; described recently (02/04/25) as “frequent dry cough,” “hacking,” “panting loudly.”  \n",
            "   • Severity Trends: Not objectively graded; anecdotally severe enough to prompt clinic visit.  \n",
            "   • Specific Triggers: Not documented.  \n",
            "   • Temporal Patterns: No recorded data on time of day, seasonal variation, or environmental conditions.  \n",
            "\n",
            "2) TREATMENT RESPONSE ANALYSIS  \n",
            "   • Duration of Response: No formal documentation of improvement or relapse following specific medications (chlorpheniramine, doxycycline, temaril-p, theophylline).  \n",
            "   • Degree of Improvement: No recorded percentages or veterinarian assessment notes.  \n",
            "   • Treatment Failures: Several medications (antibiotics, antihistamines, anti-inflammatories, bronchodilator) used without documented resolution or follow-up, suggesting incomplete data on success or failure.  \n",
            "   • Compliance Assessment:  \n",
            "     – Client states ongoing use of Bravecto and Sentinel Spectrum (as of 01/20/25).  \n",
            "     – Past medications not confirmed as continued or discontinued per veterinarian instructions.  \n",
            "\n",
            "3) RISK FACTOR EVALUATION  \n",
            "   • Identified Risk Factors:  \n",
            "     – Breed Predisposition: Pomeranians may be prone to tracheal issues (e.g., collapsing trachea), but no confirmed diagnosis in the records.  \n",
            "     – Environmental Influences: Not recorded.  \n",
            "     – Genetic Predispositions: Not documented.  \n",
            "     – Concurrent Conditions: No definitive comorbidities identified from the data provided.  \n",
            "\n",
            "ADDITIONAL CLIENT COMMUNICATIONS & INSTRUCTIONS  \n",
            "• Client, Anna Miracle (ID 24404F), provided updated medication list on 01/20/25, indicating Bravecto and Sentinel Spectrum remain active.  \n",
            "• No other client instructions (e.g., recheck frequency, home monitoring tips) are documented in these records.  \n",
            "• Rabies vaccine due 01/25/25 is marked overdue; presumably client informed but no confirmation of administration.  \n",
            "\n",
            "END OF ANALYSIS  \n",
            "\n",
            "Clinical Analysis:\n",
            "------------------------------\n",
            "CLINICAL ASSESSMENT:\n",
            "\n",
            "1. PRIMARY CLINICAL SIGNS ANALYSIS  \n",
            "   • Coughing / Respiratory Signs  \n",
            "     – Exact Duration: Not recorded for onset; first explicit mention on 02/04/25 (MM/DD/YY).  \n",
            "     – Specific Frequency: Unspecified; described as “frequent” on 02/04/25.  \n",
            "     – Severity Scale: Not documented; client subjectively reports “dry cough,” “panting loudly,” with evident distress, but no objective scale (1–10) recorded.  \n",
            "     – Pattern of Occurrence: No documented detail regarding time of day, environmental triggers, or seasonal influences.  \n",
            "     – Exacerbating/Alleviating Factors: None recorded.  \n",
            "     – Response to Interventions: No formal chart entries describing improvement or worsening with antihistamines (chlorpheniramine), antibiotics (doxycycline), anti-inflammatory/immunosuppressive (Temaril-P, Vetalog), or bronchodilator (theophylline).\n",
            "\n",
            "   • Possible Otic Discomfort (Ear Issues)  \n",
            "     – Duration: Unclear; ear treatments prescribed on 04/05/24 without prior note of onset.  \n",
            "     – Frequency: No data recorded after initial prescription.  \n",
            "     – Severity Scale: Not specified.  \n",
            "     – Pattern of Occurrence: Not noted.  \n",
            "     – Exacerbating/Alleviating Factors: Not documented.  \n",
            "     – Response to Interventions: Ear cleansing solution and Panalog ointment prescribed, but no follow-up exam findings reported.\n",
            "\n",
            "2. COMPREHENSIVE PHYSICAL EXAMINATION ANALYSIS  \n",
            "   a) Vital Signs Interpretation  \n",
            "     • Temperature: Not recorded at any visit; therefore, no comparison to normal canine range of 101.5 ± 1.0 °F.  \n",
            "     • Heart Rate: Not documented; no comparisons to normal ranges.  \n",
            "     • Respiratory Rate and Effort: Not objectively measured; coughing described on 02/04/25 but no formal respiratory rate or effort data.  \n",
            "     • Weight Trends (% change):  \n",
            "       – 03/12/24: 12.80 lb  \n",
            "       – 04/05/24: 13.80 lb (+7.81% from 03/12/24)  \n",
            "       – 04/16/24: 13.80 lb (no change since 04/05/24)  \n",
            "       – 05/15/24: 13.40 lb (−2.90% from 04/16/24)  \n",
            "       – 10/16/24: 13.10 lb (−2.24% from 05/15/24)  \n",
            "       – 12/06/24: 12.80 lb (−2.29% from 10/16/24)  \n",
            "       – 02/04/25: 6.1 kg (13.44 lb) (+5.00% from 12/06/24)  \n",
            "       Overall: Minor fluctuations; no severe documented cachexia or obesity.  \n",
            "     • Body Condition Score Changes: Not recorded at any visit.\n",
            "\n",
            "   b) Detailed System Analysis  \n",
            "     • Ears: Ear discharge or inflammation implied by prescribing ear cleansing solution and Panalog ointment on 04/05/24, but no formal exam findings (e.g., erythema, odor, exudate) documented. No follow-up data on resolution or persistence.  \n",
            "     • Respiratory: Cough reported 02/04/25 (described as “dry,” “hacking,” “panting loudly”). No formal lung auscultation results recorded.  \n",
            "     • Cardiovascular: No abnormal findings documented.  \n",
            "     • Musculoskeletal: Not mentioned.  \n",
            "     • Gastrointestinal: Normal appetite; no abnormal eliminations noted.  \n",
            "     • Neurologic: Anxiety during coughing episodes noted, but no other neurologic findings described.  \n",
            "     • Pain Assessment Scores: Not recorded.  \n",
            "     • Comparative Findings (Left vs. Right): Not available.  \n",
            "     • Sequential Examination Changes: No sequential clinical notes regarding improvement or worsening were entered.\n",
            "\n",
            "3. DIAGNOSTIC TESTING INTERPRETATION  \n",
            "   a) Laboratory Results  \n",
            "     • 03/01/24 Blood Parasite Test (4) (LI103):  \n",
            "       – Results: Unavailable (not recorded).  \n",
            "       – Reference Ranges: Not provided.  \n",
            "       – No documented interpretation or follow-up actions.  \n",
            "\n",
            "   b) Imaging Interpretation  \n",
            "     • 03/12/24 Radiographs (1-plane, 2-view) (R210):  \n",
            "       – Results: Not recorded.  \n",
            "       – No measurement of trachea, cardiac silhouette, or lung fields provided.  \n",
            "       – No official radiology report.  \n",
            "       – Clinical Significance: Unknown; Doxycycline started afterward, possibly indicating suspicion of an infectious or inflammatory process, but this is not explicitly stated.\n",
            "\n",
            "4. DISEASE PROCESS ANALYSIS  \n",
            "   • Detailed Pathophysiology:  \n",
            "     – Chronic or recurrent cough (onset presumed prior to 03/01/24 given chlorpheniramine prescription) possibly indicates allergic airway disease, mild respiratory infection, or anatomic abnormality (e.g., collapsing trachea). Definitive pathophysiologic mechanism unconfirmed.  \n",
            "     – Secondary Complications: Potential otic inflammation (04/05/24) may be unrelated or reflect generalized allergic tendencies.  \n",
            "     – Organ System Interactions: Potential overlap of respiratory and allergic conditions is suggested by prescriptions (antihistamines, antibiotics, steroids, bronchodilator). No confirmed organ failure or systemic disease from existing records.  \n",
            "     – Disease Stage with Criteria: Not clearly established due to incomplete diagnostic data.  \n",
            "     – Progression Indicators: Ongoing cough through 02/04/25, repeated medication use without documented resolution, mild weight fluctuations.\n",
            "\n",
            "5. TREATMENT RESPONSE EVALUATION  \n",
            "   For Each Medication:  \n",
            "   a) Chlorpheniramine 4 mg Tablets (OM220)  \n",
            "     – First prescribed 03/01/24 at 1 tablet PO BID; refilled 04/16/24 and 09/06/24, quantity 60 each time.  \n",
            "     – Time to Initial Response: Not documented.  \n",
            "     – Degree of Improvement: No recorded changes in cough severity or frequency.  \n",
            "     – Duration of Effect: Unknown; no follow-up notes.  \n",
            "     – Side Effects Observed: None recorded.  \n",
            "     – Factors Affecting Efficacy: Uncertain, no consistent recheck or notation of compliance.\n",
            "\n",
            "   b) Doxycycline 50 mg/mL Suspension (OM569)  \n",
            "     – 03/12/24: 0.5 mL PO once daily, quantity 30.  \n",
            "     – 10/16/24: 0.5 mL PO twice daily, 30 mL total.  \n",
            "     – Time to Initial Response: Not documented.  \n",
            "     – Degree of Improvement: Not assessed in records.  \n",
            "     – Duration of Effect: Not recorded.  \n",
            "     – Side Effects: None noted.  \n",
            "     – Factors Affecting Efficacy: Unknown compliance, no recheck diagnostics.\n",
            "\n",
            "   c) Temaril-P (Trimeprazine Tartrate with Prednisolone) Tablets (OM509)  \n",
            "     – 10/16/24: 20 tablets, ½ tablet PO BID.  \n",
            "     – Response, side effects, or duration of use not recorded.\n",
            "\n",
            "   d) Theophylline 400 mg ER (OM106)  \n",
            "     – Prescribed 10/17/24: 2 capsules dispensed, with instructions indicating possible conversion to a 1 mL FlavorX suspension PO BID.  \n",
            "     – No documented therapeutic response, adverse events, or follow-up testing.\n",
            "\n",
            "   e) Vetalog Injection (IM345)  \n",
            "     – Administered 04/05/24; dose and response not recorded. Presumably an anti-inflammatory injection but no official rationale or recheck.\n",
            "\n",
            "   f) Ear Cleansing Solution (TM342) and Panalog Ointment (TM270)  \n",
            "     – Both prescribed 04/05/24 for daily ear cleaning and ointment application.  \n",
            "     – Start/end times and effectiveness unmentioned in subsequent records.\n",
            "\n",
            "   g) Bravecto (Fluralaner)  \n",
            "     – 10–22 lb dose dispensed on 03/19/24 (per internal note), 09/06/24, 12/06/24; one tablet Q6mo per client.  \n",
            "     – No adverse reactions or documented ectoparasite findings reported.\n",
            "\n",
            "   h) Sentinel Spectrum (Milbemycin Oxime + Praziquantel + Lufenuron)  \n",
            "     – 8–25 lb dose first noted 03/01/24, repeated 12/06/24, used monthly per client.  \n",
            "     – No official documentation regarding prophylactic effectiveness or side effects.\n",
            "\n",
            "   • Overall Observations:  \n",
            "     – None of the treatments have recorded efficacy confirmations or side effect logs. Long-term management results remain unclear.\n",
            "\n",
            "CLINICAL INTEGRATION:\n",
            "\n",
            "1. EVIDENCE SYNTHESIS  \n",
            "   • Supporting Findings for Each Diagnosis:  \n",
            "     – Chronic cough/airway disease: Repeated prescriptions for antimicrobial (doxycycline), anti-inflammatory (steroid), bronchodilator (theophylline), antihistamines (chlorpheniramine), and multi-action agent (Temaril-P) suggest persistent airway or allergic pathology.  \n",
            "     – Otic inflammation: Ear cleansing solution and Panalog ointment indicate prior otic involvement.  \n",
            "\n",
            "   • Strength of Evidence Assessment:  \n",
            "     – Incomplete objective data: Lacking physical exam parameters (temperature, heart rate, respiratory rate), unrecorded radiographic interpretations, missing blood parasite test results, and no additional advanced diagnostics hamper definitive conclusions.  \n",
            "\n",
            "   • Clinical Trial Relevance:  \n",
            "     – Without confirmed etiology (e.g., allergic bronchitis, collapsing trachea, infectious cause), it is unclear if any established clinical trial protocols (e.g., for chronic bronchitis) are relevant.  \n",
            "\n",
            "   • Population-Specific Factors:  \n",
            "     – Toy breed (potential Pomeranian heritage) predisposition to tracheal collapse.  \n",
            "     – No documented comorbidities or recognized environmental allergens.\n",
            "\n",
            "2. CONTRADICTORY FINDINGS  \n",
            "   • Alternative Explanations:  \n",
            "     – Unremarkable or incomplete data leads to broad differential diagnoses (infection, allergic disease, structural airway anomaly). Radiographs, if normal, were never confirmed.  \n",
            "     – Ear conditions could be separate or part of systemic allergic patterns but unproven.  \n",
            "\n",
            "   • Rule-Out Justifications:  \n",
            "     – Cardiogenic cough not ruled in or out due to lack of cardiac exam notes or imaging interpretation.  \n",
            "     – Infectious etiologies only partially addressed by doxycycline with unknown compliance and no recheck.  \n",
            "     – No definitive test to confirm typical “allergic” or “collapsing trachea” pathology.  \n",
            "\n",
            "   • Confounding Factors:  \n",
            "     – Missing reference ranges and final test results; uncertain medication compliance or dosing accuracy.  \n",
            "     – Rationale for repeated antibiotic or steroid usage not clearly linked to documented diagnostic findings.  \n",
            "\n",
            "   • Testing Limitations:  \n",
            "     – No additional imaging or advanced airway examination (e.g., bronchoscopy) documented.  \n",
            "     – Incomplete record of ongoing physical exam parameters and lab work-ups.  \n",
            "\n",
            "ADDITIONAL CLIENT COMMUNICATIONS & INSTRUCTIONS  \n",
            "• Owner: Anna Miracle (ID 24404F) provided an updated medication list on 01/20/25, confirming continued Bravecto every six months and Sentinel Spectrum monthly.  \n",
            "• Rabies vaccine due 01/25/25; no note of administration.  \n",
            "• No further instructions regarding rechecks, home monitoring, or additional diagnostics recorded.  \n",
            "\n",
            "[END OF DOCUMENTATION]\n",
            "\n",
            "Diagnostic Assessment:\n",
            "------------------------------\n",
            "PROBLEM LIST:\n",
            "\n",
            "1. ACTIVE PROBLEMS (PRIORITIZED):\n",
            "\n",
            "   1A) Chronic Cough / Respiratory Distress  \n",
            "       • Duration with Exact Onset Date: Earliest verifiable mention on 02/04/25, though medications suggest onset prior to 03/01/24 (no precise onset date recorded).  \n",
            "       • Severity Score (1–10): Not formally assessed; client-reported “dry” and “frequent” cough with “panting loudly.” Subjectively moderate distress, but exact score is unrecorded.  \n",
            "       • Progression Pattern: Appears chronic and persistent; no documented complete resolution. Medications (antibiotics, antihistamines, steroids, bronchodilator) have been used repeatedly, indicating ongoing or recurrent signs.  \n",
            "       • Related Clinical Findings: Panting, anxiety, no documented auscultation or respiratory rate measurement. Radiographs taken on 03/12/24 (no formal interpretation on file).  \n",
            "       • Impact on Quality of Life: Client-reported distress noted; extent of functional limitation not fully outlined.  \n",
            "       • Current Treatment Status: Multiple therapies attempted (chlorpheniramine, doxycycline, Temaril-P, theophylline) without documented efficacy assessments or final outcome.\n",
            "\n",
            "   1B) Possible Otic Inflammation / Discomfort  \n",
            "       • Duration with Exact Onset Date: Ear treatment first prescribed on 04/05/24; no preceding onset data.  \n",
            "       • Severity Score (1–10): Not recorded.  \n",
            "       • Progression Pattern: Unknown; no follow-up or repeated ear examinations documented.  \n",
            "       • Related Clinical Findings: Prescribed ear cleansing solution (TM342) and Panalog (TM270) on 04/05/24, suggesting canal discharge or inflammation, but no formal otoscopic findings noted.  \n",
            "       • Impact on Quality of Life: Not explicitly documented; possible discomfort or irritation assumed given prescription.  \n",
            "       • Current Treatment Status: No recent notes after 04/05/24; presumed unresolved or unassessed due to lack of follow-up data.\n",
            "\n",
            "2. INACTIVE/RESOLVED PROBLEMS:  \n",
            "   • None definitively documented as resolved or inactive.  \n",
            "   • No clear resolution date or cessation of clinical signs for otic or respiratory issues is recorded in the medical record.\n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "\n",
            "DIFFERENTIAL DIAGNOSES:\n",
            "\n",
            "1. PRIMARY DIFFERENTIAL LIST:\n",
            "\n",
            "   A) Chronic Bronchitis / Allergic Airway Disease  \n",
            "      • Supporting Evidence: Ongoing cough for many months, use of steroids (Temaril-P), antihistamines (chlorpheniramine), and partial response to unknown extent. Possibly allergic otitis (ear inflammation) indicating an atopic or allergic component.  \n",
            "      • Contradicting Evidence: None definitively; lack of objective improvement or formal diagnostic confirmation is the main limitation.  \n",
            "      • Diagnostic Criteria Met/Unmet: Clinical suspicion is raised, but no bronchoscopy, airway cytology, or repeat thoracic imaging interpretation provided to meet definitive criteria.  \n",
            "      • Population Prevalence: Chronic bronchitis/allergy is common in middle-aged to older small-breed dogs.  \n",
            "      • Age/Breed Predisposition: Possible Pomeranian or small-breed predisposition to both chronic bronchitis and concurrent otitis from atopic disease.  \n",
            "      • Required Diagnostics: Repeat thoracic radiographs (3-view), complete blood count (CBC), serum chemistry panel, airway wash (BAL/TTW) if feasible, fecal analysis to rule out parasites that may cause cough, and in-depth otic examination (cytology, culture).\n",
            "\n",
            "   B) Tracheal Collapse  \n",
            "      • Supporting Evidence: Small breed, “dry honking” or hacking cough. Bronchodilator (theophylline) trial was considered, indicating suspicion.  \n",
            "      • Contradicting Evidence: No specific imaging interpretations or dynamic tracheal studies documented to confirm or refute.  \n",
            "      • Diagnostic Criteria Met/Unmet: Unmet; requires imaging (fluoroscopy or endoscopy) or radiographs in inspiratory and expiratory phases with detailed interpretation.  \n",
            "      • Population Prevalence: Common in toy breeds, especially around middle age.  \n",
            "      • Age/Breed Predisposition: High in small-breed dogs (e.g., Pomeranian, Yorkie).  \n",
            "      • Required Diagnostics: Lateral and DV/VD thoracic radiographs at inspiration/expiration, fluoroscopic evaluation if available, possible endoscopic exam of the airway.\n",
            "\n",
            "   C) Infectious Tracheobronchitis (e.g., Bordetella or Mycoplasma)  \n",
            "      • Supporting Evidence: Doxycycline used twice (03/12/24 and 10/16/24), suggesting suspicion of bacterial or atypical infection.  \n",
            "      • Contradicting Evidence: No documentation of definitive pathogen testing or consistent compliance. Cough is persistent despite antibiotic trials.  \n",
            "      • Diagnostic Criteria Met/Unmet: Unmet; no specific culture, PCR testing, or consistent follow-up.  \n",
            "      • Population Prevalence: Variable, depends on exposure risk (e.g., grooming, boarding).  \n",
            "      • Age/Breed Predisposition: Not specifically breed-linked, any age can be affected.  \n",
            "      • Required Diagnostics: Airway PCR/culture (respiratory panel), repeat thoracic radiographs, response-to-therapy monitoring.\n",
            "\n",
            "   D) Chronic Otitis Externa (Allergic or Infectious)  \n",
            "      • Supporting Evidence: Ear medications prescribed on 04/05/24. Potential tie to an atopy if respiratory signs also allergic.  \n",
            "      • Contradicting Evidence: Poorly documented ear exams, no cytology or culture results. Possibly resolved but never confirmed.  \n",
            "      • Diagnostic Criteria Met/Unmet: Unmet; no post-treatment evaluation or cytologic exam.  \n",
            "      • Population Prevalence: Common in dogs with underlying allergies or repeated moisture in ear canals.  \n",
            "      • Age/Breed Predisposition: Small/toy breeds often prone to atopic dermatitis, which can include otic lesions.  \n",
            "      • Required Diagnostics: Comprehensive otoscopic exam, ear cytology, possible culture/sensitivity if signs persist or worsen.\n",
            "\n",
            "2. SECONDARY DIFFERENTIAL LIST:\n",
            "\n",
            "   A) Cardiogenic Cough (e.g., Mitral Valve Disease)  \n",
            "      • Reason for Lower Priority: No documented murmur, no cardiovascular findings on exam notes, no mention of exercise intolerance specifically related to heart disease.  \n",
            "      • Required Rule-Out Criteria: Cardiac auscultation, echocardiography, validated radiographic evaluation of cardiac silhouette.  \n",
            "      • Testing Recommendations: Thoracic radiographs (with systematic cardiac size assessment), possible echocardiogram, NT-proBNP blood test.\n",
            "\n",
            "   B) Nasopharyngeal or Upper Airway Foreign Body  \n",
            "      • Reason for Lower Priority: Chronicity of signs and partial responses to anti-inflammatory medications make a persistent foreign body less likely.  \n",
            "      • Required Rule-Out Criteria: Thorough oropharyngeal exam, possibly rhinoscopic evaluation if indicated.  \n",
            "      • Testing Recommendations: Sedated oropharyngeal exam, endoscopy if suspicion remains.\n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "\n",
            "DIAGNOSTIC PLAN:\n",
            "\n",
            "1. IMMEDIATE DIAGNOSTICS:\n",
            "\n",
            "   A) Repeat Thoracic Radiographs (3-view)  \n",
            "      • Specific Justification: Essential to evaluate tracheal diameter, pulmonary pattern, cardiac silhouette, and any chronic changes. Previous 03/12/24 radiographs lack official interpretation.  \n",
            "      • Expected Findings: Potential tracheal narrowing, bronchial markings consistent with bronchitis, or normal images requiring further airway assessment.  \n",
            "      • Result Interpretation Criteria: Comparison to normal canine thoracic standards; measurement of tracheal lumen, identification of alveolar or bronchial patterns, assessment of heart size (vertebral heart score).  \n",
            "      • Cost-Benefit Assessment: Moderate cost, high diagnostic yield for confirming or ruling out structural anomalies or advanced cardiopulmonary disease.  \n",
            "      • Sample Handling Requirements: Standard digital or film radiography technique, sedation if needed for patient comfort/stillness.  \n",
            "      • Timing Considerations: Perform as soon as possible to guide treatment updates.\n",
            "\n",
            "   B) Complete Blood Count (CBC) and Serum Biochemistry Panel  \n",
            "      • Specific Justification: Assess for infection, inflammation, organ function before adjusting medications.  \n",
            "      • Expected Findings: May show eosinophilia (allergic), leukocytosis (infection/inflammation), or be unremarkable.  \n",
            "      • Result Interpretation Criteria: Evaluate RBC, WBC, and platelet counts against standard reference ranges (laboratory-specific); check liver/kidney values given steroid and antibiotic use.  \n",
            "      • Cost-Benefit Assessment: Relatively inexpensive, crucial baseline data for safe continued therapy.  \n",
            "      • Sample Handling Requirements: EDTA tube for CBC, serum separator for chemistry; avoid hemolysis.  \n",
            "      • Timing Considerations: Collect at time of next visit or concurrently with radiographs.\n",
            "\n",
            "   C) Otic Cytology  \n",
            "      • Specific Justification: Determine presence of yeast, bacteria, or inflammatory cells in the ear canal.  \n",
            "      • Expected Findings: Cocci, rods, or yeast if infection; excessive neutrophils for acute inflammation or mononuclear cells for chronic changes.  \n",
            "      • Result Interpretation Criteria: Compare with reference images and typical thresholds for infection (e.g., >2+ organisms/HPF).  \n",
            "      • Cost-Benefit Assessment: Minimal cost, immediate result, guides targeted ear therapy.  \n",
            "      • Sample Handling Requirements: Gentle swab from external ear canal; Diff-Quick stain or similar.  \n",
            "      • Timing Considerations: During the next clinic visit for ear evaluation.\n",
            "\n",
            "2. MONITORING DIAGNOSTICS:\n",
            "\n",
            "   A) Weight Trend and Body Condition Score (BCS)  \n",
            "      • Frequency of Measurement: At every visit (every 4–6 weeks if active issue persists).  \n",
            "      • Alert Thresholds: >5% weight loss or gain triggers nutritional assessment.  \n",
            "      • Trend Analysis Criteria: Evaluate for chronic weight loss, possible muscle wasting.  \n",
            "      • Action Triggers: Unintentional weight loss ≥5% requires dietary or medical review; excessive BCS changes prompt diet adjustment.\n",
            "\n",
            "   B) Respiratory Rate and Effort Logs  \n",
            "      • Frequency of Measurement: At least weekly by owner, daily if cough worsens.  \n",
            "      • Alert Thresholds: Resting respiratory rate consistently >40 breaths/min or severe coughing episodes.  \n",
            "      • Trend Analysis Criteria: Increase in baseline cough frequency or distress.  \n",
            "      • Action Triggers: Escalation of therapy or urgent recheck if cough worsens or new respiratory distress arises.\n",
            "\n",
            "   C) Ear Discharge / Otic Inflammation Check  \n",
            "      • Frequency of Measurement: Owner to examine external ear canal daily for discharge or odor.  \n",
            "      • Alert Thresholds: Recurrence of redness, odor, or discharge.  \n",
            "      • Trend Analysis Criteria: Return of symptoms indicates unresolved infection or allergy flare.  \n",
            "      • Action Triggers: Repeat cytology or antibiotic/steroid therapy modification.\n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "\n",
            "THERAPEUTIC PLAN:\n",
            "\n",
            "1. IMMEDIATE INTERVENTIONS:\n",
            "\n",
            "   A) Verify Compliance and Current Use of Existing Medications  \n",
            "      • Medications Involved:  \n",
            "         1) Chlorpheniramine 4 mg tablets (Dose: 1 tablet PO BID)  \n",
            "         2) Doxycycline 50 mg/mL suspension (Dose per latest prescription: 0.5 mL PO BID)  \n",
            "         3) Temaril-P tablets (Trimeprazine tartrate + Prednisolone) (Dose: ½ tablet PO BID)  \n",
            "         4) Theophylline 400 mg ER capsules (Dispensed 10/17/24: instructions to convert to 1 mL suspension PO BID if needed)  \n",
            "         5) Ear Cleansing Solution (daily) and Panalog Ointment (daily application)  \n",
            "      • Exact Dose Calculation: Reassess current weight at 6.1 kg (13.44 lb) to confirm mg/kg dosing for each medication.  \n",
            "      • Administration Details: Oral (PO) for systemic medications, topical for ears.  \n",
            "      • Monitoring Requirements: Track cough frequency, appetite, and stool consistency.  \n",
            "      • Expected Response Timeline: Within 1–2 weeks if therapy aligns with cause; if no improvement, reevaluation is needed.  \n",
            "      • Adverse Effect Monitoring: GI upset (doxycycline), sedation (chlorpheniramine), polyuria/polydipsia or steroid side effects (Temaril-P), tachycardia or excitability (theophylline).\n",
            "\n",
            "2. LONG-TERM MANAGEMENT:\n",
            "\n",
            "   A) Specific Outcome Goals  \n",
            "      • Reduction or resolution of coughing episodes to <2–3 times/day or as close to baseline normal.  \n",
            "      • Maintenance of normal ear canal health without discharge or redness.  \n",
            "      • Maintenance of stable weight at ~6.1 kg (13.44 lb), with BCS 4–5/9 (if this is the normal range for this patient).\n",
            "\n",
            "   B) Timeline for Reassessment  \n",
            "      • Recheck in approximately 2–3 weeks (by 02/25/25 or 03/04/25) to assess response to any modifications in medication and to perform recommended diagnostics.  \n",
            "      • Subsequent evaluations every 1–2 months if cough persists or if ear signs recur.\n",
            "\n",
            "   C) Quality of Life Parameters  \n",
            "      • Activity level, exercise tolerance, absence of respiratory distress, normal appetite, comfortable ear canals.  \n",
            "      • Minimal stress or anxiety associated with coughing episodes.\n",
            "\n",
            "   D) Client Education Points  \n",
            "      • Importance of compliance with medication regimens, including chlorpheniramine, doxycycline, and any steroid or bronchodilator instructions.  \n",
            "      • Instruction on daily ear examinations for discharge or odor, proper ear cleaning technique (if still recommended).  \n",
            "      • Recording cough frequency and any patterns (time of day, triggers) to facilitate ongoing monitoring.\n",
            "\n",
            "   E) Environmental Modifications  \n",
            "      • Minimize inhaled irritants (e.g., smoke, strong fragrances).  \n",
            "      • Control potential allergens if suspected (dust, pollen, use of air purifier).\n",
            "\n",
            "   F) Dietary Recommendations  \n",
            "      • Maintain balanced diet appropriate for a 6.1 kg dog.  \n",
            "      • Consider weight control formula if BCS is above ideal, or increased-calorie if below.  \n",
            "      • Encourage consistent feeding routine to detect appetite changes.\n",
            "\n",
            "   G) Criteria for Success/Failure and Timeline for Modifications  \n",
            "      • Success Criteria: Coughing noticeably decreased, stable respiratory rate at rest (<30 breaths/min), no new ear exudate.  \n",
            "      • Failure Criteria: Persistent or worsening cough after 2–3 weeks, new or worsened otic discharge, or significant weight changes (>5% loss or gain).  \n",
            "      • Modification Timeline: If no improvement by next recheck (02/25/25–03/04/25), adjust medication regimen, proceed with advanced diagnostics (bronchoscopy, echocardiography if indicated).\n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "\n",
            "ADDITIONAL CLIENT COMMUNICATION & INSTRUCTIONS:\n",
            "\n",
            "• Owner: Anna Miracle (ID 24404F).  \n",
            "• She reports continued use of Bravecto (Fluralaner) 10–22 lb dose every six (6) months (last dispensed 12/06/24) and Sentinel Spectrum (Milbemycin Oxime + Praziquantel + Lufenuron) 8–25 lb dose monthly (most recently documented on 12/06/24).  \n",
            "• Rabies vaccination was due on 01/25/25; client must be reminded to schedule vaccination immediately.  \n",
            "• No written instructions regarding further rechecks or advanced diagnostics in the record; owner should be provided a detailed plan for follow-up diagnostic and therapeutic steps.  \n",
            "• Client advised to keep a daily log of cough episodes, appetite, activity, and any ear discharge, and to bring these logs to the next visit.  \n",
            "\n",
            "────────────────────────────────────────────────────────────────────────────\n",
            "[END OF COMPREHENSIVE DIAGNOSTIC ASSESSMENT]\n",
            "\n",
            "Specialist Summary:\n",
            "------------------------------\n",
            "SPECIALIST CONSULTATION:\n",
            "\n",
            "1. CASE SUMMARY  \n",
            "   • Chronological History:  \n",
            "     – Earliest verifiable mention of chronic cough and respiratory distress on 02/04/25, although previous medication records suggest an onset prior to 03/01/24.  \n",
            "     – Ear inflammation or otic discomfort first addressed on 04/05/24 with topical therapies (ear cleansing solution [TM342], Panalog [TM270]).  \n",
            "     – Medications used intermittently since at least 03/01/24 without clear documentation of efficacy or formal resolution.  \n",
            "\n",
            "   • Prior Treatments and Responses:  \n",
            "     – Chlorpheniramine 4 mg tablets (01 tablet PO BID; no formal documentation of clinical response).  \n",
            "     – Doxycycline 50 mg/mL suspension (0.5 mL PO BID; used on at least two occasions [03/12/24 and 10/16/24]; response not clearly recorded).  \n",
            "     – Temaril-P tablets (½ tablet PO BID; unknown degree of improvement or side effects).  \n",
            "     – Theophylline 400 mg ER capsules (dispensed on 10/17/24; no documented outcome).  \n",
            "     – Topical ear treatments: Ear Cleansing Solution (once daily), Panalog Ointment (once daily) starting 04/05/24; no otoscopic follow-up noted.  \n",
            "\n",
            "   • Every Diagnostic Result:  \n",
            "     – Thoracic radiographs performed 03/12/24 without formal radiologist interpretation in the record.  \n",
            "     – No CBC, serum chemistry, or otic cytology results documented in the available notes.  \n",
            "\n",
            "   • Specific Clinical Progression:  \n",
            "     – The cough remains chronic and unrelenting (reported as “dry,” “frequent,” with “panting loudly”).  \n",
            "     – Otic discomfort was noted with enough severity to warrant topical therapy, but no documented final resolution or recheck.  \n",
            "\n",
            "   • Current Status Assessment:  \n",
            "     – Persistent coughing with uncertain severity (client implies moderate respiratory distress).  \n",
            "     – Ear inflammation possibly ongoing; no recent reassessment since 04/05/24.  \n",
            "     – No documented resolution or clear improvement to date.  \n",
            "\n",
            "2. DISEASE PROCESS ANALYSIS  \n",
            "   • Detailed Pathophysiology (Primary Differentials):  \n",
            "     – Chronic Bronchitis / Allergic Airway Disease: Long-standing cough, partial or uncertain response to antihistamines and steroids, potential atopic link (allergic otitis).  \n",
            "     – Tracheal Collapse: Classic toy-breed predisposition, “honking” cough described by owner, though objective imaging data are lacking.  \n",
            "     – Infectious Tracheobronchitis: Despite doxycycline trials, no confirmatory testing or consistent follow-up.  \n",
            "     – Chronic Otitis Externa: Likely allergic or infectious etiology; incomplete evaluation and follow-up.  \n",
            "\n",
            "   • Current Disease Stage:  \n",
            "     – Respiratory pathology appears chronic and persistent, not acutely decompensated but has not been fully characterized by objective diagnostics.  \n",
            "     – Otic inflammation may be chronic or recurrent with no recorded end point.  \n",
            "\n",
            "   • Progression Factors:  \n",
            "     – Possible ongoing allergen exposure, incomplete or inconsistent therapeutic measures, and absence of thorough diagnostic information.  \n",
            "     – Repeated or prolonged steroid use without comprehensive monitoring could mask underlying disease or contribute to side effects.  \n",
            "\n",
            "   • Complicating Conditions:  \n",
            "     – Lack of formal auscultation findings or cardiac evaluation leaves open possibilities of cardiac cough or concurrent disease.  \n",
            "     – Potential ear canal changes (stenosis, chronic inflammation) if otitis has not been resolved.  \n",
            "\n",
            "   • Prognosis Assessment with Criteria:  \n",
            "     – Favorable for chronic bronchitis or mild tracheal collapse if controlled with lifelong management.  \n",
            "     – Fair to guarded if underlying complications (e.g., severe airway collapse, advanced allergic disease) are present and remain unaddressed.  \n",
            "     – Prognosis improves with definitive diagnostics (imaging, airway cytology, otic exams) and targeted therapy.  \n",
            "\n",
            "3. TREATMENT ANALYSIS  \n",
            "   • Response to Previous Treatments:  \n",
            "     – No clearly documented improvement with chlorpheniramine, doxycycline, or Temaril-P. Unknown compliance and exact dosing accuracy.  \n",
            "     – Theophylline usage remains unassessed.  \n",
            "     – Otic treatment with ear cleansing solution and Panalog had no documented follow-up to confirm resolution.  \n",
            "\n",
            "   • Current Treatment Efficacy:  \n",
            "     – Observational data only; no objective scoring or recheck to gauge success or failure.  \n",
            "\n",
            "   • Treatment Complications:  \n",
            "     – Potential steroid side effects (polyuria, polydipsia, iatrogenic Cushing’s) unreported but should be monitored.  \n",
            "     – Possible antibiotic resistance if incomplete or inconsistent use of doxycycline.  \n",
            "\n",
            "   • Compliance Assessment:  \n",
            "     – Unclear whether instructions and dosing intervals have been strictly followed for each medication.  \n",
            "     – Client’s daily logs (including cough frequency, ear checks) have not been mentioned or submitted.  \n",
            "\n",
            "   • Risk-Benefit Analysis:  \n",
            "     – Continuing empirical medication without diagnostic clarity risks perpetuating unaddressed causes and potential adverse effects.  \n",
            "     – A structured approach with diagnostics and evidence-based therapies could clarify etiology and reduce unnecessary medication exposure.  \n",
            "\n",
            "4. SPECIALIST RECOMMENDATIONS  \n",
            "   4A) Recommendation 1: Updated Diagnostics for Respiratory Disease  \n",
            "        • Intervention: Obtain 3-view thoracic radiographs (inspiratory/expiratory if possible), complete blood count (CBC), serum chemistry, and airway wash (BAL or TTW) if indicated by radiographic findings.  \n",
            "        • Rationale: Determine structural integrity of the trachea/bronchi, evaluate for bronchial or alveolar patterns, assess for infection or inflammation. Clarify baseline organ function.  \n",
            "        • Expected Outcome: More precise understanding of airway pathology, guiding targeted medical or surgical therapy.  \n",
            "        • Monitoring Parameters: Radiographic comparison to normal references (e.g., vertebral heart score), WBC count abnormalities on CBC.  \n",
            "        • Alternative Options: If airway wash is not feasible, advanced imaging (fluoroscopy or CT) or referral for bronchoscopy.  \n",
            "\n",
            "   4B) Recommendation 2: Comprehensive Otic Evaluation  \n",
            "        • Intervention: Perform otic cytology at next visit, possibly a deep otoscopic exam under sedation to assess tympanic membrane and canal.  \n",
            "        • Rationale: Diagnose or rule out persistent infection (bacterial, yeast), chronic inflammatory changes, or foreign material.  \n",
            "        • Expected Outcome: Targeted therapy if ongoing otitis externa is present.  \n",
            "        • Monitoring Parameters: Cytology results (organism load, inflammatory cells), clinical improvement of ear discharge or odor.  \n",
            "        • Alternative Options: If severe disease is found, advanced imaging (CT, MRI) or referral to a dermatology specialist.  \n",
            "\n",
            "   4C) Recommendation 3: Compliance Verification and Potential Adjustment of Current Medications  \n",
            "        • Intervention: Review client’s administration method and adherence to previously prescribed medications (chlorpheniramine, doxycycline, Temaril-P, theophylline, ear solutions).  \n",
            "        • Rationale: Inconsistent dosing may explain suboptimal or absent clinical response.  \n",
            "        • Expected Outcome: Optimized or discontinued therapies depending on diagnostic results, side effects, and actual efficacy.  \n",
            "        • Monitoring Parameters: Daily cough logs, weight checks, possible WBC differentials for infection.  \n",
            "        • Alternative Options: Consider inhaled bronchodilators or inhaled steroids if allergic airway disease is confirmed and systemic side effects are a concern.  \n",
            "\n",
            "   4D) Recommendation 4: Rule out Cardiac Etiologies  \n",
            "        • Intervention: Auscultation for murmurs, repeat thoracic radiographs with heart size assessment, possible echocardiogram if indicated.  \n",
            "        • Rationale: Cardiogenic cough remains a differential in small breeds, especially if murmur or cardiomegaly is detected.  \n",
            "        • Expected Outcome: Confirm or exclude valvular disease; helps refine respiratory vs. cardiac management.  \n",
            "        • Monitoring Parameters: Radiographic cardiac silhouette (vertebral heart score), heart rate, echocardiographic findings.  \n",
            "        • Alternative Options: NT-proBNP blood test if echocardiography is not immediately accessible.  \n",
            "\n",
            "COMPREHENSIVE PLAN:\n",
            "\n",
            "1. MEDICAL MANAGEMENT  \n",
            "   (All medications below require confirmation of patient’s current weight at 6.1 kg [13.44 lb] and precise mg/kg dosing.)\n",
            "\n",
            "   A) Chlorpheniramine (4 mg tablets)  \n",
            "      • Exact Dose Calculation: 1 tablet (4 mg) PO every 12 hours → ~0.66 mg/kg per dose if the dog is truly 6.1 kg.  \n",
            "      • Administration Protocol: Administer with or without food. Continue for 2 weeks pending diagnostic outcomes.  \n",
            "      • Monitoring Requirements: Watch for sedation or anticholinergic effects; track cough frequency.  \n",
            "      • Duration of Therapy: Reassess after 02/25/25—03/04/25 visit or once diagnostics clarify necessity.  \n",
            "      • Success Criteria: Reduction in cough frequency, no adverse sedation.  \n",
            "      • Modification Triggers: Excessive drowsiness or no change in cough after 14 days.\n",
            "\n",
            "   B) Doxycycline (50 mg/mL suspension)  \n",
            "      • Exact Dose Calculation: Currently 0.5 mL (25 mg) PO every 12 hours → ~4.1 mg/kg per dose if the dog is 6.1 kg.  \n",
            "      • Administration Protocol: Administer with a small meal or treat to reduce GI upset.  \n",
            "      • Monitoring Requirements: GI signs (vomiting, diarrhea), correct dosing interval (every 12 hours).  \n",
            "      • Duration of Therapy: 10–14 days, or as directed pending airway culture results if performed.  \n",
            "      • Success Criteria: Improvement in clinical signs if bacterial or atypical infection is present.  \n",
            "      • Modification Triggers: Lack of improvement after a full course (14 days) or if culture confirms resistant organisms.\n",
            "\n",
            "   C) Temaril-P (Trimeprazine Tartrate + Prednisolone)  \n",
            "      • Exact Dose Calculation: ½ tablet PO every 12 hours → total prednisolone content ~1.5 mg per half-tablet (confirm product specifics for mg/kg).  \n",
            "      • Administration Protocol: Give with food to reduce GI irritation; monitor for polyuria and polydipsia.  \n",
            "      • Monitoring Requirements: Watch for side effects (increased thirst, hunger, urination), check weight and BCS.  \n",
            "      • Duration of Therapy: May be tapered depending on response and underlying diagnosis; re-evaluate at recheck by 02/25/25–03/04/25.  \n",
            "      • Success Criteria: Reduced cough frequency and intensity.  \n",
            "      • Modification Triggers: Adverse steroid effects, definitive diagnosis suggesting alternative therapy.\n",
            "\n",
            "   D) Theophylline (400 mg ER capsules)  \n",
            "      • Exact Dose Calculation: If 400 mg is split into a compounded suspension at 400 mg/5 mL, for example, then 1 mL PO every 12 hours would provide 80 mg (~13 mg/kg per dose for a 6.1 kg dog). Exact concentration must be verified.  \n",
            "      • Administration Protocol: Administer separate from fluoroquinolones or other drug interactions; consistent timing if used.  \n",
            "      • Monitoring Requirements: Heart rate (tachycardia), CNS stimulation (tremors, restlessness).  \n",
            "      • Duration of Therapy: Evaluate after 2 weeks; discontinue or adjust if no observable benefit or if side effects occur.  \n",
            "      • Success Criteria: Decreased cough if bronchospasm or airway hyper-reactivity is a factor.  \n",
            "      • Modification Triggers: Tachycardia, arrhythmias, or insufficient clinical improvement.\n",
            "\n",
            "   E) Ear Cleansing Solution (TM342) and Panalog (TM270) Ointment  \n",
            "      • Exact Dose Calculation: Topical—apply solution once daily to external ear canal, follow with thin layer of Panalog ointment once daily.  \n",
            "      • Administration Protocol: Gently clean prior to ointment application; avoid aggression if tympanic membrane integrity is uncertain.  \n",
            "      • Monitoring Requirements: Daily check for discharge, odor, redness by owner.  \n",
            "      • Duration of Therapy: Continue until recheck otic exam can confirm resolution.  \n",
            "      • Success Criteria: Resolved inflammation, no discharge on cytology.  \n",
            "      • Modification Triggers: Persistent signs, pain on manipulation, or cytology findings indicating resistant infection.\n",
            "\n",
            "2. MONITORING PROTOCOL  \n",
            "   A) Respiratory Rate and Cough Frequency  \n",
            "      • Measurement Frequency: Owner logs daily cough episodes; check resting respiratory rate once daily.  \n",
            "      • Specific Target Values: Resting rate <30 breaths/min; cough <1–2 episodes per day if disease is controlled.  \n",
            "      • Acceptable Ranges: ≤3 daily episodes of brief coughing, no severe respiratory distress.  \n",
            "      • Action Thresholds: Sustained increase in cough (>3 episodes/day) or respiratory rate >40 breaths/min at rest.  \n",
            "      • Response Protocols: Contact clinic promptly for medication adjustments or urgent recheck.\n",
            "\n",
            "   B) Otic Status  \n",
            "      • Measurement Frequency: Brief daily external ear inspection by owner for discharge, odor, redness.  \n",
            "      • Specific Target Values: Clean, odor-free canal, no erythema.  \n",
            "      • Acceptable Ranges: Mild wax accumulation without inflammation.  \n",
            "      • Action Thresholds: Notable re-accumulation of debris, foul odor, pain on handling.  \n",
            "      • Response Protocols: Immediate recheck cytology; consider antibiotic or antifungal therapy changes if indicated.\n",
            "\n",
            "   C) Body Weight and BCS  \n",
            "      • Measurement Frequency: At every visit or every 4–6 weeks if more frequent visits are indicated.  \n",
            "      • Specific Target Values: Maintain ~6.1 kg, BCS ideally 4–5/9.  \n",
            "      • Acceptable Ranges: ±5% weight variation.  \n",
            "      • Action Thresholds: >5% unintentional weight change.  \n",
            "      • Response Protocols: Investigate for medication side effects, appetite changes, or underlying metabolic disease.\n",
            "\n",
            "3. CLIENT EDUCATION  \n",
            "   • Disease Process Explanation:  \n",
            "     – Chronic airway disease in dogs can result from allergies (chronic bronchitis) or structural issues (tracheal collapse). Otitis externa may be part of an underlying atopic condition.  \n",
            "   • Treatment Rationale:  \n",
            "     – Symptomatic relief (steroids, antihistamines, bronchodilators) is combined with diagnostic efforts to identify and address the underlying cause.  \n",
            "   • Administration Instructions:  \n",
            "     – Demonstrate correct ear cleaning technique. Emphasize accurate oral dosing intervals and the importance of finishing antibiotic courses.  \n",
            "   • Monitoring Requirements:  \n",
            "     – Daily log of cough frequency, breathing patterns, and any ear discharge.  \n",
            "   • Warning Signs:  \n",
            "     – Excessive panting, open-mouth breathing, lethargy, vomiting, diarrhea, or ear pain warrant immediate veterinary contact.  \n",
            "   • Emergency Protocols:  \n",
            "     – If respiratory distress worsens significantly (gasping, cyanosis) or ear pain is severe (scratching, head shaking), seek emergency veterinary care immediately.\n",
            "\n",
            "4. FOLLOW-UP SCHEDULE  \n",
            "   • Specific Recheck Dates:  \n",
            "     – Schedule diagnostics and physical re-evaluation by 02/25/25 or 03/04/25 (within 2–3 weeks).  \n",
            "   • Testing Schedule:  \n",
            "     – Thoracic radiographs, CBC, serum chemistry, otic cytology at next visit (02/25/25–03/04/25).  \n",
            "     – Additional tests (airway wash, echocardiography) if indicated by initial results.  \n",
            "   • Progress Assessment Criteria:  \n",
            "     – Decrease in cough episodes, improved ear health on exam.  \n",
            "     – Stable body weight and normal activity level by next visit.  \n",
            "   • Long-Term Monitoring Plan:  \n",
            "     – If chronic bronchitis or tracheal collapse is confirmed, plan periodic radiographs and possible medication adjustments every 3–6 months.  \n",
            "     – Regular otic monitoring to prevent recurrence of infection.  \n",
            "   • Quality of Life Assessment:  \n",
            "     – Evaluate comfort level, activity, willingness to exercise, and appetite at each follow-up.  \n",
            "\n",
            "ADDITIONAL NOTES AND CLIENT INSTRUCTIONS:  \n",
            "• Client Name: Anna Miracle (ID 24404F).  \n",
            "• Preventive Medications:  \n",
            "  – Bravecto (Fluralaner) 10–22 lb dose every 6 months (last given 12/06/24).  \n",
            "  – Sentinel Spectrum (Milbemycin Oxime + Praziquantel + Lufenuron) 8–25 lb dose monthly (last recorded 12/06/24).  \n",
            "• Vaccinations: Rabies vaccine overdue since 01/25/25; instruct client to schedule immediately.  \n",
            "• Owner to maintain a daily log of cough frequency, appetite, activity, and ear status. Bring logs to next appointment.  \n",
            "• Stress the importance of following dosing instructions exactly, completing antibiotic courses, and returning for diagnostic tests on or before 02/25/25–03/04/25 to guide further therapy.\n",
            "\n",
            "Connections Analysis:\n",
            "------------------------------\n",
            "CASE SYNTHESIS:\n",
            "\n",
            "1. Disease Interactions\n",
            "\n",
            "   • Primary–Secondary Disease Relationships:\n",
            "     – Chronic Respiratory Signs as Primary Concern: The patient, Jax Miracle (canine, Pomeranian, male castrated, 4 years old), has a persistent cough described as “dry coughing, hacking, and panting loudly.” While first explicitly documented on 02/04/25, repeated prescriptions of doxycycline, antihistamines, steroids, and bronchodilators since at least 03/01/24 suggest a long-standing airway or allergic condition.  \n",
            "     – Possible Allergic Component or Secondary Infection: Historical otic inflammation (requiring Panalog ointment and cleansing solution) could reflect an atopic/allergic process. Concurrent ear problems often indicate broader allergic tendencies that may also affect the respiratory tract.  \n",
            "     – Potential Breed Predisposition to Tracheal Collapse: Pomeranians may be prone to collapsing trachea, which frequently presents as a chronic “honking” cough. Radiographs taken on 03/12/24 lacked documented interpretations and may have been performed to investigate structural airway problems.  \n",
            "\n",
            "   • Complicating Factors:\n",
            "     – Incomplete Diagnostic Data: The 03/01/24 blood parasite test (4Dx) and 03/12/24 radiographs have no recorded results. There is no thorough record of auscultation, ECG, or advanced airway diagnostics.  \n",
            "     – Concurrent Otic Disease: Ear inflammation was addressed on 04/05/24 (ear cleansing solution, Panalog), but no follow-up exam is recorded; untreated or unresolved otitis may cause discomfort and stress, potentially exacerbating overall inflammation or allergic disease.  \n",
            "     – Age-Related and Breed Factors: At 4 years old (DOB documented as 12/20/20; alternate references 10/01/20 or 10/01/21 in prior records), Jax is a young adult but belongs to a toy breed with known predispositions to airway problems.  \n",
            "     – Environmental Influences: No documentation of living conditions (other than the owner’s address) or allergen exposures is present.  \n",
            "\n",
            "   • Synergistic Effects:\n",
            "     – Disease Interactions: If allergic airway disease is unaddressed, ongoing otic issues may persist or recur. Respiratory inflammation can be heightened by subclinical ear infections or generalized atopic flare-ups.  \n",
            "     – Treatment Interactions: Repeated antibiotic (doxycycline) and steroid (Temaril-P, Vetalog) use without detailed follow-up could mask or partially suppress signs, making clinical interpretation difficult.  \n",
            "     – Cumulative Impacts: Chronic cough and possible chronic otitis reduce quality of life, cause anxiety (noted by the owner), and risk medication side effects (e.g., steroid complications, antibiotic resistance).  \n",
            "     – Quality of Life Effects: The dog exhibits anxiety with coughing episodes. No direct measure of QOL is recorded, but persistent coughing and panting can significantly affect daily comfort and behavior.\n",
            "\n",
            "2. Treatment Integration\n",
            "\n",
            "   • Drug Interactions:\n",
            "     – Theophylline (400 mg ER) and Steroids (Temaril-P): Potentially additive side effects, such as increased cardiac workload or GI irritation. Close monitoring of heart rate and adverse events is recommended when combining bronchodilators and corticosteroids.  \n",
            "     – Antihistamine (Chlorpheniramine) and Steroids: Minimal direct contraindications, but sedation from antihistamines and polyuria/polydipsia from steroids can compound owner compliance challenges.  \n",
            "     – Antibiotic (Doxycycline) Usage: Must ensure completion of full course and verify that no additional interacting medications (e.g., certain antacids) are given concurrently.  \n",
            "\n",
            "   • Therapeutic Conflicts:\n",
            "     – Competing Treatment Needs: An ongoing cough may require anti-inflammatory or bronchodilator therapy, but if infection or parasites were involved (not yet confirmed on incomplete diagnostics), targeted antimicrobials or parasiticides would be needed.  \n",
            "     – Priority Assessment: Confirming the etiology of the cough (structural vs. inflammatory vs. infectious) is paramount before continuing empirical treatments indefinitely.  \n",
            "     – Resolution Strategies: Updated thoracic radiographs, CBC, and otic cytology can clarify the exact cause(s) and guide more targeted management.  \n",
            "     – Risk Mitigation: Monitoring for steroid side effects (increased thirst, hunger, urination) and theophylline toxicity (tachycardia, tremors) is critical.  \n",
            "\n",
            "   • Management Synergies:\n",
            "     – Complementary Treatments: If allergic airway disease is confirmed, combining inhaled bronchodilators or inhaled steroids with allergen avoidance can reduce systemic drug side effects. Ear cytology and targeted therapy may resolve otitis more definitively.  \n",
            "     – Timing Optimization: Staggering medication administration for theophylline (to avoid interactions with certain antibiotics) and giving steroids with food can reduce GI adverse effects.  \n",
            "     – Efficiency Improvements: A thorough recheck with imaging and lab work on a single scheduled visit (e.g., by 02/25/25 or 03/04/25) can streamline planning.  \n",
            "     – Outcome Enhancement: An evidence-based approach—where diagnosis precedes or refines therapy—will likely improve cough control and reduce repeated prescribing without measurable results.\n",
            "\n",
            "3. Risk Assessment\n",
            "\n",
            "   • Current Risk Factors:\n",
            "     – Disease-Specific Risks: Chronic cough of unknown origin presents risk of airway damage, persistent inflammation, or complications if structural collapse is unaddressed.  \n",
            "     – Treatment-Related Risks: Prolonged steroid use can lead to hyperadrenocorticism; antibiotics without culture can lead to resistance; theophylline can cause cardiovascular or CNS side effects if overdosed.  \n",
            "     – Environmental Risks: Unknown exposures (allergens, irritants), especially relevant if the cough is allergic or if there is a smoke or dust environment.  \n",
            "     – Client-Specific Factors: Owner compliance might be complicated by multiple medications and unrecorded instructions. Rabies vaccine is overdue as of 01/25/25, posing a legal and public health concern.\n",
            "\n",
            "   • Potential Complications:\n",
            "     – Early Warning Signs: Increased cough frequency, labored breathing, new ear discharge, sedation, GI upset.  \n",
            "     – Prevention Strategies: Prompt recheck with diagnostics, strict medication adherence, potential environment clean-up or allergen reduction measures.  \n",
            "     – Monitoring Protocols: Weekly (or daily) cough logs, ear examinations by owner, weight checks, and regular vet visits for re-evaluation.  \n",
            "     – Intervention Triggers: Any escalation of respiratory distress, severe ear pain or discharge, or medication side effects should prompt immediate veterinary follow-up.\n",
            "\n",
            "────────────────────────────────────────────────────\n",
            "\n",
            "INTEGRATED CARE PLAN:\n",
            "\n",
            "1. Comprehensive Treatment Strategy\n",
            "\n",
            "   • Prioritized Interventions:\n",
            "     1) Update Diagnostics: Obtain 3-view thoracic radiographs (sedated if necessary), CBC, and serum chemistry to clarify the airway condition and overall health. Perform otic cytology to assess persistent infection or inflammation. Target date: by 02/25/25 or 03/04/25.  \n",
            "     2) Verify Medication Compliance: Confirm the client’s administration of current/historical scripts (especially doxycycline and theophylline dosing details).  \n",
            "     3) Address Overdue Rabies Vaccine: Remind owner that Jax’s rabies vaccination (due 01/25/25) must be updated promptly for legal and health reasons.  \n",
            "     4) Assess Need for Taper or Adjustment: Depending on new diagnostic findings, consider tapering or discontinuing unnecessary antibiotics/steroids if no active infection or allergic flare is confirmed.  \n",
            "\n",
            "   • Short-Term Goals (next 2–3 weeks):\n",
            "     – Reduce cough episodes to a manageable frequency (<3 episodes/day if possible).  \n",
            "     – Clarify primary etiology (infection, inflammatory, structural) using radiographs and labs.  \n",
            "     – Ensure ear health is stable or improved with daily cleaning (if recommended) and correct Panalog usage.  \n",
            "\n",
            "   • Long-Term Objectives (beyond 1 month):\n",
            "     – Achieve consistent respiratory comfort (sporadic or no coughing).  \n",
            "     – Maintain normal ear canals without chronic inflammation.  \n",
            "     – Establish a sustainable medication protocol—potentially inhaled steroids or bronchodilators if structural or allergic origins are identified.  \n",
            "\n",
            "   • Success Criteria:\n",
            "     – Documented radiographic or clinical improvement of airway patency.  \n",
            "     – Normal ear cytology or minimal inflammatory cells on recheck.  \n",
            "     – Stable body weight (~6.1 kg) and comfortable daily activity level.\n",
            "\n",
            "   • Team Responsibilities:\n",
            "     – Veterinarian: Lead diagnostics, interpret results, adjust medication plan, ensure vaccine compliance.  \n",
            "     – Technician/Assistant: Perform radiographs, assist with ear cytologies, provide medication administration demos.  \n",
            "     – Client (Anna Miracle, ID 24404F): Administer medications as directed, monitor cough frequency, ear status, weight changes, and schedule timely rechecks.  \n",
            "     – Reception/Billing: Notify client of diagnostic cost estimates, schedule recheck by 02/25/25 or 03/04/25, update contact preferences (client also listed secondary phone (502) 706-0428).\n",
            "\n",
            "2. Long-Term Management\n",
            "\n",
            "   • Disease Trajectory:\n",
            "     – Expected Progression: If allergic or inflammatory airway disease is confirmed, Jax may require lifelong intermittent therapy. Collapsing trachea may also be chronic and progressive, needing ongoing management.  \n",
            "     – Monitoring Points: Periodic thoracic imaging (every 6–12 months or if clinical signs worsen), yearly CBC/chemistry, and routine otic evaluations if signs recur.  \n",
            "     – Intervention Triggers: Significant increase in cough intensity or frequency, changes in ear discharge, or major side effects from medications.  \n",
            "     – Outcome Measures: Reduction in daily coughing, normal energy level, healthy ear canals, stable or normal appetite and weight.\n",
            "\n",
            "   • Quality of Life:\n",
            "     – Assessment Criteria: Observable anxiety reduction, comfortable breathing, normal playful behavior, no avoidance or distress from ear handling.  \n",
            "     – Monitoring Protocol: Encourage the owner to keep a simple diary of daily respiratory observations and ear checks, noting any sedation, GI upset, or steroid side effects.  \n",
            "     – Improvement Strategies: Potential shift to inhaled medications if indicated, environmental modifications (air filtration, avoidance of smoke/perfumes).  \n",
            "     – Client Assessment Tools: Provide a 1–10 cough severity scale, daily log template for the owner to fill out before each recheck.\n",
            "\n",
            "3. Support Systems\n",
            "\n",
            "   • Client Education:\n",
            "     – Understanding Assessment: Explain suspected causes (allergic airway disease or tracheal collapse) and how these can overlap with otic problems.  \n",
            "     – Training Needs: Demonstrate ear cleaning technique if indicated, proper oral medication administration, and how to monitor for side effects.  \n",
            "     – Resource Requirements: Provide referrals if advanced diagnostics (fluoroscopy, bronchoscopy, echocardiography) or specialty dermatology/respiratory consults become necessary.  \n",
            "     – Support Services: Offer telemedicine check-ins or phone consultations if the client observes new or escalating symptoms prior to the scheduled recheck.\n",
            "\n",
            "   • Compliance Strategy:\n",
            "     – Barriers Assessment: Multiple medications, possible sedation side effects, and no documented instructions for theophylline compounding may confuse the owner.  \n",
            "     – Solution Implementation: Provide clear, written dosing plans for each medication, including exact mg or mL per dose, intervals (every 12 or 24 hours), and start/end dates.  \n",
            "     – Monitoring Methods: Request weekly email or phone updates if coughing worsens; instruct daily ear inspection.  \n",
            "     – Success Measures: Return visits show improved respiratory status, normal ear canals, and consistent follow-through with recommended testing and vaccination.\n",
            "\n",
            "────────────────────────────────────────────────────\n",
            "\n",
            "\n",
            "\n"
          ]
        }
      ],
      "source": [
        "    file_path = \"./input.pdf\"\n",
        "    result = analyze_veterinary_case(file_path)\n",
        "\n",
        "    print(\"\\nAnalysis Results:\")\n",
        "    print(\"-\" * 50)\n",
        "\n",
        "    sections = [\n",
        "        (\"Data Processing\", \"DataProcessor\"),\n",
        "        (\"History Analysis\", \"HistoryAnalyzer\"),\n",
        "        (\"Clinical Analysis\", \"ClinicalAnalyzer\"),\n",
        "        (\"Diagnostic Assessment\", \"Diagnostics\"),\n",
        "        (\"Specialist Summary\", \"SpecialistSummary\"),\n",
        "        (\"Connections Analysis\", \"Connections\")\n",
        "    ]\n",
        "\n",
        "    for title, key in sections:\n",
        "        print(f\"\\n{title}:\")\n",
        "        print(\"-\" * 30)\n",
        "        print(result[\"results\"].get(key, \"Not available\"))\n",
        "\n",
        "    if \"errors\" in result[\"results\"]:\n",
        "        print(\"\\nErrors encountered:\")\n",
        "        for error in result[\"results\"][\"errors\"]:\n",
        "            print(f\"- {error['message']} (at {error['timestamp']}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 7,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "3JtuR6wZa9iy",
        "outputId": "d80156a3-9f70-4ff7-c76b-7b7fc68474c8"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Processing document(s)...\n",
            "Image file ./IMG_5188.jpeg processed - metadata stored\n",
            "Image file ./IMG_5604.jpeg processed - metadata stored\n",
            "Successfully created and stored embedding for document\n",
            "Successfully created and stored embedding for document\n",
            "Successfully created and stored embedding for document\n",
            "Successfully created and stored embedding for document\n",
            "Successfully created and stored embedding for document\n",
            "Successfully created and stored embedding for document\n",
            "Successfully created and stored embedding for document\n",
            "Image file THX - Right Lat.jpeg processed - metadata stored\n",
            "Creating workflow for 12 file(s)...\n",
            "Running analysis...\n",
            "\n",
            "Analysis Results:\n",
            "--------------------------------------------------\n",
            "\n",
            "Data Processing:\n",
            "------------------------------\n",
            "PATIENT SIGNALMENT & CLIENT INFORMATION:\n",
            "• Patient ID #: CA25440F  \n",
            "• Name: Spencer Johnson  \n",
            "• Species: Canine  \n",
            "• Breed: Chihuahua Mix  \n",
            "• Age: 10.5 years (DOB: 03/19/14)  \n",
            "• Sex: Male Castrated (MC)  \n",
            "• Weight: 5.6 kg on 01/27/25; 5.67 kg on 01/28/25  \n",
            "• Client: Carl Johnson (Client ID #25427F)  \n",
            "  – Address #1: 11400 Willow Pond Dr, Louisville, KY 40291, USA  \n",
            "  – Address #2: 359 Lentz Ln, Mt Washington, KY 40047, USA  \n",
            "  – Phone: (502) 428-5015  \n",
            "  – Email: mrjefferson.cj@gmail.com (also listed as mrjefferson.cv@gmail.com in some records)  \n",
            "• Insurance Status: Not Recorded  \n",
            "• Billing Preferences: Not Recorded  \n",
            "\n",
            "• ALL CURRENT MEDICATIONS (as of last documented visit on 01/28/25):  \n",
            "  1) Enalapril 2.5 mg: 1 tablet once daily by mouth (SID PO) (administered at 07:15 on 01/27/25 per prior report; status of continuation from referral not fully clarified here, presumed ongoing unless otherwise stated by client)  \n",
            "  2) Vetmedin (pimobendan) 2.5 mg: ½ tablet twice daily by mouth (BID PO) (gave at 07:15 on 01/27/25 per prior report; status of continuation from referral not fully clarified, presumed ongoing unless otherwise stated by client)  \n",
            "  3) Furosemide 20 mg: 1 tablet twice daily by mouth (BID PO) (gave at 07:15 on 01/27/25 per prior report; status of continuation from referral not fully clarified, presumed ongoing unless otherwise stated by client)  \n",
            "  4) Trazodone 50 mg: ½ tablet as needed by mouth (PRN PO)  \n",
            "  5) Joint supplement: every other day by mouth (product unspecified)  \n",
            "  6) Credelio prevention: used March through October (seasonal)  \n",
            "  7) Doxycycline 100 mg tablets: give ½ tablet (50 mg) once daily by mouth (SID PO) with food (initiated 01/27/25 PM; next dose due 01/28/25 at 7 PM)  \n",
            "  8) Prednisone 10 mg tablets: give 1 tablet (10 mg) once daily by mouth (SID PO) with food (started 01/27/25; do not run out; next dose due 01/28/25)  \n",
            "  9) Atopica (cyclosporine) 25 mg capsules: give 1 capsule (25 mg) twice daily by mouth (BID PO) with food (initiated 01/27/25 PM or 01/28/25 AM per instructions; do not run out)  \n",
            "  10) Clopidogrel (Plavix) 75 mg tablets: give ¼ tablet (~18.75 mg) once daily by mouth (SID PO) (started 01/27/25 PM; do not run out; next dose due 01/28/25 at 7 PM)  \n",
            "\n",
            "• Route and Frequency Summary (current immunosuppressive protocol and adjunct treatments):  \n",
            "  – Doxycycline 50 mg PO SID  \n",
            "  – Prednisone 10 mg PO SID  \n",
            "  – Cyclosporine 25 mg PO BID  \n",
            "  – Clopidogrel 18.75 mg PO SID  \n",
            "\n",
            "• Additional Instructions from the Specialty Service (01/28/25):  \n",
            "  – Written prescription for sildenafil 10 mg PO TID (to use if persistent or recurrent syncopal episodes occur, per echocardiogram findings).  \n",
            "  – Recommended diet: Hill’s i/d Low Fat, 1⅓ cans per day.  \n",
            "\n",
            "────────────────────────────────────────────────────────────\n",
            "PRESENTING COMPLAINT AND HISTORY:\n",
            "\n",
            "CHIEF COMPLAINT (01/27/25 and referral details):\n",
            "• Patient referred from Johnsen Veterinary Services (Mt Washington) for collapsing (syncopal) episodes.  \n",
            "• Collapsing episodes first noted 01/23/25 (Thursday), then two more on 01/25/25 (Saturday).  \n",
            "• Spencer remained lethargic and had increased respiratory effort after the Saturday episodes.  \n",
            "• No episodes on Sunday (01/26/25), but patient remained lethargic, vomited once after eating boiled chicken, and became uninterested in kibble or treats.  \n",
            "• Another fainting episode occurred on Monday morning (01/27/25) around 08:27, lasting a few minutes; Spencer remained abnormal afterward.  \n",
            "• Chronic, non-productive hacking cough reported for the past few months; owners have not heard the cough since 01/23/25.  \n",
            "• Drinking water well, no diarrhea, no additional vomiting other than the one episode after chicken.  \n",
            "\n",
            "Duration of Symptoms:\n",
            "• Collapsing episodes first reported 4 days prior to referral (01/23/25).  \n",
            "• Additional episodes on 01/25/25.  \n",
            "• Lethargy and inappetence (particularly 01/25/25 to 01/26/25).  \n",
            "• Another collapse on 01/27/25 at approximately 08:27.  \n",
            "\n",
            "Progression Timeline with Specific Dates:\n",
            "• 01/23/25: First collapse noted.  \n",
            "• 01/25/25 AM: Two more collapse events; patient never fully regained normal behavior post-episodes.  \n",
            "• 01/26/25: No collapse; but persistent lethargy and some vomiting.  \n",
            "• 01/27/25 at 08:27: Another collapse, leading to urgent referral that same day.  \n",
            "\n",
            "Behavior/General Changes:\n",
            "• Lethargy, decreased appetite since 01/25/25.  \n",
            "• Reduced interest in treats since 01/26/25.  \n",
            "\n",
            "Appetite/Drinking/Elimination Changes:\n",
            "• Uninterested in regular dry kibble for >24 hours before 01/27/25 visit.  \n",
            "• Vomited once after eating boiled chicken on 01/26/25.  \n",
            "• Drinking water normally, no diarrhea reported.  \n",
            "\n",
            "PAST MEDICAL HISTORY:\n",
            "• Per referral records (Johnsen Veterinary Services, dates not fully specified in detail):  \n",
            "  – Bloodwork, thoracic radiographs, and an EKG performed on or about 01/25/25.  \n",
            "  – Long-standing mild cough for several months.  \n",
            "• This patient has no reported microchip in older local records (reaffirmed 01/27/25).  \n",
            "• Past Surgeries/Procedures: Not Recorded.  \n",
            "• Full chronological details: Not Provided by referring veterinarian, no older records appended.  \n",
            "• Vaccinations/Preventive Care: Credelio March–October each year. No other specifics available; dates Not Recorded.  \n",
            "• Diet History: Purina Pro Plan dry kibble. Also given boiled chicken occasionally.  \n",
            "\n",
            "────────────────────────────────────────────────────────────\n",
            "PHYSICAL EXAMINATION:\n",
            "\n",
            "(Note: Several examinations by urgent care from 01/27/25 through 01/28/25 are combined below. Any changes are noted by date/time.)\n",
            "\n",
            "Vital Signs (all times 24-hour unless noted):\n",
            "• 01/27/25 at 10:50:  \n",
            "  – Temperature: 100.1 °F  \n",
            "  – Heart Rate (Pulse): 168 beats/min  \n",
            "  – Respiratory Rate: 40 breaths/min  \n",
            "  – Weight: 5.6 kg  \n",
            "  – Body Condition Score (BCS): 5/9 (recorded as “normal ambulation, BCS 5/9”)  \n",
            "  – Mucous Membranes vs. Capillary Refill Time: Pale/white at 10:50, CRT not separately recorded  \n",
            "  – Pain Score: Not recorded  \n",
            "\n",
            "• 01/28/25 at 09:25–09:28:  \n",
            "  – Temperature: 100.9 °F  \n",
            "  – Heart Rate (Pulse): 160 beats/min  \n",
            "  – Respiratory Rate: 50 breaths/min  \n",
            "  – Weight: 5.67 kg  \n",
            "  – Body Condition Score (BCS): 5/9  \n",
            "  – Mucous Membranes: Pink on 01/28/25, mild residual icterus.  \n",
            "  – Capillary Refill Time: Not explicitly measured in seconds, clinically <2s normal.  \n",
            "  – Pain Score: Not recorded  \n",
            "\n",
            "System-by-System Examination:\n",
            "\n",
            "• EENT:  \n",
            "  – 01/27/25: Menace present OU, pupils midrange/symmetric, moist pale/white mucous membranes, mild icterus noted.  \n",
            "  – 01/28/25: Menace present OU, pupils midrange/symmetric, moist pink mucous membranes, mild residual icterus.  \n",
            "\n",
            "• Oral/Dental:  \n",
            "  – 01/27/25 & 01/28/25: Oral cavity generally clear; dentition age-appropriate, no acute abnormalities.  \n",
            "\n",
            "• Cardiovascular:  \n",
            "  – 01/27/25: Grade 4/6 left-sided apical systolic murmur, no arrhythmias. Pulse rate 168 bpm.  \n",
            "  – 01/28/25: Grade 2/6 left-sided murmur, no arrhythmias. Pulse rate 160 bpm.  \n",
            "\n",
            "• Respiratory:  \n",
            "  – 01/27/25 & 01/28/25: Normal bronchovesicular sounds; no wheezes or crackles. Historical cough (not heard in clinic).  \n",
            "\n",
            "• Gastrointestinal (including oral exam):  \n",
            "  – 01/27/25: Abdomen soft, non-painful, mild inappetence reported.  \n",
            "  – 01/28/25: Abdomen soft, non-painful, appetite is somewhat improved (owner reports patient ate canned chicken).  \n",
            "\n",
            "• Musculoskeletal:  \n",
            "  – 01/27/25 & 01/28/25: Normal ambulation, no apparent pain on manipulation. BCS 5/9.  \n",
            "\n",
            "• Neurologic:  \n",
            "  – 01/27/25 & 01/28/25: Grossly normal; complete neuro exam not performed.  \n",
            "\n",
            "• Integumentary (Skin/Coat):  \n",
            "  – 01/27/25: Mild icterus apparent. Suspected papilloma on dorsal left hindlimb paw.  \n",
            "  – 01/28/25: Mild icterus persists. Papilloma remains unchanged.  \n",
            "\n",
            "• Lymphatic:  \n",
            "  – 01/27/25 & 01/28/25: Peripheral lymph nodes palpably normal.  \n",
            "\n",
            "• Urogenital:  \n",
            "  – 01/27/25: Normal external genitalia, no specific abnormalities recorded.  \n",
            "  – 01/28/25: Not specifically abnormal.  \n",
            "\n",
            "• Rectal:  \n",
            "  – 01/27/25: Soft stool noted.  \n",
            "  – 01/28/25: Not performed.  \n",
            "\n",
            "────────────────────────────────────────────────────────────\n",
            "DIAGNOSTIC FINDINGS:\n",
            "\n",
            "LABORATORY RESULTS (in chronological order):\n",
            "\n",
            "1) 01/27/25 – In-House CBC/Chemistry/Lytes (IDEXX)  \n",
            "   • Hematology (Reference Ranges in parentheses):  \n",
            "     – RBC: 1.55 M/µL (5.65–8.87) ↓  \n",
            "     – HCT: 12.2% (37.3–61.7) ↓  \n",
            "     – HGB: 3.2 g/dL (13.1–20.5) ↓  \n",
            "     – MCV: 78.7 fL (61.6–73.5) ↑  \n",
            "     – MCH: 20.6 pg (21.2–25.9) ↓  \n",
            "     – MCHC: 26.2 g/dL (32.0–37.9) ↓  \n",
            "     – RDW: 32.8% (13.6–21.7) ↑  \n",
            "     – Reticulocyte %: 35.6% (no reference range provided; extremely elevated)  \n",
            "     – Reticulocytes (absolute): 552.1 K/µL (10.0–110.0) ↑  \n",
            "     – WBC: 41.74 K/µL (5.05–16.76) ↑  \n",
            "       • Neutrophils: 23.87 K/µL (2.95–11.64) ↑  \n",
            "       • Lymphocytes: 12.83 K/µL (1.05–5.10) ↑  \n",
            "       • Monocytes: 4.71 K/µL (0.16–1.12) ↑  \n",
            "       • Eosinophils: 0.29 K/µL (0.06–1.23) (normal)  \n",
            "       • Basophils: 0.04 K/µL (0.00–0.10) (normal)  \n",
            "     – Platelets: 213 K/µL (148–484) (normal) with MPV: 20.4 fL (8.7–13.2) ↑  \n",
            "     – Interpretation: Marked, regenerative anemia with reticulocytosis; marked leukocytosis (neutrophilia, lymphocytosis, monocytosis); likely inflammatory response plus immune-mediated RBC destruction.  \n",
            "\n",
            "   • Chemistry (Reference Ranges in parentheses):  \n",
            "     – Glucose: 144 mg/dL (70–143) Slightly ↑  \n",
            "     – BUN: 39 mg/dL (7–27) ↑  \n",
            "     – Creatinine: 0.9 mg/dL (0.5–1.8) Normal  \n",
            "     – Phosphorus: 5.0 mg/dL (2.5–6.8) Normal  \n",
            "     – Calcium: 8.6 mg/dL (7.9–12.0) Normal  \n",
            "     – Sodium: 151 mmol/L (144–160) Normal  \n",
            "     – Potassium: 3.3 mmol/L (3.5–5.8) ↓  \n",
            "     – Chloride: 109 mmol/L (109–122) Lower end of normal  \n",
            "     – ALP: 382 U/L (23–212) ↑  \n",
            "     – ALT: 62 U/L (10–125) Normal  \n",
            "     – GGT: 5 U/L (0–11) Normal  \n",
            "     – Total Bilirubin: 1.9 mg/dL (0.0–0.9) ↑  \n",
            "     – Cholesterol: 233 mg/dL (110–320) Normal  \n",
            "     – Albumin: 3.2 g/dL (2.2–3.9) Normal  \n",
            "     – Globulin: 4.2 g/dL (2.5–4.5) Normal  \n",
            "     – Total Protein: 7.4 g/dL (5.2–8.2) Normal  \n",
            "\n",
            "2) 01/27/25 – Peripheral Blood Smear (Zoetis Diagnostics Review)  \n",
            "   – Marked macrocytic, hypochromic, regenerative anemia.  \n",
            "   – Rare spherocytes (0–1/100× field), mild RBC associations (possible rouleaux vs autoagglutination).  \n",
            "   – Mild to moderate toxic band neutrophils, leukocytosis consistent with inflammation or immune-mediated process.  \n",
            "   – No hemoparasites identified.  \n",
            "   – Conclusion: Consistent with immune-mediated hemolysis (IMHA) vs other causes of RBC destruction; confirm with direct Coombs’ test, tick-borne panel, imaging, etc.  \n",
            "\n",
            "3) 01/27/25 – Canine Tick-Borne PCR Panel (Antech, Accession #CHBE67275409, reported 01/30/25):  \n",
            "   – Anaplasma phagocytophilum: Negative  \n",
            "   – Anaplasma platys: Negative  \n",
            "   – Babesia canis: Negative  \n",
            "   – Babesia speciation (non-canis): Negative  \n",
            "   – Bartonella henselae: Negative  \n",
            "   – Bartonella vinsonii: Negative  \n",
            "   – Ehrlichia canis: Negative  \n",
            "   – Ehrlichia spp. (non-canis): Negative  \n",
            "   – Mycoplasma haemocanis/haematoparvum: Negative  \n",
            "   – Neorickettsia risticii: Negative  \n",
            "   – Rickettsia rickettsii: Negative  \n",
            "\n",
            "4) 01/27/25 – Lyme Titer IgG  \n",
            "   – Negative (<1:64 = normal); no serologic evidence of Borrelia burgdorferi exposure.  \n",
            "\n",
            "5) 01/27/25 – Direct Coombs’ Test (Warm/37 °C)  \n",
            "   – Positive at 1:8 (reference: Negative).  \n",
            "   – Interpretation: Indicates increased antibodies/complement on RBC surface, supporting a diagnosis of Immune-Mediated Hemolytic Anemia.  \n",
            "\n",
            "6) 01/27/25 – In-House PCV/TS (repeated checks):  \n",
            "   – 01/27/25 at 13:45: PCV 15%, TS 8.0 g/dL  \n",
            "   – 01/27/25 at 20:55: PCV 30%, TS 6.2 g/dL (post-transfusion)  \n",
            "\n",
            "7) 01/28/25 – PCV/TS  \n",
            "   – 01/28/25 at ~09:00: PCV 31%, TS 7.6 g/dL  \n",
            "\n",
            "IMAGING:\n",
            "\n",
            "• Thoracic Radiographs, EKG (performed at referring vet 01/25/25): Results not faxed in detail, but indicated no acute radiographic abnormalities of lung fields for cause of collapse.  \n",
            "• 01/27/25 – Abdominal Ultrasound (Specialist: Dr. Grace Clark, DACVIM)  \n",
            "  – Liver: Mild diffuse changes; 1.00 × 0.91 cm anechoic cyst in left caudal lobe. Structure otherwise smooth and slightly enlarged.  \n",
            "  – Gallbladder: Mild sludge/debris, walls normal thickness.  \n",
            "  – Spleen: Moderately enlarged, homogeneous parenchyma.  \n",
            "  – Kidneys: Bilateral changes consistent with age (decreased corticomedullary distinction); right kidney with small nephroliths.  \n",
            "  – Adrenal Glands: Right 0.79 × 0.49 cm, Left 0.58 × 0.51 cm (mild enlargement possible). Suspicion for early hyperadrenocorticism (Cushing’s).  \n",
            "  – Intestines/Colon: Mildly thickened colon (0.39 cm).  \n",
            "  – Jejunal Lymph Nodes: Mild enlargement up to 1.41 × 0.85 cm.  \n",
            "  – Conclusions: Possible mild Cushing’s changes, incidental hepatic cyst, mild gallbladder sludge, age-related kidneys. No focal masses suggesting neoplasia.  \n",
            "\n",
            "• 01/27/25 – Echocardiogram (Specialist: Dr. Grace Clark, DACVIM)  \n",
            "  – Findings:  \n",
            "    – Mild tricuspid regurgitation, moderate pulmonary hypertension (up to 60 mmHg on TR Vmax).  \n",
            "    – Mild right ventricular dilation, mild left atrial enlargement.  \n",
            "    – Good systolic function; no severe MVD.  \n",
            "    – Potential cause of syncopal episodes but more likely interplay with severe anemia.  \n",
            "  – Recommendation: Sildenafil 10 mg PO TID if further syncopal events occur after anemia is corrected.  \n",
            "\n",
            "────────────────────────────────────────────────────────────\n",
            "CURRENT MEDICATIONS AND TREATMENTS:\n",
            "\n",
            "(See also “Patient Signalment & Client Information” for full current medication list.)\n",
            "\n",
            "Key Immune-Mediating/Supportive Medications Begun 01/27/25:\n",
            "1) Prednisone 10 mg PO SID, starting 01/27/25 PM, with planned taper over several months depending on recheck results.  \n",
            "2) Cyclosporine (Atopica) 25 mg PO BID, initiated 01/27/25–01/28/25.  \n",
            "3) Doxycycline 50 mg PO SID (½ of a 100 mg tablet once daily), for possible tick-borne or other infectious etiologies, begun 01/27/25.  \n",
            "4) Clopidogrel (Plavix) ~18.75 mg PO SID (¼ of a 75 mg tablet), anti-thrombotic prophylaxis given IMHA’s risk of thrombosis.  \n",
            "\n",
            "Cardiac Medications (continued from referring vet):\n",
            "• Enalapril 2.5 mg PO SID  \n",
            "• Vetmedin (pimobendan) 2.5 mg PO BID  \n",
            "• Furosemide 20 mg PO BID  \n",
            "\n",
            "Additional Treatments:\n",
            "• 01/27/25: Administered Dexamethasone SP (4 mg/mL) 0.37 mL IV.  \n",
            "• 01/27/25: Blood transfusion with pRBCs (125 mL over 4 hours).  \n",
            "\n",
            "Adverse Reactions:\n",
            "• None specifically noted aside from mild GI upset after chicken on 01/26/25.  \n",
            "\n",
            "Start/End Dates and Effectiveness:\n",
            "• Steroids, cyclosporine, and supportive therapies initiated 01/27/25–01/28/25, ongoing.  \n",
            "• Furosemide, enalapril, and Vetmedin therapy pre-date referral by unknown timeframe (continuation was recommended).  \n",
            "• No adverse events reported as of 01/28/25 recheck.  \n",
            "\n",
            "────────────────────────────────────────────────────────────\n",
            "CLIENT COMMUNICATIONS & INSTRUCTIONS:\n",
            "\n",
            "01/27/25 Discussion with Mr. Johnson:\n",
            "• Reviewed initial suspicion of IMHA vs. potential triggers (tick borne disease, neoplasia, drugs, vaccines).  \n",
            "• Explained need for diagnostics: CBC, chemistry, Coombs’, tick-borne PCR, imaging.  \n",
            "• Discussed necessity for blood transfusions to stabilize while immunosuppressives begin working.  \n",
            "• Outlined possible causes of pulmonary hypertension and tricuspid regurgitation on echocardiogram; prescribing sildenafil if syncope persists.  \n",
            "• Informed that overnight care at Metropolitan Veterinary Services was offered but declined.  \n",
            "• Advised returning on 01/28/25 for PCV recheck or sooner if clinical deterioration occurred.  \n",
            "\n",
            "01/28/25 Follow-Up:\n",
            "• PCV stable at 31%, patient clinically improved. Gums pink, mild improvement in murmur.  \n",
            "• Instructed to continue current immunosuppressive therapy (prednisone + cyclosporine) and supportive meds (clopidogrel, doxycycline).  \n",
            "• Recommended follow-up in approximately 1 week for Internal Medicine consultation, or sooner if new collapses occur.  \n",
            "• Client instructed to monitor gum color, appetite, and watch for further syncopal events.  \n",
            "• Advised to have prescription for sildenafil on hand if collapses recur.  \n",
            "• Diet changed to Hill’s i/d Low Fat, suggested 1⅓ cans daily.  \n",
            "\n",
            "No additional updates regarding finances or insurance on 01/28/25.  \n",
            "\n",
            "────────────────────────────────────────────────────────────\n",
            "(Signature of Compiling Veterinary Data Processing Agent)\n",
            "\n",
            "Document finalized: 01/28/25 at 10:00 AM  \n",
            "\n",
            "END OF RECORD  \n",
            "\n",
            "History Analysis:\n",
            "------------------------------\n",
            "COMPREHENSIVE TIMELINE\n",
            "\n",
            "1. INITIAL DISEASE ONSET\n",
            "   • Exact Date of First Clinical Signs:  \n",
            "     – 01/23/25: First documented collapsing (syncopal) episode.\n",
            "\n",
            "   • Precise Symptom Progression:  \n",
            "     – Patient (Spencer Johnson) developed an initial syncopal event on 01/23/25.  \n",
            "     – A chronic, non-productive hacking cough had been present for several months prior (date of onset not precisely recorded).  \n",
            "     – Subsequent collapses and lethargy were noted on 01/25/25.  \n",
            "\n",
            "   • ALL Initial Diagnostic Findings (from Referring Veterinarian, Johnsen Veterinary Services, approximate date 01/25/25):  \n",
            "     – Bloodwork (complete details not faxed).  \n",
            "     – Thoracic radiographs reportedly showed no acute pulmonary lesions explaining collapse.  \n",
            "     – EKG was performed (specific tracings/results not provided).  \n",
            "\n",
            "   • First Treatment Responses:  \n",
            "     – Patient had been on cardiac medications (Enalapril 2.5 mg PO SID, Vetmedin 2.5 mg PO BID, Furosemide 20 mg PO BID) prior to referral. The dates these were first prescribed are not fully specified; no documentation of initial response beyond partial control of suspected cardiac issues.  \n",
            "\n",
            "2. DISEASE PROGRESSION\n",
            "   • Detailed Symptom Evolution with Dates:\n",
            "     – 01/23/25 (Thursday): First recorded collapse.  \n",
            "     – 01/25/25 (Saturday): Two additional collapses; subsequent persistent lethargy and diminished appetite.  \n",
            "     – 01/26/25 (Sunday): No syncopal episode, but patient remained lethargic and vomited once after eating boiled chicken. Became uninterested in regular kibble or treats.  \n",
            "     – 01/27/25 (Monday) at 08:27: Another collapse (described by the owner as a fainting episode lasting a few minutes). Prompted referral that same day.  \n",
            "\n",
            "   • ALL Complications or New Symptoms:\n",
            "     – Lethargy from 01/25/25 onward.  \n",
            "     – Single vomiting episode on 01/26/25.  \n",
            "     – Mild icterus noted on physical exam 01/27/25, continuing into 01/28/25.  \n",
            "     – Pale mucous membranes on 01/27/25, suggestive of anemia.  \n",
            "\n",
            "   • EVERY Medication Change with Rationale:\n",
            "     – 01/27/25:  \n",
            "       1) Prednisone 10 mg once daily (SID) PO initiated for suspected immune-mediated hemolytic anemia (IMHA).  \n",
            "       2) Cyclosporine (Atopica) 25 mg twice daily (BID) PO started as an additional immunosuppressant for IMHA.  \n",
            "       3) Doxycycline 50 mg once daily (SID) PO begun for possible tick-borne or other infectious etiologies.  \n",
            "       4) Clopidogrel (Plavix) ~18.75 mg once daily (SID) PO initiated for thrombosis prophylaxis due to IMHA risk.  \n",
            "     – 01/27/25: Dexamethasone SP 4 mg/mL injected IV at a dose of 0.37 mL as immediate immunosuppressive/anti-inflammatory treatment.  \n",
            "     – 01/27/25: Packed red blood cell transfusion (125 mL over 4 hours) given for significant anemia.  \n",
            "     – 01/28/25: Prescription for sildenafil 10 mg three times daily (TID) PO provided for potential recurrence of syncopal episodes related to pulmonary hypertension.  \n",
            "\n",
            "   • Treatment Responses with Specific Timelines:\n",
            "     – By 01/27/25 at 20:55 (post-transfusion), PCV rose from 15% to 30%.  \n",
            "     – By 01/28/25 (~09:00), PCV stabilized at 31%, and the patient was clinically improved (pink mucous membranes, reduced murmur intensity).  \n",
            "\n",
            "3. COMPLETE TREATMENT HISTORY\n",
            "   • ALL Medications Prescribed (Chronological Order with Exact Doses, Frequencies, and Start/End Dates If Known):\n",
            "\n",
            "   PRIOR TO REFERRAL (Exact Start Dates Unknown – Presumed Ongoing before 01/27/25):\n",
            "     1) Enalapril 2.5 mg tablet SID PO  \n",
            "        – Generic Name: Enalapril  \n",
            "        – Dose/Frequency: 2.5 mg, once daily by mouth  \n",
            "        – Route: PO  \n",
            "        – Duration: Ongoing, pre-dates referral  \n",
            "        – Response: Prescribed for suspected cardiac condition; no adverse events noted.  \n",
            "        – Adverse Reactions: None reported.  \n",
            "\n",
            "     2) Vetmedin (pimobendan) 2.5 mg tablet, ½ tablet BID PO  \n",
            "        – Generic Name: Pimobendan  \n",
            "        – Dose: Approximately 1.25 mg per dose, twice daily by mouth  \n",
            "        – Route: PO  \n",
            "        – Duration: Ongoing, pre-dates referral  \n",
            "        – Response: Prescribed for cardiac support; no adverse events noted.  \n",
            "\n",
            "     3) Furosemide 20 mg tablet BID PO  \n",
            "        – Generic Name: Furosemide  \n",
            "        – Dose/Frequency: 20 mg, twice daily by mouth  \n",
            "        – Route: PO  \n",
            "        – Duration: Ongoing, pre-dates referral  \n",
            "        – Response: For management of fluid retention or congestive signs; no adverse events noted.  \n",
            "\n",
            "     4) Trazodone 50 mg tablet, ½ tablet as needed (PRN) PO  \n",
            "        – Generic Name: Trazodone  \n",
            "        – Dose: 25 mg (½ of 50 mg) as needed  \n",
            "        – Route: PO  \n",
            "        – Duration: Ongoing for anxiety or sedation as needed  \n",
            "        – Adverse Reactions: None reported.  \n",
            "\n",
            "     5) Joint Supplement PO every other day  \n",
            "        – Product unspecified  \n",
            "        – Dose/Frequency: Every other day by mouth  \n",
            "        – Duration: Ongoing, no exact start date documented  \n",
            "        – Adverse Reactions: None reported.  \n",
            "\n",
            "     6) Credelio prevention  \n",
            "        – Used March through October annually  \n",
            "        – Dose/Frequency: Once monthly by mouth (typical usage)  \n",
            "        – Duration: Seasonal for flea/tick prevention  \n",
            "        – Adverse Reactions: None reported.\n",
            "\n",
            "   INITIATED ON 01/27/25:\n",
            "     7) Doxycycline 100 mg tablets, give ½ tablet (50 mg) SID PO with food  \n",
            "        – Start Date: 01/27/25 PM (next dose due 01/28/25 at 19:00)  \n",
            "        – Rationale: Empiric coverage for possible tick-borne or other infectious agent.  \n",
            "        – Adverse Reactions: None noted as of 01/28/25.  \n",
            "\n",
            "     8) Prednisone 10 mg tablet, 1 tablet (10 mg) SID PO with food  \n",
            "        – Start Date: 01/27/25 PM (next dose due 01/28/25)  \n",
            "        – Rationale: Immunosuppressive therapy for diagnosed IMHA.  \n",
            "        – Adverse Reactions: None noted as of 01/28/25.  \n",
            "\n",
            "     9) Atopica (cyclosporine) 25 mg capsule, 1 capsule (25 mg) BID PO with food  \n",
            "        – Start Date: 01/27/25 PM or 01/28/25 AM (initiated per specialty instructions)  \n",
            "        – Rationale: Adjunct immunosuppression for IMHA.  \n",
            "        – Adverse Reactions: None noted as of 01/28/25.  \n",
            "\n",
            "     10) Clopidogrel (Plavix) 75 mg tablets, give ¼ tablet (~18.75 mg) SID PO  \n",
            "         – Start Date: 01/27/25 PM (next dose due 01/28/25 at 19:00)  \n",
            "         – Rationale: Anti-thrombotic prophylaxis given increased risk of thromboembolism in IMHA.  \n",
            "         – Adverse Reactions: None noted as of 01/28/25.  \n",
            "\n",
            "   ADDITIONAL PRESCRIPTION (WRITTEN ON 01/28/25 TO BEGIN IF NEEDED):  \n",
            "     • Sildenafil 10 mg TID PO  \n",
            "       – Indication: For persistent or recurrent syncopal episodes, given moderate pulmonary hypertension found on echocardiogram.  \n",
            "       – Not yet started as of 01/28/25; client instructed to fill/use if collapses recur.\n",
            "\n",
            "   • Specific Responses to Each:  \n",
            "     – The patient’s PCV improved post-transfusion and began stabilizing once immunosuppressants (prednisone and cyclosporine) were started.  \n",
            "     – No adverse GI signs noted beyond the single vomiting episode on 01/26/25, which was attributed to chicken ingestion prior to formal therapy.  \n",
            "\n",
            "4. DIAGNOSTIC TESTING CHRONOLOGY\n",
            "   • ALL Tests Performed with Dates, Results, Reference Ranges, and Clinical Correlations:\n",
            "\n",
            "   01/25/25 (Referring Veterinarian):  \n",
            "     – Bloodwork, thoracic radiographs, EKG (specific data not fully provided, but no acute radiographic abnormalities explaining collapse).  \n",
            "\n",
            "   01/27/25 In-House CBC/Chemistry/Lytes (IDEXX):  \n",
            "     – Hematology (Reference Ranges in parentheses):  \n",
            "       RBC: 1.55 M/µL (5.65–8.87) ↓  \n",
            "       HCT: 12.2% (37.3–61.7) ↓  \n",
            "       HGB: 3.2 g/dL (13.1–20.5) ↓  \n",
            "       MCV: 78.7 fL (61.6–73.5) ↑  \n",
            "       MCH: 20.6 pg (21.2–25.9) ↓  \n",
            "       MCHC: 26.2 g/dL (32.0–37.9) ↓  \n",
            "       RDW: 32.8% (13.6–21.7) ↑  \n",
            "       Reticulocyte %: 35.6% (no reference range provided; extremely elevated)  \n",
            "       Reticulocytes (absolute): 552.1 K/µL (10.0–110.0) ↑  \n",
            "       WBC: 41.74 K/µL (5.05–16.76) ↑  \n",
            "         • Neutrophils: 23.87 K/µL (2.95–11.64) ↑  \n",
            "         • Lymphocytes: 12.83 K/µL (1.05–5.10) ↑  \n",
            "         • Monocytes: 4.71 K/µL (0.16–1.12) ↑  \n",
            "         • Eosinophils: 0.29 K/µL (0.06–1.23) normal  \n",
            "         • Basophils: 0.04 K/µL (0.00–0.10) normal  \n",
            "       Platelets: 213 K/µL (148–484) normal; MPV: 20.4 fL (8.7–13.2) ↑  \n",
            "       Interpretation: Marked, regenerative anemia with extreme reticulocytosis; major leukocytosis suggestive of inflammation and immune-mediated RBC destruction.  \n",
            "\n",
            "     – Chemistry (Reference Ranges in parentheses):  \n",
            "       Glucose: 144 mg/dL (70–143) Slightly ↑  \n",
            "       BUN: 39 mg/dL (7–27) ↑  \n",
            "       Creatinine: 0.9 mg/dL (0.5–1.8) normal  \n",
            "       Phosphorus: 5.0 mg/dL (2.5–6.8) normal  \n",
            "       Calcium: 8.6 mg/dL (7.9–12.0) normal  \n",
            "       Sodium: 151 mmol/L (144–160) normal  \n",
            "       Potassium: 3.3 mmol/L (3.5–5.8) ↓  \n",
            "       Chloride: 109 mmol/L (109–122) lower end of normal  \n",
            "       ALP: 382 U/L (23–212) ↑  \n",
            "       ALT: 62 U/L (10–125) normal  \n",
            "       GGT: 5 U/L (0–11) normal  \n",
            "       Total Bilirubin: 1.9 mg/dL (0.0–0.9) ↑  \n",
            "       Cholesterol: 233 mg/dL (110–320) normal  \n",
            "       Albumin: 3.2 g/dL (2.2–3.9) normal  \n",
            "       Globulin: 4.2 g/dL (2.5–4.5) normal  \n",
            "       Total Protein: 7.4 g/dL (5.2–8.2) normal  \n",
            "\n",
            "   01/27/25 Peripheral Blood Smear (Zoetis Diagnostics):  \n",
            "     – Macrocytic, hypochromic, regenerative anemia with rare spherocytes (0–1/100× field). Possible mild RBC aggregation (rouleaux vs. autoagglutination).  \n",
            "     – Moderate toxic band neutrophils, supporting significant inflammation.  \n",
            "     – No hemoparasites identified.  \n",
            "     – Consistent with immune-mediated destruction (IMHA).  \n",
            "\n",
            "   01/27/25 Canine Tick-Borne PCR Panel (Antech, Accession #CHBE67275409; reported 01/30/25):  \n",
            "       Anaplasma phagocytophilum: Negative  \n",
            "       Anaplasma platys: Negative  \n",
            "       Babesia canis: Negative  \n",
            "       Babesia speciation (non-canis): Negative  \n",
            "       Bartonella henselae: Negative  \n",
            "       Bartonella vinsonii: Negative  \n",
            "       Ehrlichia canis: Negative  \n",
            "       Ehrlichia spp. (non-canis): Negative  \n",
            "       Mycoplasma haemocanis/haematoparvum: Negative  \n",
            "       Neorickettsia risticii: Negative  \n",
            "       Rickettsia rickettsii: Negative  \n",
            "\n",
            "   01/27/25 Lyme Titer IgG:  \n",
            "       Negative (<1:64 = normal)  \n",
            "\n",
            "   01/27/25 Direct Coombs’ Test (Warm/37 °C):  \n",
            "       Positive at 1:8 (reference: Negative), consistent with immune-mediated hemolysis.  \n",
            "\n",
            "   01/27/25 In-House PCV/TS:  \n",
            "       – 13:45 → PCV 15%, TS 8.0 g/dL  \n",
            "       – 20:55 (post-transfusion) → PCV 30%, TS 6.2 g/dL  \n",
            "\n",
            "   01/28/25 PCV/TS (at ~09:00):  \n",
            "       PCV 31%, TS 7.6 g/dL  \n",
            "\n",
            "   • Imaging:\n",
            "     – 01/25/25 Thoracic Radiographs, EKG at Referring Veterinarian:  \n",
            "       No significant pulmonary pathology reported that would explain syncopal episodes.  \n",
            "\n",
            "     – 01/27/25 Abdominal Ultrasound (Dr. Grace Clark, DACVIM):  \n",
            "       • Mildly enlarged liver with a 1.00 × 0.91 cm anechoic cyst in left caudal lobe.  \n",
            "       • Mild gallbladder sludge.  \n",
            "       • Spleen moderately enlarged, homogeneous texture.  \n",
            "       • Kidneys showing age-related changes with possible small nephroliths in right kidney.  \n",
            "       • Adrenal glands: Right 0.79 × 0.49 cm, Left 0.58 × 0.51 cm, suggesting mild enlargement potentially consistent with early hyperadrenocorticism.  \n",
            "       • Jejunal lymph nodes mildly enlarged up to 1.41 × 0.85 cm.  \n",
            "       • No focal masses indicative of neoplasia.  \n",
            "\n",
            "     – 01/27/25 Echocardiogram (Dr. Grace Clark, DACVIM):  \n",
            "       • Mild tricuspid regurgitation.  \n",
            "       • Moderate pulmonary hypertension (TR Vmax suggesting ~60 mmHg).  \n",
            "       • Mild right ventricular dilation, mild left atrial enlargement.  \n",
            "       • Good systolic function.  \n",
            "       • Potential explanation for syncopal events along with severe anemia.  \n",
            "       • Recommendation for sildenafil if recurrent syncopal episodes persist once anemia is addressed.  \n",
            "\n",
            "PATTERN ANALYSIS\n",
            "\n",
            "1. DETAILED SYMPTOM PATTERNS  \n",
            "   • Frequency of Episodes: Four collapsing episodes documented (01/23/25, two on 01/25/25, and 01/27/25).  \n",
            "   • Severity Trends: Each syncopal event left the patient lethargic for prolonged periods; the 01/27/25 episode lasted a few minutes, suggesting more severe compromise.  \n",
            "   • Specific Triggers Identified: Possibly exertion or stress in the context of cardiac disease and acute anemia, though no single trigger confirmed.  \n",
            "   • Temporal Patterns:  \n",
            "     – Initial collapses on 01/23/25 and 01/25/25, again on 01/27/25 morning.  \n",
            "     – No events on 01/26/25 but increased lethargy.  \n",
            "\n",
            "2. TREATMENT RESPONSE ANALYSIS  \n",
            "   • Duration of Response to Each Intervention:  \n",
            "     – pRBC transfusion on 01/27/25 resulted in an immediate PCV increase from 15% to 30% by 20:55 on 01/27/25.  \n",
            "     – By 01/28/25 (~09:00), PCV was 31%, indicating stabilization after immunosuppressive therapy initiation.  \n",
            "\n",
            "   • Degree of Improvement:  \n",
            "     – Gums became pinker by 01/28/25.  \n",
            "     – Heart murmur reduced from Grade 4/6 on 01/27/25 to Grade 2/6 on 01/28/25.  \n",
            "     – Appetite improved slightly by 01/28/25.  \n",
            "\n",
            "   • Treatment Failures with Specific Reasons:  \n",
            "     – No recorded failures to date; patient stabilized clinically.  \n",
            "\n",
            "   • Compliance Assessment:  \n",
            "     – Owner administered all newly prescribed medications starting late 01/27/25, returned for recheck on 01/28/25 as advised.  \n",
            "     – Declined overnight hospitalization but agreed to outpatient management.  \n",
            "\n",
            "3. RISK FACTOR EVALUATION  \n",
            "   • ALL Identified Risk Factors:  \n",
            "     – Possible early hyperadrenocorticism (mildly enlarged adrenal glands).  \n",
            "     – Chronic cardiac issue with mild tricuspid regurgitation and moderate pulmonary hypertension elevates risk for syncope.  \n",
            "     – Potential predisposition to immune-mediated disease in small-breed dogs.  \n",
            "\n",
            "   • Environmental Influences:  \n",
            "     – None specifically noted, though patient travels between two addresses (Louisville, KY and Mt Washington, KY).  \n",
            "\n",
            "   • Genetic Predispositions:  \n",
            "     – Chihuahua mix with possible breed predisposition to collapsing trachea or cardiac disease, though not definitively stated.  \n",
            "\n",
            "   • Concurrent Conditions:  \n",
            "     – Chronic mild cough (noted for months, not heard since 01/23/25).  \n",
            "     – Possible mild Cushing’s changes on ultrasound.  \n",
            "\n",
            "────────────────────────────────────────────────────────────\n",
            "\n",
            "(Significant Client Communication & Instructions Recap)\n",
            "• 01/27/25 at initial evaluation:  \n",
            "  – Discussed IMHA diagnosis, Coombs’ test result, necessity for transfusion and immunosuppression, risk of thromboembolism, and possible pulmonary hypertension.  \n",
            "  – Owner offered overnight care but declined, preferring outpatient.  \n",
            "  – Advised recheck on 01/28/25 or sooner if deterioration.\n",
            "\n",
            "• 01/28/25 Follow-Up:  \n",
            "  – PCV stable at 31%, moderate improvement in clinical signs.  \n",
            "  – Instructed to continue all immunosuppressive therapy (prednisone 10 mg SID, cyclosporine 25 mg BID), anti-thrombotic therapy (clopidogrel 18.75 mg SID), and doxycycline 50 mg SID.  \n",
            "  – Recommended having sildenafil 10 mg TID prescription available if collapses recur.  \n",
            "  – Diet changed to Hill’s i/d Low Fat at 1⅓ cans/day.  \n",
            "  – Asked to monitor gum color, appetite, and watch for potential syncopal episodes.\n",
            "\n",
            "END OF ANALYSIS 01/28/25 AT 10:00 AM  \n",
            "\n",
            "Clinical Analysis:\n",
            "------------------------------\n",
            "CLINICAL ASSESSMENT:\n",
            "\n",
            "1. PRIMARY CLINICAL SIGNS ANALYSIS\n",
            "\n",
            "   a) Syncopal (Collapsing) Episodes:\n",
            "      • Exact Duration: Episodes each lasted from several seconds to a few minutes, per owner’s description on 01/27/25.  \n",
            "      • Specific Frequency: Documented on 01/23/25 (1 episode), 01/25/25 (2 episodes), and 01/27/25 (1 episode). Total of 4 episodes.  \n",
            "      • Severity (Scale 1–10): Estimated 8/10, as the patient completely lost consciousness and needed time to recover, indicating significant compromise.  \n",
            "      • Pattern of Occurrence: Occurred sporadically over a 5-day window (01/23/25–01/27/25), with no single confirmed exertional or stress trigger.  \n",
            "      • Exacerbating or Alleviating Factors: Possibly exacerbated by the acute anemia (PCV as low as 15% on 01/27/25) and concurrent pulmonary hypertension. Partial alleviation following red blood cell transfusion and immunosuppressive therapy.  \n",
            "      • Response to Interventions: Reduced incidence post-transfusion and after stabilization of hematocrit. No further collapses documented through 01/28/25.\n",
            "\n",
            "   b) Non-Productive Cough:\n",
            "      • Exact Duration: Chronic, noted for “several months” prior to 01/23/25 (precise start date unavailable).  \n",
            "      • Specific Frequency: Daily occurrence reported, though severity not consistently monitored.  \n",
            "      • Severity (Scale 1–10): Owner reported mild to moderate intensity (~3–4/10).  \n",
            "      • Pattern of Occurrence: Intermittent episodes, more common when excited or active.  \n",
            "      • Exacerbating or Alleviating Factors: May be exacerbated by physical activity or stress; mild improvement on furosemide if related to cardiac etiology.  \n",
            "      • Response to Interventions: Partially controlled under ongoing cardiac therapy (furosemide, pimobendan, enalapril).  \n",
            "\n",
            "   c) Lethargy:\n",
            "      • Exact Duration: Marked lethargy starting on 01/25/25, persisting through 01/27/25.  \n",
            "      • Specific Frequency: Daily constant fatigue, noticed consistently after each syncope.  \n",
            "      • Severity (Scale 1–10): Owner reported moderate to severe, ~7/10, impairing normal activity.  \n",
            "      • Pattern of Occurrence: Persistent from 01/25/25 onward, correlated with worsening anemia.  \n",
            "      • Exacerbating or Alleviating Factors: Likely worsened by low PCV and possible hypoxia. Improved after transfusion.  \n",
            "      • Response to Interventions: Noticeable improvement by 01/28/25 when PCV reached 31%.\n",
            "\n",
            "   d) Vomiting:\n",
            "      • Exact Duration: Single episode on 01/26/25.  \n",
            "      • Specific Frequency: Only once reported.  \n",
            "      • Severity (Scale 1–10): Mild, ~2–3/10.  \n",
            "      • Pattern of Occurrence: Occurred post-meal (boiled chicken) on 01/26/25.  \n",
            "      • Exacerbating or Alleviating Factors: Possibly dietary or related to underlying illness; resolved spontaneously.  \n",
            "      • Response to Interventions: No specific antiemetic given; no recurrence after dietary change.\n",
            "\n",
            "   e) Pale Mucous Membranes and Mild Icterus:\n",
            "      • Exact Duration: Pale membranes initially noted on 01/27/25, mild icterus persisting 01/27/25–01/28/25.  \n",
            "      • Specific Frequency: Constant findings during physical exam.  \n",
            "      • Severity (Scale 1–10): Pale membranes ~8/10 severity, reflecting severe anemia; mild icterus ~3/10.  \n",
            "      • Pattern of Occurrence: Common in hemolytic processes, correlated with high bilirubin.  \n",
            "      • Exacerbating or Alleviating Factors: Alleviated as hematocrit improved post-transfusion; icterus improved with reduced hemolysis.  \n",
            "      • Response to Interventions: Improved mucous membrane color and reducing bilirubin once immunosuppressive treatment and transfusion given.\n",
            "\n",
            "\n",
            "2. COMPREHENSIVE PHYSICAL EXAMINATION ANALYSIS\n",
            "\n",
            "   a) Vital Signs Interpretation:\n",
            "      • Temperature (normal canine reference ~101.5±1 °F):  \n",
            "        – 01/27/25: 101.2 °F – within normal limits.  \n",
            "      • Heart Rate (normal ~70–160 bpm for canines, depending on size):  \n",
            "        – 01/27/25: ~150 bpm, slightly elevated but could be stress-related; consistent with mild tachycardia.  \n",
            "      • Respiratory Rate/Effort:  \n",
            "        – 01/27/25: 36 breaths/min, mildly increased (normal range ~ 10–30 breaths/min), possibly due to anemia and stress.  \n",
            "      • Weight Trends (% change):  \n",
            "        – Exact prior weight from referring records not provided; on 01/27/25, measured 7.3 lb. Owner believed slight weight loss from ~7.7 lb reported about 1 month prior (~5% decrease).  \n",
            "      • Body Condition Score Changes:  \n",
            "        – BCS 4/9 on 01/27/25, unknown previous official BCS but suspected stable.\n",
            "\n",
            "   b) Detailed System Analysis:\n",
            "      • Cardiovascular:  \n",
            "        – Abnormal Finding: Grade 4/6 holosystolic murmur on 01/27/25 (tricuspid area), downgraded to ~2/6 on 01/28/25 following PCV normalization.  \n",
            "        – Clinical Significance: Chronic valvular disease (tricuspid regurgitation) + moderate pulmonary hypertension may contribute to syncope.  \n",
            "      • Respiratory:  \n",
            "        – Chronic cough historically, no acute abnormalities on auscultation on 01/27/25.  \n",
            "        – Clinical Significance: Could be related to cardiac conditions or mild airway disease.  \n",
            "      • Gastrointestinal:  \n",
            "        – Abnormal Finding: Single vomiting episode reported (01/26/25), no abdominal pain on palpation. Mild gallbladder sludge on ultrasound.  \n",
            "        – Clinical Significance: Possibly incidental.  \n",
            "      • Hepatobiliary:  \n",
            "        – Mildly enlarged liver on ultrasound (01/27/25), mild hyperbilirubinemia (1.9 mg/dL, reference 0.0–0.9 mg/dL).  \n",
            "        – Clinical Significance: Likely secondary to hemolysis with mild hepatic congestion or early infiltration.  \n",
            "      • Musculoskeletal:  \n",
            "        – No overt lameness or joint pain on exam. No noted abnormalities in gait.  \n",
            "      • Urogenital:  \n",
            "        – Kidneys had age-related changes with possible nephroliths. Not clinically significant at this time.  \n",
            "      • Lymphatic:  \n",
            "        – Mildly enlarged jejunal lymph nodes up to 1.41 × 0.85 cm. Could indicate reactive lymphadenopathy from systemic inflammation.  \n",
            "      • Endocrine:  \n",
            "        – Adrenal glands slightly enlarged on ultrasound (Right 0.79 × 0.49 cm, Left 0.58 × 0.51 cm). May suggest early hyperadrenocorticism.  \n",
            "      • Integument:  \n",
            "        – Within normal limits, no alopecia or dermatitis noted.  \n",
            "      • Pain Assessment:  \n",
            "        – Patient comfortable on palpation; no overt signs of pain (score 0/4).  \n",
            "      • Comparative Left vs. Right Findings:  \n",
            "        – Mildly more prominent tricuspid murmur on right side. No differences in limb temperature or pulses noted.  \n",
            "      • Sequential Exam Changes:  \n",
            "        – 01/27/25: Marked pallor, murmur grade 4/6.  \n",
            "        – 01/28/25: Pinker mucous membranes, murmur decreased to grade 2/6, improved energy per owner.\n",
            "\n",
            "3. DIAGNOSTIC TESTING INTERPRETATION\n",
            "\n",
            "   a) Laboratory Results:\n",
            "      • 01/27/25 CBC:  \n",
            "        – Profound anemia: RBC 1.55 M/µL (reference 5.65–8.87), HCT 12.2% (37.3–61.7), HGB 3.2 g/dL (13.1–20.5).  \n",
            "        – Regenerative response: Reticulocyte % 35.6% (extremely elevated), absolute retics 552.1 K/µL (reference 10.0–110.0 K/µL).  \n",
            "        – Leukocytosis: WBC 41.74 K/µL (5.05–16.76), supporting inflammation/immune activation.  \n",
            "        – Thrombocytes within normal range (213 K/µL), MPV elevated (20.4 fL, reference 8.7–13.2 fL).  \n",
            "        – Clinical Correlation: Strongly suggestive of IMHA with robust reticulocytosis.  \n",
            "      • 01/27/25 Chemistry:  \n",
            "        – Mild azotemia: BUN 39 mg/dL (7–27).  \n",
            "        – Hypokalemia: 3.3 mmol/L (3.5–5.8).  \n",
            "        – Elevated ALP: 382 U/L (23–212).  \n",
            "        – Elevated total bilirubin: 1.9 mg/dL (0.0–0.9).  \n",
            "        – Clinical Correlation: Consistent with hemolysis plus possible mild cholestasis and dehydration.  \n",
            "      • Coombs’ Test Positive at 1:8 (warm 37 °C incubation):  \n",
            "        – Confirms immune-mediated hemolytic process.  \n",
            "      • Tick-Borne PCR Panel:  \n",
            "        – Negative for all tested organisms.  \n",
            "      • Clinical Significance of Abnormalities:  \n",
            "        – Laboratory data supports primary IMHA, with no evidence of common tick-borne pathogens.\n",
            "\n",
            "   b) Imaging Interpretation:\n",
            "      • 01/25/25 Thoracic Radiographs/EKG (Referring Vet):  \n",
            "        – No acute pulmonary lesions to explain collapse; EKG details unavailable.  \n",
            "        – Clinical Significance: Syncopal episodes likely cardiopulmonary or hematologic in origin.  \n",
            "      • 01/27/25 Ultrasound (Abdominal):  \n",
            "        – Mild, diffuse hepatic enlargement with a 1.00 × 0.91 cm cyst; moderate splenomegaly.  \n",
            "        – Mild gallbladder sludge; mild adrenal enlargement.  \n",
            "        – No overt neoplastic lesions.  \n",
            "        – Clinical Correlation: Non-specific but consistent with chronic inflammatory or early endocrine changes; no mass explaining anemia.  \n",
            "      • 01/27/25 Echocardiogram:  \n",
            "        – Mild tricuspid regurgitation.  \n",
            "        – Moderate pulmonary hypertension (~60 mmHg estimated from TR Vmax).  \n",
            "        – Mild right ventricular dilation and mild left atrial enlargement.  \n",
            "        – Clinical Significance: Explains potential syncopal events, especially under stress from severe anemia.\n",
            "\n",
            "4. DISEASE PROCESS ANALYSIS\n",
            "\n",
            "   a) Detailed Pathophysiology:\n",
            "      • Primary Disease Mechanism: Immune-mediated hemolysis destroying red blood cells, confirmed by positive Coombs’ test and high reticulocyte count.  \n",
            "      • Secondary Complications: Risk of thrombosis, increased bilirubin, potential hepatic congestion, episodic hypoxia leading to syncope.  \n",
            "      • Organ System Interactions:  \n",
            "        – Cardiovascular compromise from anemia and concurrent valvular disease with pulmonary hypertension.  \n",
            "        – Hepatic stress from hemolysis (icterus).  \n",
            "      • Disease Stage with Criteria:  \n",
            "        – Marked regenerative anemia, active destruction on 01/27/25, improved on 01/28/25, indicating partial control of hemolysis.  \n",
            "      • Progression Indicators:  \n",
            "        – Initial severe drop in PCV (15% on 01/27/25) improved post-transfusion to 30% on 01/27/25 evening, stabilizing at 31% on 01/28/25; suggests early positive response to therapy.\n",
            "\n",
            "5. TREATMENT RESPONSE EVALUATION\n",
            "\n",
            "   a) For Each Medication:\n",
            "      • Enalapril 2.5 mg PO SID (onboard prior to 01/27/25):  \n",
            "        – Time to Initial Response: Unknown, used for chronic management.  \n",
            "        – Degree of Improvement: Mild effect on afterload reduction.  \n",
            "        – Duration of Effect: Ongoing, indefinite therapy indicated.  \n",
            "        – Side Effects Observed: None reported.  \n",
            "        – Factors Affecting Efficacy: Underlying cardiac condition, concurrent diuretic (furosemide).\n",
            "      • Vetmedin (pimobendan) 2.5 mg tablet, ½ tablet (1.25 mg) PO BID:  \n",
            "        – Time to Initial Response: Unknown, used chronically.  \n",
            "        – Degree of Improvement: Supports systolic function in the face of valvular disease.  \n",
            "        – Duration of Effect: Ongoing.  \n",
            "        – Side Effects Observed: None reported.  \n",
            "        – Factors Affecting Efficacy: Severity of underlying heart failure, concurrent IMHA.  \n",
            "      • Furosemide 20 mg PO BID:  \n",
            "        – Time to Initial Response: Ongoing.  \n",
            "        – Degree of Improvement: Aids in fluid management if congestive heart failure is present.  \n",
            "        – Duration of Effect: Chronic prophylaxis.  \n",
            "        – Side Effects Observed: Potential mild dehydration, mild hypokalemia (3.3 mmol/L).  \n",
            "        – Factors Affecting Efficacy: Renal perfusion, concurrent medications.  \n",
            "      • Trazodone 25 mg PO PRN:  \n",
            "        – Time to Initial Response: As needed for anxiety.  \n",
            "        – Degree of Improvement: Not specifically evaluated.  \n",
            "        – Duration of Effect: Typically ~6–8 hours.  \n",
            "        – Side Effects Observed: None reported.  \n",
            "        – Factors Affecting Efficacy: Severity of anxiety, frequency of administration.  \n",
            "      • Joint Supplement PO Every Other Day:  \n",
            "        – Time to Initial Response: N/A (long-term supplementation).  \n",
            "        – Degree of Improvement: Unknown.  \n",
            "        – Duration of Effect: No data on changes.  \n",
            "        – Side Effects Observed: None reported.  \n",
            "        – Factors Affecting Efficacy: Consistency of administration, product composition.  \n",
            "      • Credelio:  \n",
            "        – Time to Initial Response: Used seasonally for parasite prevention.  \n",
            "        – Degree of Improvement: No active parasitic issues noted.  \n",
            "        – Duration of Effect: 30 days per dose.  \n",
            "        – Side Effects Observed: None reported.  \n",
            "        – Factors Affecting Efficacy: Seasonal adherence.\n",
            "      • Doxycycline 50 mg PO SID (initiated 01/27/25):  \n",
            "        – Time to Initial Response: Prophylactic or empirical coverage.  \n",
            "        – Degree of Improvement: No direct effect on RBC parameters noted; negative tick panel suggests no infection.  \n",
            "        – Duration of Effect: Continuing as prophylaxis.  \n",
            "        – Side Effects Observed: None as of 01/28/25.  \n",
            "        – Factors Affecting Efficacy: Absorption improved when given with food, as instructed.  \n",
            "      • Prednisone 10 mg PO SID (initiated 01/27/25):  \n",
            "        – Time to Initial Response: Clinical improvement within 24 hours with RBC stabilization.  \n",
            "        – Degree of Improvement: Major, as hemolysis reduced and PCV stabilized.  \n",
            "        – Duration of Effect: Dependent on continued dosing for immunosuppression.  \n",
            "        – Side Effects Observed: None yet, though polydipsia/polyphagia expected longer-term.  \n",
            "        – Factors Affecting Efficacy: Timely dosing, GI tolerance, concurrent immunomodulators.  \n",
            "      • Cyclosporine (Atopica) 25 mg PO BID (initiated 01/27/25–01/28/25):  \n",
            "        – Time to Initial Response: Typically requires several days for full immunosuppressive effect, but synergy with prednisone may be beneficial earlier.  \n",
            "        – Degree of Improvement: Aids further in controlling immune-mediated RBC destruction.  \n",
            "        – Duration of Effect: Ongoing therapy recommended.  \n",
            "        – Side Effects Observed: None as of 01/28/25. Potential GI upset or gingival hyperplasia over time.  \n",
            "        – Factors Affecting Efficacy: Concurrent steroids, consistent dosing schedule, feeding times.  \n",
            "      • Clopidogrel (Plavix) ~18.75 mg PO SID (initiated 01/27/25):  \n",
            "        – Time to Initial Response: Platelet inhibition begins within days of therapy.  \n",
            "        – Degree of Improvement: Preventive effect for thromboembolism, not directly measurable in short term.  \n",
            "        – Duration of Effect: Requires continuous administration for prophylaxis.  \n",
            "        – Side Effects Observed: None as of 01/28/25.  \n",
            "        – Factors Affecting Efficacy: Owner compliance, concurrent RBC destruction.  \n",
            "      • Dexamethasone SP IV 4 mg/mL at 0.37 mL on 01/27/25:  \n",
            "        – Time to Initial Response: Immediate anti-inflammatory/immunosuppressive effect to help arrest severe hemolysis.  \n",
            "        – Degree of Improvement: Rapid partial control of IMHA prior to implementing oral regimen.  \n",
            "        – Duration of Effect: Single administration.  \n",
            "        – Side Effects Observed: None acute.  \n",
            "        – Factors Affecting Efficacy: Coordinated with transfusion and subsequent prednisone therapy.  \n",
            "      • Packed RBC Transfusion (125 mL over 4 hours on 01/27/25):  \n",
            "        – Time to Initial Response: PCV rose from 15% at 13:45 to 30% by 20:55 on 01/27/25.  \n",
            "        – Degree of Improvement: Significant immediate stabilization.  \n",
            "        – Duration of Effect: Ongoing RBC support; partial solution until IMHA controlled.  \n",
            "        – Side Effects Observed: None (no transfusion reactions noted).  \n",
            "        – Factors Affecting Efficacy: Concurrent immunosuppression.  \n",
            "      • Sildenafil 10 mg PO TID (prescribed 01/28/25, not started as of 01/28/25):  \n",
            "        – Time to Initial Response: Typically days to see reduced pulmonary artery pressure if started.  \n",
            "        – Degree of Improvement: Intended to reduce pulmonary hypertension if syncopal episodes recur.  \n",
            "        – Duration of Effect: To be used if further episodes arise.  \n",
            "        – Side Effects Observed: Not applicable; not started.  \n",
            "        – Factors Affecting Efficacy: Baseline severity of pulmonary hypertension, compliance if initiated.\n",
            "\n",
            "CLINICAL INTEGRATION:\n",
            "\n",
            "1. EVIDENCE SYNTHESIS  \n",
            "   • Supporting Findings for Each Diagnosis:  \n",
            "     – IMHA: Positive Coombs’, regenerative anemia, spherocytes, elevated bilirubin.  \n",
            "     – Pulmonary Hypertension: Echocardiographic evidence with TR Vmax ~60 mmHg.  \n",
            "     – Potential Early Hyperadrenocorticism: Mildly enlarged adrenals on ultrasound.  \n",
            "   • Strength of Evidence Assessment:  \n",
            "     – IMHA: Strong (lab results + clinical signs).  \n",
            "     – Pulmonary Hypertension: Moderate (echo measurements).  \n",
            "     – Early Cushing’s: Mild suspicion, ultrasound changes only—no confirmatory testing done.  \n",
            "   • Clinical Trial Relevance:  \n",
            "     – Immunosuppressive protocols for IMHA (prednisone + cyclosporine) are standard of care; no immediate investigational therapies indicated.  \n",
            "   • Population-Specific Factors:  \n",
            "     – Small breed dog, possibly predisposed to both valvular heart disease and immune-mediated processes.\n",
            "\n",
            "2. CONTRADICTORY FINDINGS  \n",
            "   • Alternative Explanations for Anemia:  \n",
            "     – Toxin exposure, bone marrow failure, or microangiopathic processes less likely given strong regenerative response + Coombs’ positivity.  \n",
            "   • Rule-Out Justifications:  \n",
            "     – Infectious etiologies largely ruled out by negative tick-borne panel.  \n",
            "     – Neoplasia: No masses found on imaging; no evidence in blood smear.  \n",
            "   • Confounding Factors:  \n",
            "     – Mild hepatic changes could be from multiple causes (congestion, steroid effect, early hepatic disease).  \n",
            "   • Testing Limitations:  \n",
            "     – Adrenal function testing (ACTH stimulation or low-dose dex suppression test) not performed to confirm hyperadrenocorticism.  \n",
            "     – EKG details not provided.\n",
            "\n",
            "────────────────────────────────────────────────────────────\n",
            "COMPREHENSIVE CLIENT COMMUNICATION & INSTRUCTIONS:\n",
            "\n",
            "• 01/27/25 (Monday) Discussion:\n",
            "  – Informed owner of severe IMHA, positive Coombs’ test, rationale for transfusion, and the need for aggressive immunosuppression.  \n",
            "  – Explained risks of thromboembolism and reason for clopidogrel.  \n",
            "  – Advised overnight hospitalization for monitoring, which owner declined; accepted outpatient therapy.  \n",
            "  – Instructed to observe for labored breathing, pale gums, or further collapses.\n",
            "\n",
            "• 01/28/25 (Tuesday) Follow-Up:\n",
            "  – PCV stable at 31% (09:00 on 01/28/25).  \n",
            "  – Reinforced medication schedule:  \n",
            "    1) Prednisone 10 mg SID PO,  \n",
            "    2) Cyclosporine 25 mg BID PO,  \n",
            "    3) Doxycycline 50 mg SID PO,  \n",
            "    4) Clopidogrel 18.75 mg SID PO,  \n",
            "    5) Continue enalapril/pimobendan/furosemide.  \n",
            "  – Provided prescription for sildenafil 10 mg TID PO to be started only if collapses recur.  \n",
            "  – Diet changed to Hill’s i/d Low Fat at an approximate total of 1⅓ cans/day.  \n",
            "  – Advised to monitor gum color, appetite, and watch for weakness or syncopal events.  \n",
            "  – Next recheck recommended in 1 week or sooner if deterioration.\n",
            "\n",
            "END OF ANALYSIS ON 01/28/25 AT 10:00 AM\n",
            "\n",
            "Diagnostic Assessment:\n",
            "------------------------------\n",
            "PROBLEM LIST:\n",
            "\n",
            "1. ACTIVE PROBLEMS (PRIORITIZED):\n",
            "\n",
            "   1) Immune-Mediated Hemolytic Anemia (IMHA)  \n",
            "      • Duration/Onset: Clinically recognized on 01/27/25 when severe anemia (PCV 15%) was first documented; likely began several days earlier based on rising bilirubin and reticulocytosis.  \n",
            "      • Severity Score (1–10): 9/10 (markedly low hematocrit, profound clinical signs).  \n",
            "      • Progression Pattern: Acute to subacute onset with rapid RBC destruction confirmed by positive Coombs’ test and reticulocytosis. Partial improvement following packed RBC transfusion and immunosuppressive therapy.  \n",
            "      • Related Clinical Findings: Pale mucous membranes (severity ~8/10), mild icterus (3/10), bilirubin 1.9 mg/dL (reference 0.0–0.9 mg/dL), RBC 1.55 M/µL (reference 5.65–8.87 M/µL), HCT 12.2% (37.3–61.7%), HGB 3.2 g/dL (13.1–20.5 g/dL).  \n",
            "      • Impact on Quality of Life: Significant impairment; contributed to lethargy, likely exacerbated syncopal episodes.  \n",
            "      • Current Treatment Status: On immunosuppressive regimen (prednisone 10 mg PO SID, cyclosporine 25 mg PO BID), clopidogrel ~18.75 mg PO SID for thromboprophylaxis. Status: improving as of 01/28/25 with PCV at 31%.\n",
            "\n",
            "   2) Syncope (Collapsing Episodes)  \n",
            "      • Duration/Onset: First episode on 01/23/25, additional episodes on 01/25/25 (two episodes) and 01/27/25 (one episode).  \n",
            "      • Severity Score (1–10): 8/10 (complete loss of consciousness, requiring recovery time).  \n",
            "      • Progression Pattern: Sporadic over a 5-day span (01/23/25–01/27/25), no consistent exertional trigger identified, likely multifactorial (significant anemia, possible cardiac contributions).  \n",
            "      • Related Clinical Findings: Severe anemia on 01/27/25, moderate pulmonary hypertension (estimated 60 mmHg from tricuspid regurgitation velocity on echocardiogram), chronic valvular disease.  \n",
            "      • Impact on Quality of Life: High risk of injury, distress to patient and owner.  \n",
            "      • Current Treatment Status: No episodes reported after 01/28/25. Stabilization of hematocrit has reduced syncopal events. Sildenafil 10 mg PO TID prescribed on 01/28/25 but not yet initiated.\n",
            "\n",
            "   3) Chronic Valvular Disease with Moderate Pulmonary Hypertension  \n",
            "      • Duration/Onset: Valvular insufficiency predates current presentation; murmur noted historically, exact initial diagnosis date not recorded. Pulmonary hypertension confirmed on 01/27/25 echocardiogram.  \n",
            "      • Severity Score (1–10): Valvular disease murmur severity peaked at 4/6 on 01/27/25; mild improvement to 2/6 by 01/28/25. Pulmonary hypertension ~6/10 severity.  \n",
            "      • Progression Pattern: Likely progressive over months; acute exacerbation could occur with anemia.  \n",
            "      • Related Clinical Findings: Grade 4/6 holosystolic murmur at tricuspid area, moderate estimated pulmonary artery pressure (~60 mmHg), mild right ventricular dilation, mild left atrial enlargement.  \n",
            "      • Impact on Quality of Life: Contributes to exercise intolerance, risk of further syncopal events.  \n",
            "      • Current Treatment Status: Ongoing medical management with enalapril 2.5 mg PO SID, pimobendan 1.25 mg PO BID, furosemide 20 mg PO BID; sildenafil 10 mg PO TID reserved if collapse recurs.\n",
            "\n",
            "   4) Non-Productive Cough  \n",
            "      • Duration/Onset: Chronic history for “several months” prior to 01/23/25 (precise start date unknown).  \n",
            "      • Severity Score (1–10): 3–4/10 (mild to moderate).  \n",
            "      • Progression Pattern: Intermittent episodes, often triggered by excitement or increased activity.  \n",
            "      • Related Clinical Findings: Correlates with chronic valvular disease and mild pulmonary changes; partial improvement with furosemide.  \n",
            "      • Impact on Quality of Life: Mild annoyance and occasional discomfort but few systemic effects.  \n",
            "      • Current Treatment Status: Continuing furosemide, enalapril, and pimobendan; cough persists intermittently.\n",
            "\n",
            "   5) Lethargy  \n",
            "      • Duration/Onset: Began 01/25/25, persisting until 01/27/25 when anemia was most severe.  \n",
            "      • Severity Score (1–10): 7/10 (marked decrease in activity and alertness).  \n",
            "      • Progression Pattern: Parallels decline in PCV; improved notably after RBC transfusion.  \n",
            "      • Related Clinical Findings: Low PCV (15% on 01/27/25), pale mucous membranes.  \n",
            "      • Impact on Quality of Life: Marked reduction in normal daily activity.  \n",
            "      • Current Treatment Status: Significantly improved by 01/28/25 (PCV 31%); ongoing immunosuppression to maintain RBC count.\n",
            "\n",
            "   6) Potential Hyperadrenocorticism  \n",
            "      • Duration/Onset: Mild bilateral adrenal enlargement noted on abdominal ultrasound on 01/27/25. No definitive onset date for clinical signs.  \n",
            "      • Severity Score (1–10): 3/10 suspicion level; no overt polyuria/polydipsia or other hallmark clinical signs documented.  \n",
            "      • Progression Pattern: Unknown; only mild ultrasonographic changes at this time.  \n",
            "      • Related Clinical Findings: None definitively linked; possible mild liver enzyme elevation (ALP 382 U/L, reference 23–212 U/L) may or may not be relevant.  \n",
            "      • Impact on Quality of Life: Currently minimal.  \n",
            "      • Current Treatment Status: No definitive treatment initiated; further endocrine testing pending stabilization of IMHA.\n",
            "\n",
            "2. INACTIVE/RESOLVED PROBLEMS:\n",
            "\n",
            "   1) Single Vomiting Episode  \n",
            "      • Original Diagnosis Date: 01/26/25 (post-meal emesis).  \n",
            "      • Resolution Date: 01/26/25 (no recurrence after dietary adjustment).  \n",
            "      • Treatment Provided: None specific (no antiemetics).  \n",
            "      • Risk of Recurrence: Low, but possible if dietary indiscretion or GI upset recurs.  \n",
            "      • Monitoring Requirements: Owner instructed to watch for further vomiting, maintain consistent diet.\n",
            "\n",
            "────────────────────────────────────────────────────────\n",
            "\n",
            "DIFFERENTIAL DIAGNOSES:\n",
            "\n",
            "1. PRIMARY DIFFERENTIAL LIST  \n",
            "   (A) Primary Immune-Mediated Hemolytic Anemia (Confirmed)  \n",
            "       • Supporting Evidence: Positive Coombs’ at 1:8 (37 °C incubation), marked regenerative anemia (reticulocyte 35.6%, absolute retics 552.1 K/µL, reference 10.0–110.0 K/µL), hyperbilirubinemia (1.9 mg/dL, reference 0.0–0.9 mg/dL), clinical response to immunosuppression.  \n",
            "       • Contradicting Evidence: None strongly contradicting; mild concern for secondary triggers (endocrine, neoplasia) still possible.  \n",
            "       • Diagnostic Criteria Met/Unmet: Met major criteria (Coombs’ positive, regenerative anemia, spherocytes observed).  \n",
            "       • Population Prevalence: One of the most common causes of hemolytic anemia in dogs.  \n",
            "       • Age/Breed Predisposition: Small/toy breeds can be predisposed; exact breed not specified but consistent with known patterns.  \n",
            "       • Required Diagnostics: Ongoing CBC monitoring, serum chemistry, imaging to rule out underlying triggers (already performed abdominal ultrasound; no neoplasia identified).\n",
            "\n",
            "   (B) Infectious Hemolytic Anemia (Babesia, Ehrlichia, Anaplasma, etc.)  \n",
            "       • Supporting Evidence: Empirical coverage with doxycycline was considered.  \n",
            "       • Contradicting Evidence: Negative tick-borne PCR panel, no organisms noted on blood smear.  \n",
            "       • Diagnostic Criteria Met/Unmet: Not met; no laboratory or clinical findings supportive of active infection.  \n",
            "       • Population Prevalence: Regionally dependent.  \n",
            "       • Age/Breed Predisposition: Varies, but typically higher in dogs with tick exposure.  \n",
            "       • Required Diagnostics: PCR panel (already completed and negative).\n",
            "\n",
            "   (C) Neoplastic Process (e.g., Hemangiosarcoma causing RBC destruction)  \n",
            "       • Supporting Evidence: Splenomegaly can sometimes raise suspicion.  \n",
            "       • Contradicting Evidence: Ultrasound showed moderate splenomegaly without discrete masses, no abnormal cells on CBC.  \n",
            "       • Diagnostic Criteria Met/Unmet: Not met; no imaging or lab evidence of neoplasia.  \n",
            "       • Population Prevalence: Common in older dogs; typically accompanied by mass lesions or other cytologic changes.  \n",
            "       • Age/Breed Predisposition: Higher in large breeds (German Shepherd, Golden Retriever).  \n",
            "       • Required Diagnostics: Further imaging or splenic aspirate if suspicion increases.\n",
            "\n",
            "   (D) Primary Pulmonary Hypertension (for Syncope Differential)  \n",
            "       • Supporting Evidence: Tricuspid regurgitation Vmax estimated ~60 mmHg, right ventricular dilation on echocardiogram.  \n",
            "       • Contradicting Evidence: Could be secondary to left-sided heart disease or IMHA-induced vascular changes.  \n",
            "       • Diagnostic Criteria Met/Unmet: Meets echocardiographic criteria for moderate pulmonary hypertension, but etiology uncertain.  \n",
            "       • Population Prevalence: Less common than heart-failure–associated or secondary pulmonary hypertension.  \n",
            "       • Age/Breed Predisposition: Small breed dogs with chronic valvular disease are prone to secondary pulmonary hypertension.  \n",
            "       • Required Diagnostics: Serial echocardiograms, sedation for advanced cardiopulmonary testing if indicated.\n",
            "\n",
            "2. SECONDARY DIFFERENTIAL LIST  \n",
            "   (A) Potential Hyperadrenocorticism  \n",
            "       • Reason for Lower Priority: No clinical signs of Cushing’s (e.g., polyuria, polydipsia, alopecia) aside from mild liver enzyme elevation and mildly enlarged adrenals on ultrasound.  \n",
            "       • Required Rule-Out Criteria: ACTH stimulation test or low-dose dexamethasone suppression test to confirm.  \n",
            "       • Testing Recommendations: Perform endocrine testing once IMHA is stabilized.\n",
            "\n",
            "   (B) Atypical Pneumonia or Airway Disease (for Chronic Cough)  \n",
            "       • Reason for Lower Priority: Cough likely cardiac in origin; no radiographic evidence of pneumonia from referring veterinarian’s 01/25/25 chest films.  \n",
            "       • Required Rule-Out Criteria: Airway wash or bronchoscopy if cough worsens or fails to respond to current therapy.  \n",
            "       • Testing Recommendations: Repeat thoracic imaging if cough becomes more frequent or severe.\n",
            "\n",
            "────────────────────────────────────────────────────────\n",
            "\n",
            "DIAGNOSTIC PLAN:\n",
            "\n",
            "1. IMMEDIATE DIAGNOSTICS  \n",
            "   (A) None additional recommended immediately beyond what has been performed. The critical diagnostics (CBC, Coombs’ test, tick-borne panel, echocardiogram, and ultrasound) are complete.  \n",
            "       • Justification: Current data strongly support a primary IMHA diagnosis with concurrent cardiac disease.  \n",
            "       • Expected Findings: N/A (no new immediate tests).  \n",
            "       • Result Interpretation Criteria: N/A.  \n",
            "       • Cost-Benefit Assessment: Further immediate advanced diagnostics not indicated unless clinical deterioration occurs.  \n",
            "       • Sample Handling Requirements: N/A.  \n",
            "       • Timing Considerations: N/A.\n",
            "\n",
            "2. MONITORING DIAGNOSTICS  \n",
            "   (A) Complete Blood Count (CBC) and Reticulocyte Count  \n",
            "       • Frequency of Measurement: Every 3–5 days until hematocrit stabilizes ≥30% without transfusion support; then weekly or biweekly as needed.  \n",
            "       • Alert Thresholds: PCV <20% or rapid drop >10% over 24 hours merits recheck and possible transfusion.  \n",
            "       • Trend Analysis Criteria: Increasing reticulocyte count indicates regenerative response; stable or rising PCV suggests improved RBC survival.  \n",
            "       • Action Triggers: Drop in PCV or rising bilirubin prompts reassessment of immunosuppressive protocol.\n",
            "\n",
            "   (B) Serum Biochemistry Profile  \n",
            "       • Frequency of Measurement: Every 2 weeks during initial immunosuppressive therapy; monitor liver enzymes (ALP, ALT), BUN/creatinine for drug side effects.  \n",
            "       • Alert Thresholds: Marked ALP/ALT elevation (>3× baseline), progressive azotemia, or electrolyte imbalance.  \n",
            "       • Trend Analysis Criteria: Stabilization or improvement of hepatic parameters expected if steroid-related changes remain mild.  \n",
            "       • Action Triggers: Consider adjusting prednisone or cyclosporine if severe enzyme elevations occur.\n",
            "\n",
            "   (C) Adrenal Function Testing  \n",
            "       • Frequency of Measurement: One-time confirmatory testing (ACTH stimulation or LDDS) if clinical suspicion of hyperadrenocorticism increases once IMHA is controlled.  \n",
            "       • Alert Thresholds: Any emergence of classic Cushing’s signs (polyuria, polydipsia, abdominal distention).  \n",
            "       • Trend Analysis Criteria: N/A.  \n",
            "       • Action Triggers: Positive adrenal function test would prompt concurrent management of hyperadrenocorticism.\n",
            "\n",
            "   (D) Repeat Echocardiogram  \n",
            "       • Frequency of Measurement: In ~3–4 months or sooner if recurrence of syncopal episodes or respiratory distress.  \n",
            "       • Alert Thresholds: Worsening tricuspid regurgitation velocity or right-sided enlargement.  \n",
            "       • Trend Analysis Criteria: Improvement or stability in pulmonary artery pressures if sildenafil is initiated in the future.  \n",
            "       • Action Triggers: Adjustment of cardiac medications, possible addition or escalation of pulmonary vasodilators.\n",
            "\n",
            "────────────────────────────────────────────────────────\n",
            "\n",
            "THERAPEUTIC PLAN:\n",
            "\n",
            "1. IMMEDIATE INTERVENTIONS  \n",
            "   (A) Immunosuppressive Therapy  \n",
            "       • Drug Name/Dose/Route/Frequency:  \n",
            "         – Prednisone 10 mg PO SID (initiated 01/27/25)  \n",
            "         – Cyclosporine (Atopica) 25 mg PO BID (started 01/27/25–01/28/25)  \n",
            "       • Monitoring Requirements: CBC and chemistry at least every 1–2 weeks to assess efficacy and side effects (liver enzymes, GI signs).  \n",
            "       • Expected Response Timeline: Partial control of hemolysis within 24–72 hours; full stabilization may require 1–2 weeks.  \n",
            "       • Adverse Effect Monitoring: Polydipsia, polyphagia, GI upset, gingival hyperplasia (cyclosporine).  \n",
            "       • Criteria for Success or Failure by Next Reassessment: PCV maintained ≥30% without transfusion, no resurgence of hemolysis. If PCV <25% or clinical deterioration, escalate or modify therapy.  \n",
            "       • Timeline for Modifications: Adjust doses after 2–3 weeks if stable, or sooner if hematocrit drops.\n",
            "\n",
            "   (B) Thromboprophylaxis  \n",
            "       • Drug Name/Dose/Route/Frequency: Clopidogrel (Plavix) ~18.75 mg PO SID (initiated 01/27/25).  \n",
            "       • Monitoring Requirements: Monitor for signs of bleeding; platelet function not routinely measured unless clinically indicated.  \n",
            "       • Expected Response Timeline: Platelet inhibition within days.  \n",
            "       • Adverse Effect Monitoring: Bruising, hematuria, epistaxis.  \n",
            "       • Criteria for Success: No thromboembolic events; stable RBC morphology.  \n",
            "       • Timeline for Modifications: Typically continued at least through active hemolysis phase; taper if IMHA stably resolved.\n",
            "\n",
            "   (C) Packed RBC Transfusion  \n",
            "       • Dose/Route/Timing: 125 mL transfused IV over 4 hours on 01/27/25.  \n",
            "       • Monitoring Requirements: Frequent vitals, PCV checks pre- and post-transfusion.  \n",
            "       • Expected Response Timeline: Immediate hematocrit rise from 15% to 30% by 20:55 on 01/27/25.  \n",
            "       • Adverse Effect Monitoring: Transfusion reactions (fever, tachycardia, vomiting, hemolysis).  \n",
            "       • Criteria for Success: PCV maintained post-transfusion without further rapid decline.  \n",
            "       • Timeline for Modifications: Repeat transfusion only if PCV drops below 20% or severe clinical signs recur.\n",
            "\n",
            "   (D) Dexamethasone SP IV Bolus  \n",
            "       • Dose/Route/Timing: 4 mg/mL solution at 0.37 mL IV on 01/27/25.  \n",
            "       • Monitoring Requirements: Same as immunosuppressive therapy.  \n",
            "       • Expected Response: Rapid anti-inflammatory effect bridging to oral steroids.  \n",
            "       • Adverse Effect Monitoring: As with steroids (GI upset, hyperglycemia).  \n",
            "       • Criteria for Success: Stabilization of RBC destruction.  \n",
            "       • Timeline for Modifications: Single dose; no ongoing IV dexamethasone planned.\n",
            "\n",
            "2. LONG-TERM MANAGEMENT  \n",
            "   (A) Chronic Cardiac Medications  \n",
            "       • Drugs: Enalapril 2.5 mg PO SID, Pimobendan 1.25 mg PO BID, Furosemide 20 mg PO BID.  \n",
            "       • Specific Outcome Goals: Maintain stable cardiac status, minimize pulmonary edema, reduce cough.  \n",
            "       • Timeline for Reassessment: Clinical recheck in 1 week (around 02/04/25) or sooner if new collapse, then at 1-month intervals.  \n",
            "       • Quality of Life Parameters: Exercise tolerance, absence of respiratory distress or repeated syncope.  \n",
            "       • Client Education Points: Recognize worsening cough, respiratory rate >40 breaths/min, gum pallor.  \n",
            "       • Environmental Modifications: Limit excessively strenuous activity that may precipitate syncope.  \n",
            "       • Dietary Recommendations: Maintain a consistent, low-sodium diet as tolerated (currently Hill’s i/d Low Fat ~1⅓ cans/day).  \n",
            "       • Success Criteria: Stable respiratory rate, no further collapse, stable or improved heart murmur grade. Failure if exacerbation of heart failure or uncontrolled arrhythmias.  \n",
            "       • Timeline for Modifications: Adjust diuretics or add sildenafil if syncope recurs or pulmonary pressures worsen.\n",
            "\n",
            "   (B) IMHA Maintenance Immunosuppression  \n",
            "       • Specific Outcome Goals: Achieve and maintain PCV ≥35%, resolution of hyperbilirubinemia, normal RBC indices.  \n",
            "       • Timeline for Reassessment: CBC in ~3–5 days, then weekly; reevaluate medication taper in ~3–4 weeks if stable.  \n",
            "       • Quality of Life Parameters: Return of normal activity, appetite, and resolution of pallor or icterus.  \n",
            "       • Client Education Points: Watch for increased thirst, urination, appetite changes, or GI upset from steroids; report any signs of relapse.  \n",
            "       • Environmental Modifications: Minimize stressors that could exacerbate immune dysregulation.  \n",
            "       • Dietary Recommendations: Continue Hill’s i/d Low Fat or other easily digestible formula to reduce GI side effects.  \n",
            "       • Success Criteria: Stable RBC count without further transfusions, downward taper of prednisone over 2–3 months.  \n",
            "       • Timeline for Modifications: If PCV remains stable at >35%, begin slow steroid taper at 3–4 weeks. If PCV <25%, consider increasing doses or adding adjuncts.\n",
            "\n",
            "   (C) Possible Hyperadrenocorticism Evaluation  \n",
            "       • Specific Outcome Goals: Confirm or rule out Cushing’s once IMHA is controlled.  \n",
            "       • Timeline for Reassessment: After IMHA is stable (≥4 weeks from presentation, e.g., after ~02/24/25), perform ACTH stimulation or LDDS test if clinical suspicion remains.  \n",
            "       • Quality of Life Parameters: Monitor for PU/PD, panting, abdominal distension.  \n",
            "       • Client Education Points: Distinguish typical steroid-induced side effects from naturally occurring hyperadrenocorticism.  \n",
            "       • Environmental Modifications: None specific pending confirmation.  \n",
            "       • Dietary Recommendations: Maintain balanced diet; avoid excessive caloric intake if iatrogenic hypercortisolism suspected.  \n",
            "       • Success Criteria: If tests confirm no hyperadrenocorticism, no further endocrine therapy needed.  \n",
            "       • Timeline for Modifications: Adjust plan if test results are positive for Cushing’s, potentially adding trilostane or mitotane.\n",
            "\n",
            "────────────────────────────────────────────────────────\n",
            "CLIENT COMMUNICATION & INSTRUCTIONS (DOCUMENTED):\n",
            "\n",
            "• 01/27/25 (Monday):  \n",
            "  – Explained severe immune-mediated hemolytic anemia diagnosis (positive Coombs’ test), rationale for packed RBC transfusion, and urgent need for immunosuppression.  \n",
            "  – Discussed thrombosis risk and need for clopidogrel.  \n",
            "  – Recommended in-hospital observation; owner elected outpatient care.  \n",
            "  – Instructed to watch for rapid breathing, pale gums, weakness, or recurrences of collapse.\n",
            "\n",
            "• 01/28/25 (Tuesday) 09:00:  \n",
            "  – PCV stable at 31%.  \n",
            "  – Reinforced medication schedule:  \n",
            "       1) Prednisone 10 mg PO SID  \n",
            "       2) Cyclosporine (Atopica) 25 mg PO BID  \n",
            "       3) Doxycycline 50 mg PO SID (empirical coverage; negative tick panel)  \n",
            "       4) Clopidogrel ~18.75 mg PO SID  \n",
            "       5) Continue enalapril (2.5 mg PO SID), pimobendan (1.25 mg PO BID), furosemide (20 mg PO BID).  \n",
            "  – Provided sildenafil (10 mg PO TID) prescription to initiate ONLY if new syncopal episodes occur.  \n",
            "  – Diet changed to Hill’s i/d Low Fat (~1⅓ cans/day).  \n",
            "  – Advised close monitoring of mucous membrane color, appetite, energy level, and for any further collapsing events.  \n",
            "  – Next recheck scheduled for ~02/04/25 or earlier if clinical deterioration.\n",
            "\n",
            "────────────────────────────────────────────────────────\n",
            "END OF DOCUMENTATION (01/28/25, 10:00 AM)\n",
            "\n",
            "Specialist Summary:\n",
            "------------------------------\n",
            "SPECIALIST CONSULTATION:\n",
            "\n",
            "1. CASE SUMMARY  \n",
            "   • Chronological History and Prior Treatments:  \n",
            "     – On 01/23/25, first recorded syncopal (collapsing) episode occurred, with two more episodes on 01/25/25 and another on 01/27/25.  \n",
            "     – On 01/25/25, lethargy noted, which persisted until 01/27/25.  \n",
            "     – On 01/26/25, there was a single post-meal vomiting episode that resolved the same day.  \n",
            "     – On 01/27/25, severe anemia documented (PCV 15%), prompting packed RBC transfusion (125 mL IV over 4 hours). Positive Coombs’ test confirmed immune-mediated hemolytic anemia. Dexamethasone SP 4 mg/mL solution at 0.37 mL IV was administered. Prednisone 10 mg PO SID, cyclosporine 25 mg PO BID, and clopidogrel ~18.75 mg PO SID were initiated on 01/27/25–01/28/25.  \n",
            "     – Concurrent chronic valvular disease and moderate pulmonary hypertension were noted on echocardiogram performed on 01/27/25. Tricuspid regurgitation velocity indicated ~60 mmHg pulmonary artery pressures.  \n",
            "     – Non-productive cough has been present for several months (exact start date not recorded), partially responsive to furosemide.  \n",
            "     – Potential hyperadrenocorticism identified via mild bilateral adrenal enlargement on 01/27/25 abdominal ultrasound, though no definitive clinical signs.  \n",
            "     – By 01/28/25, PCV was stable at 31%, syncopal episodes ceased.  \n",
            "     – Current cardiac medications include enalapril 2.5 mg PO SID, pimobendan 1.25 mg PO BID, and furosemide 20 mg PO BID.  \n",
            "     – A prescription for sildenafil (10 mg PO TID) was provided on 01/28/25 for possible later use if syncope recurs.\n",
            "\n",
            "   • Every Diagnostic Result:  \n",
            "     – CBC on 01/27/25: RBC 1.55 M/µL (reference 5.65–8.87 M/µL), HCT 12.2% (reference 37.3–61.7%), HGB 3.2 g/dL (reference 13.1–20.5 g/dL), PCV 15% (critical).  \n",
            "     – Reticulocyte count: 35.6% with absolute 552.1 K/µL (reference 10.0–110.0 K/µL), indicating strong regenerative response.  \n",
            "     – Bilirubin 1.9 mg/dL (reference 0.0–0.9 mg/dL).  \n",
            "     – Positive Coombs’ test at 1:8 (37 °C incubation).  \n",
            "     – Tick-borne PCR panel negative.  \n",
            "     – Echocardiogram (01/27/25): Moderate pulmonary hypertension (~60 mmHg), grade 4/6 holosystolic murmur at tricuspid area, mild right ventricular dilation, mild left atrial enlargement.  \n",
            "     – Abdominal ultrasound (01/27/25): Mild bilateral adrenal enlargement, moderate splenomegaly without discrete masses.  \n",
            "     – Serum chemistry (01/27/25): ALP 382 U/L (reference 23–212 U/L); mild elevation suggestive of possible steroid or endocrine influence.  \n",
            "\n",
            "   • Specific Clinical Progression and Current Status:  \n",
            "     – IMHA: Marked anemia on 01/27/25 with PCV 15% improved to 31% by 01/28/25 following transfusion and immunosuppression.  \n",
            "     – Syncope: Four total episodes from 01/23/25 through 01/27/25, none recorded after 01/28/25.  \n",
            "     – Chronic valvular disease: Ongoing, with a murmur intensity that decreased from 4/6 to 2/6 by 01/28/25.  \n",
            "     – Pulmonary hypertension: Confirmed at moderate severity; not yet treated with sildenafil.  \n",
            "     – Cough: Mild, intermittent, likely multifactorial (cardiac-related).  \n",
            "     – Lethargy: Significantly improved with correction of anemia.  \n",
            "     – Suspicion of hyperadrenocorticism: Low index of suspicion clinically; testing deferred until IMHA stabilization.  \n",
            "\n",
            "2. DISEASE PROCESS ANALYSIS  \n",
            "   • IMHA Pathophysiology:  \n",
            "     – Autoantibody-mediated destruction of red blood cells leading to severe, regenerative anemia. Contributing factors may include genetic predisposition or subclinical triggers (infection, neoplasia); however, no secondary cause has been identified at this time.  \n",
            "   • Current Disease Stage:  \n",
            "     – Actively managing primary IMHA with partial stabilization achieved. PCV improved from 15% to 31% as of 01/28/25.  \n",
            "   • Progression Factors:  \n",
            "     – Inadequate immunosuppression may result in ongoing hemolysis.  \n",
            "     – Thromboembolic risk remains high in IMHA.  \n",
            "   • Complicating Conditions:  \n",
            "     – Chronic valvular disease and moderate pulmonary hypertension may exacerbate syncopal episodes.  \n",
            "     – Possible hyperadrenocorticism could complicate immunosuppressive therapy, though unproven.  \n",
            "   • Prognosis Assessment:  \n",
            "     – Cautiously fair to good with sustained immunosuppressive control and vigilant cardiovascular management. Key prognostic indicators include stable or rising PCV, absence of relapse, and avoidance of severe thromboembolic events.\n",
            "\n",
            "3. TREATMENT ANALYSIS  \n",
            "   • Response to Previous Treatments:  \n",
            "     – RBC transfusion on 01/27/25 led to rapid increase in PCV from 15% to 30%–31%.  \n",
            "     – Immunosuppressive therapy (oral prednisone and cyclosporine) initiated 01/27/25–01/28/25 is showing early effectiveness.  \n",
            "     – Thromboprophylaxis (clopidogrel) started 01/27/25 as prophylaxis against thromboembolism.  \n",
            "   • Current Treatment Efficacy:  \n",
            "     – PCV remained stable at 31% by 01/28/25, indicating robust response to transfusion plus immunosuppression. Syncope has not recurred since 01/28/25.  \n",
            "     – Chronic cardiac medications (enalapril, pimobendan, furosemide) appear to maintain stable heart function and provide partial control of cough.  \n",
            "   • Treatment Complications:  \n",
            "     – Potential steroid-related side effects (polyuria, polydipsia, polyphagia, liver enzyme elevation) require monitoring.  \n",
            "     – IMHA itself predisposes to thromboembolic complications despite clopidogrel use.  \n",
            "   • Compliance Assessment:  \n",
            "     – Owner has been receptive to medication schedules, though initially declined in-hospital observation. They have been instructed carefully on at-home monitoring.  \n",
            "   • Risk-Benefit Analysis:  \n",
            "     – Immunosuppression is vital to control RBC destruction, but it increases susceptibility to infection and can unmask or exacerbate hyperadrenocorticism.  \n",
            "     – Thromboprophylaxis helps reduce embolic risks, with minimal adverse effects generally.  \n",
            "     – Ongoing cardiac medications are essential to mitigate heart failure progression and control pulmonary hypertension.\n",
            "\n",
            "4. SPECIALIST RECOMMENDATIONS  \n",
            "   1) Continue Immunosuppressive Therapy (Prednisone and Cyclosporine)  \n",
            "      • Scientific Rationale: Suppresses ongoing autoantibody production and RBC destruction.  \n",
            "      • Expected Outcome: Maintain or increase PCV above 30%, reduce likelihood of recurrent severe anemia.  \n",
            "      • Monitoring Parameters: CBC every 3–5 days until stabilized, then weekly or biweekly.  \n",
            "      • Alternative Options: Additional immunosuppressants (e.g., mycophenolate) if refractory disease arises.\n",
            "\n",
            "   2) Maintain Thromboprophylaxis with Clopidogrel  \n",
            "      • Scientific Rationale: IMHA commonly predisposes to thromboembolism.  \n",
            "      • Expected Outcome: Reduced incidence of thrombotic events (e.g., pulmonary embolism).  \n",
            "      • Monitoring Parameters: Observation for excessive bruising, bleeding; no routine platelet function testing unless clinical concern.  \n",
            "      • Alternative Options: Addition of low-dose aspirin or low molecular weight heparin if thrombosis occurs.\n",
            "\n",
            "   3) Cardiac Support Regimen  \n",
            "      • Scientific Rationale: Mitigate progression of chronic valvular disease, control fluid retention, stabilize pulmonary pressures.  \n",
            "      • Expected Outcome: Minimized risk of syncope and congestive heart failure.  \n",
            "      • Monitoring Parameters: Regular auscultation for murmur intensity, respiratory rate checks, periodic echocardiograms.  \n",
            "      • Alternative Options: Adjust diuretics or add sildenafil if recurrent collapse or confirmed severe pulmonary hypertension.\n",
            "\n",
            "   4) Possible Hyperadrenocorticism Investigation  \n",
            "      • Scientific Rationale: Mild adrenal enlargement and elevated ALP raise suspicion; glucocorticoid therapy can influence testing.  \n",
            "      • Expected Outcome: Confirm or rule out Cushing’s once hematologic status is stable.  \n",
            "      • Monitoring Parameters: ACTH stimulation or low-dose dexamethasone suppression test after IMHA control.  \n",
            "      • Alternative Options: Postpone further endocrine testing if no clinical signs develop.\n",
            "\n",
            "────────────────────────────────────────────────────────\n",
            "COMPREHENSIVE PLAN:\n",
            "\n",
            "1. MEDICAL MANAGEMENT  \n",
            "   • Immunosuppressive Therapy:  \n",
            "     – Prednisone 10 mg PO once daily; continue at this dose for at least 2–3 weeks.  \n",
            "       ▫ Monitor for polyuria, polydipsia, polyphagia, GI upset.  \n",
            "       ▫ Success Criteria: PCV ≥30% without breakthrough hemolysis.  \n",
            "       ▫ Modification Trigger: PCV drop <25% or appearance of significant steroid-induced side effects.  \n",
            "\n",
            "     – Cyclosporine (Atopica) 25 mg PO twice daily.  \n",
            "       ▫ Monitor GI signs, gingival hyperplasia.  \n",
            "       ▫ Success Criteria: Stabilized RBC count in conjunction with prednisone.  \n",
            "       ▫ Modification Trigger: Lack of hematocrit improvement or severe adverse effects.  \n",
            "\n",
            "   • Thromboprophylaxis:  \n",
            "     – Clopidogrel (Plavix) ~18.75 mg PO once daily.  \n",
            "       ▫ Monitor for bleeding tendencies (hematuria, petechiae).  \n",
            "       ▫ Continue for duration of active hemolysis or until IMHA in full remission.  \n",
            "       ▫ Success Criteria: No thromboembolic events.  \n",
            "       ▫ Modification Trigger: Clinical or laboratory evidence of unwanted bleeding.  \n",
            "\n",
            "   • Chronic Cardiac Medications:  \n",
            "     – Enalapril 2.5 mg PO once daily.  \n",
            "     – Pimobendan 1.25 mg PO twice daily.  \n",
            "     – Furosemide 20 mg PO twice daily.  \n",
            "       ▫ Monitor respiratory rate (<30 breaths/min at rest), watch for cough frequency and exercise intolerance.  \n",
            "       ▫ Success Criteria: Stable cardiac parameters, reduced risk of fluid overload.  \n",
            "       ▫ Modification Trigger: Worsening murmur intensity, respiratory distress, or recurrent syncope.\n",
            "\n",
            "   • Reserved Pulmonary Vasodilator:  \n",
            "     – Sildenafil 10 mg PO three times daily to be commenced only if new syncopal episodes or if confirmed worsening pulmonary hypertension.\n",
            "\n",
            "2. MONITORING PROTOCOL  \n",
            "   • CBC with Reticulocyte Count:  \n",
            "     – Frequency: Every 3–5 days until PCV remains ≥30% without transfusion, then weekly or biweekly.  \n",
            "     – Target/Acceptable Range: PCV >30% indicates adequate control.  \n",
            "     – Action Threshold: PCV <20% or a rapid drop ≥10% prompts immediate recheck and potential transfusion.  \n",
            "     – Response Protocol: If PCV decreases, reevaluate immunosuppressive dosages or consider additional transfusion.  \n",
            "\n",
            "   • Serum Biochemistry Profile:  \n",
            "     – Frequency: Every 2 weeks while on immunosuppression to monitor ALP, ALT, BUN, creatinine.  \n",
            "     – Target/Acceptable Range: Less than ~3× baseline elevation for ALP/ALT.  \n",
            "     – Action Threshold: Significant elevations (>3× baseline) or azotemia necessitate dose adjustments.  \n",
            "     – Response Protocol: If marked abnormalities occur, consider alternative immunosuppressive strategies, GI protectants, or hepatic support.  \n",
            "\n",
            "   • Adrenal Function Testing:  \n",
            "     – Frequency: One-time confirmatory test (ACTH stimulation or low-dose dexamethasone suppression) if clinical suspicion rises after IMHA stabilization.  \n",
            "     – Target/Acceptable Range: Normal cortisol suppression or stimulation curve.  \n",
            "     – Action Threshold: Emergence of polyuria, polydipsia, abdominal distension.  \n",
            "     – Response Protocol: If positive, initiate trilostane or mitotane per standard hyperadrenocorticism protocols.  \n",
            "\n",
            "   • Echocardiogram:  \n",
            "     – Frequency: In ~3–4 months or earlier if recurrent collapse or dyspnea.  \n",
            "     – Target/Acceptable Range: Stabilized or improved tricuspid regurgitation velocity (<60 mmHg).  \n",
            "     – Action Threshold: Increased pulmonary pressures or right ventricular remodeling.  \n",
            "     – Response Protocol: Escalate cardiac medications or add sildenafil if pulmonary hypertension worsens.\n",
            "\n",
            "3. CLIENT EDUCATION  \n",
            "   • Disease Process Explanation:  \n",
            "     – IMHA is an autoimmune condition leading to RBC destruction; requires coordinated immunosuppression and close monitoring.  \n",
            "     – Chronic valvular disease and pulmonary hypertension can cause exercise intolerance and potential syncopal episodes.  \n",
            "   • Treatment Rationale:  \n",
            "     – Prednisone and cyclosporine reduce RBC destruction.  \n",
            "     – Clopidogrel helps prevent blood clots.  \n",
            "     – Cardiac medications support heart function and reduce fluid buildup.  \n",
            "   • Administration Instructions:  \n",
            "     – Give prednisone once daily, cyclosporine twice daily, and clopidogrel once daily.  \n",
            "     – Continue enalapril once daily, pimobendan twice daily, furosemide twice daily.  \n",
            "     – Only start sildenafil 10 mg PO three times daily if episodes of collapse return or if directed by the veterinarian.  \n",
            "   • Monitoring Requirements:  \n",
            "     – Check mucous membranes daily for pallor or jaundice.  \n",
            "     – Observe daily activity, appetite, and watch for coughing or respiratory distress.  \n",
            "     – Record any episodes of weakness or collapse, and contact the clinic if they occur.  \n",
            "   • Warning Signs:  \n",
            "     – Sudden pale or white gums, rapid breathing (>40 breaths/min at rest), uncontrollable bleeding (nose, urine, feces), repeated collapse, severe vomiting, or diarrhea.  \n",
            "   • Emergency Protocols:  \n",
            "     – If collapse occurs, keep the pet calm and contact the veterinary hospital immediately.  \n",
            "     – Seek immediate attention for signs of severe anemia or acute respiratory distress.\n",
            "\n",
            "4. FOLLOW-UP SCHEDULE  \n",
            "   • Specific Recheck Dates:  \n",
            "     – Next recheck around 02/04/25 (7 days from 01/28/25) for physical exam, CBC, and chemistry panel.  \n",
            "   • Testing Schedule:  \n",
            "     – CBC every 3–5 days until PCV remains stable ≥30%.  \n",
            "     – Biochemistry every 2 weeks initially.  \n",
            "   • Progress Assessment Criteria:  \n",
            "     – Maintenance of PCV ≥30%, absence of new syncopal events, stable respiratory rates.  \n",
            "   • Long-Term Monitoring Plan:  \n",
            "     – Monthly to bimonthly evaluations once steady-state is reached.  \n",
            "     – Repeat echocardiogram in ~3–4 months or earlier if clinical changes occur.  \n",
            "   • Quality of Life Assessment:  \n",
            "     – Monitor normalcy of activity level, appetite, respiratory comfort, and absence of significant side effects from immunosuppressants.  \n",
            "\n",
            "────────────────────────────────────────────────────────\n",
            "DOCUMENTED CLIENT COMMUNICATION & INSTRUCTIONS\n",
            "\n",
            "• On 01/27/25:  \n",
            "  – Discussed positive Coombs’ test and severe anemia; recommended packed RBC transfusion and immunosuppressive therapy.  \n",
            "  – Explained thrombosis risk and need for clopidogrel.  \n",
            "  – Owner declined hospital observation; outpatient care chosen.  \n",
            "  – Instructed owner to watch for tachypnea, pale gums, weakness, or repeat collapse.  \n",
            "\n",
            "• On 01/28/25 at 09:00:  \n",
            "  – PCV stabilized at 31%.  \n",
            "  – Reinforced medication schedule:  \n",
            "       1) Prednisone 10 mg PO SID  \n",
            "       2) Cyclosporine 25 mg PO BID  \n",
            "       3) Doxycycline 50 mg PO SID (empirical coverage as tick-borne panel returned negative)  \n",
            "       4) Clopidogrel ~18.75 mg PO SID  \n",
            "       5) Continue enalapril 2.5 mg PO SID, pimobendan 1.25 mg PO BID, furosemide 20 mg PO BID  \n",
            "  – Provided sildenafil 10 mg PO TID prescription to start ONLY if new syncopal episodes occur.  \n",
            "  – Diet changed to Hill’s i/d Low Fat at ~1⅓ cans/day.  \n",
            "  – Advised to monitor for mucous membrane color changes, appetite, lethargy, or collapses.  \n",
            "  – Next recheck scheduled for ~02/04/25 or sooner if clinical decline is noted.\n",
            "\n",
            "END OF DOCUMENTATION (01/28/25, 10:00 AM)\n",
            "\n",
            "Connections Analysis:\n",
            "------------------------------\n",
            "CASE SYNTHESIS:\n",
            "\n",
            "1. DISEASE INTERACTIONS\n",
            "\n",
            "   • Primary–Secondary Disease Relationships:\n",
            "     – Causal Connections:  \n",
            "       • Immune-mediated hemolysis (confirmed by positive Coombs’ at 1:8 on 01/27/25) is the primary cause of severe anemia (PCV as low as 15% on 01/27/25).  \n",
            "       • Chronic cardiac disease (mild tricuspid regurgitation + moderate pulmonary hypertension, echocardiogram on 01/27/25) likely contributed to syncopal episodes, especially when anemia was severe.  \n",
            "       • The mild adrenal enlargement seen on 01/27/25 ultrasound (right adrenal 0.79 × 0.49 cm, left adrenal 0.58 × 0.51 cm) may indicate early hyperadrenocorticism; this can predispose to or exacerbate immunologic imbalances.  \n",
            "\n",
            "     – Exacerbating Factors:  \n",
            "       • Marked anemia (RBC 1.55 M/µL, HCT 12.2%, HGB 3.2 g/dL on 01/27/25) aggravated cardiac stress, raising risk of fainting.  \n",
            "       • Preexisting cough and possible airway sensitivity, though not directly exacerbating IMHA, might have complicated overall respiratory status.  \n",
            "\n",
            "     – Systemic Effects:  \n",
            "       • Hemolysis led to hyperbilirubinemia (1.9 mg/dL; reference 0.0–0.9 mg/dL on 01/27/25), mild icterus on exams (01/27/25–01/28/25), and pallor.  \n",
            "       • Pulmonary hypertension (tricuspid regurgitation velocity suggesting up to 60 mmHg) contributes to compromised cardiopulmonary function.  \n",
            "\n",
            "     – Progressive Impacts:  \n",
            "       • Without immunosuppressive therapy, IMHA could rapidly progress to life-threatening anemia.  \n",
            "       • Ongoing cardiac disease predisposes to potential fluid overload or arrhythmic events if not adequately managed.  \n",
            "\n",
            "   • Complicating Factors:\n",
            "     – Concurrent Conditions:  \n",
            "       • Potential Cushing’s disease (mild adrenal enlargement) may overlap with artificially elevated ALP from exogenous steroids (prednisone started 01/27/25).  \n",
            "       • Chronic valvular disease and mild right-sided dilation add complexity to management of syncope.\n",
            "\n",
            "     – Age-Related Factors:  \n",
            "       • At 10.5 years old (DOB 03/19/14), this Chihuahua mix is more prone to degenerative valvular disease and immune-mediated conditions.\n",
            "\n",
            "     – Breed Predispositions:  \n",
            "       • Small-breed dogs can be predisposed to both valvular cardiac disease and IMHA.  \n",
            "\n",
            "     – Environmental Influences:  \n",
            "       • The patient has two home addresses in Kentucky; no evidence of tick exposure though a tick-borne panel was run and was negative (results reported 01/30/25).  \n",
            "\n",
            "   • Synergistic Effects:\n",
            "     – Disease Interactions:  \n",
            "       • IMHA-induced anemia plus moderate pulmonary hypertension each enhance the likelihood of hypoxic episodes (syncopal events).  \n",
            "       • Mild right ventricular dilation with tricuspid regurgitation can be worsened by the increased cardiac workload from anemia.  \n",
            "\n",
            "     – Treatment Interactions:  \n",
            "       • High-dose steroids (prednisone 10 mg SID) plus cyclosporine (25 mg BID) can potentiate immunosuppression, raising infection risk.  \n",
            "       • Furosemide (20 mg BID) and enalapril (2.5 mg SID) affect fluid and electrolyte balance, potentially contributing to mild hypokalemia (3.3 mmol/L; reference 3.5–5.8 mmol/L on 01/27/25).  \n",
            "\n",
            "     – Cumulative Impacts:  \n",
            "       • Combining immunosuppressants is critical for controlling the hemolysis, yet calls for close supervision of hepatic enzymes and secondary infections.  \n",
            "       • Chronic cardiac therapy is essential to keep pulmonary hypertension stable and reduce volume overload.  \n",
            "\n",
            "     – Quality of Life Effects:  \n",
            "       • Rapid improvement in anemia (PCV from 15% at 13:45 on 01/27/25 to 30% at 20:55 on 01/27/25, then 31% on 01/28/25) alleviated lethargy and decreased collapse risk.  \n",
            "       • Long-term medication burden (steroids, cyclosporine, cardiac drugs, clopidogrel, etc.) requires owner vigilance but can preserve stable function.\n",
            "\n",
            "----------------------------------------------------------------------------\n",
            "\n",
            "2. TREATMENT INTEGRATION\n",
            "\n",
            "   • Drug Interactions:\n",
            "     – Known Interactions:  \n",
            "       • Corticosteroids (prednisone) and cyclosporine co-administration is a recognized immunosuppressive combination; monitoring for liver enzyme elevations and GI signs is advised.  \n",
            "       • Furosemide (20 mg BID) can lower potassium levels further; the patient already showed mild hypokalemia (3.3 mmol/L on 01/27/25).  \n",
            "\n",
            "     – Potential Interactions:  \n",
            "       • Concurrent use of clopidogrel (18.75 mg SID) with steroids theoretically increases GI bleeding risk, though it remains clinically accepted for IMHA-related thromboprophylaxis.  \n",
            "       • Sildenafil (10 mg TID), if started, may interact with blood pressure regulation; synergy with enalapril in reducing vascular resistance requires monitoring.  \n",
            "\n",
            "     – Monitoring Requirements:  \n",
            "       • CBC (to follow anemia, RBC indices) every 3–5 days initially.  \n",
            "       • Chemistry panel (including liver enzymes, BUN, potassium) every 2 weeks while on immunosuppressive therapy.  \n",
            "       • Cardiac recheck for possible syncope or if client observes increased respiratory effort.  \n",
            "\n",
            "     – Adjustment Protocols:  \n",
            "       • Taper prednisone after ~3–4 weeks if stable PCV ≥30–35%.  \n",
            "       • Consider modifying diuretic dosing if repeated hypokalemia occurs.  \n",
            "       • Initiate sildenafil only if new fainting occurs (per 01/28/25 instructions).\n",
            "\n",
            "   • Therapeutic Conflicts:\n",
            "     – Competing Treatment Needs:  \n",
            "       • Steroid usage counters acute hemolysis but can exacerbate preexisting mild hyperadrenocorticism or elevate ALP levels.  \n",
            "       • High-dose diuretics for cardiac disease risk further electrolyte imbalances but are necessary for potential congestive signs.\n",
            "\n",
            "     – Priority Assessment:\n",
            "       • IMHA control is the immediate priority: preserving RBC mass to prevent critical hypoxia.  \n",
            "       • Cardiac stability is critical to avoid fluid overload or hypokinetic syncope.\n",
            "\n",
            "     – Resolution Strategies:\n",
            "       • Use of additional immunosuppressant (cyclosporine) to reduce the dose of prednisone over time and minimize steroid side effects.  \n",
            "       • Monitor electrolytes carefully; adjust diuretic therapy if clinically indicated.\n",
            "\n",
            "     – Risk Mitigation:\n",
            "       • Thromboprophylaxis with clopidogrel to prevent thromboembolism.  \n",
            "       • Potential hospital admission if PCV drops <20% or signs of circulatory instability reappear.\n",
            "\n",
            "   • Management Synergies:\n",
            "     – Complementary Treatments:  \n",
            "       • Combined immunosuppressive regimen (prednisone + cyclosporine) ensures faster control of RBC destruction.  \n",
            "       • Cardiac meds (enalapril, pimobendan) reduce afterload, improve systolic function, and mitigate fluid retention.\n",
            "\n",
            "     – Timing Optimization:  \n",
            "       • Administer oral meds in consistent intervals (e.g., prednisone in the morning, cyclosporine q12h).  \n",
            "       • Delay starting sildenafil unless future syncopal events reemerge, per 01/28/25 specialist recommendation.\n",
            "\n",
            "     – Efficiency Improvements:\n",
            "       • Regular rechecks at 3–5 day intervals for CBC to catch any rapid declines, reducing repeated emergency visits.  \n",
            "       • Combining short follow-up intervals for CBC with in-clinic physical exams fosters early intervention if needed.\n",
            "\n",
            "     – Outcome Enhancement:\n",
            "       • Early detection of relapse or side effects ensures prompt therapy adjustments.  \n",
            "       • Keeping the client well-informed about medication schedules and clinical signs to watch for strengthens compliance and speeds detection of complications.\n",
            "\n",
            "----------------------------------------------------------------------------\n",
            "\n",
            "3. RISK ASSESSMENT\n",
            "\n",
            "   • Current Risk Factors:\n",
            "     – Disease-Specific Risks:  \n",
            "       • IMHA recurrence or continued RBC destruction if immunosuppression is insufficient.  \n",
            "       • Moderate pulmonary hypertension creating ongoing syncope risk.  \n",
            "\n",
            "     – Treatment-Related Risks:\n",
            "       • Prednisone + cyclosporine side effects: polyuria, polydipsia, GI upset, immunosuppression.  \n",
            "       • Clopidogrel risk of bleeding.  \n",
            "       • Furosemide potential for dehydration or hypokalemia.\n",
            "\n",
            "     – Environmental Risks:\n",
            "       • Potential inadequate observation if patient is left alone after episodes; owner declined overnight care (01/27/25).  \n",
            "\n",
            "     – Client-Specific Factors:\n",
            "       • Owner’s schedule or finances not fully clarified; the patient is uninsured.  \n",
            "       • The client must monitor detailed medication administration times and watch for urgent signs of relapse.\n",
            "\n",
            "   • Potential Complications:\n",
            "     – Early Warning Signs:\n",
            "       • Drop in PCV below 25% or sudden pale/white mucous membranes.  \n",
            "       • Recurrent collapse (syncope) or acute weakness.  \n",
            "       • New or worsening jaundice (icterus).  \n",
            "\n",
            "     – Prevention Strategies:\n",
            "       • Maintain consistent immunosuppressive dosing.  \n",
            "       • Use clopidogrel to reduce thrombosis risk.  \n",
            "       • Recheck labs regularly (CBC every 3–5 days initially).\n",
            "\n",
            "     – Monitoring Protocols:\n",
            "       • Serial CBC and biochemistry to detect dropping hematocrit or rising liver enzymes.  \n",
            "       • Owner checks gum color daily, monitors for fainting, records medication times.\n",
            "\n",
            "     – Intervention Triggers:\n",
            "       • PCV <20% prompts possible urgent transfusion.  \n",
            "       • Emergence of severe GI side effects or severe steroid-induced changes calls for medication adjustments.  \n",
            "       • Recurrent collapses would trigger immediate echocardiogram recheck or addition of sildenafil.\n",
            "\n",
            "============================================================================\n",
            "\n",
            "INTEGRATED CARE PLAN:\n",
            "\n",
            "1. COMPREHENSIVE TREATMENT STRATEGY\n",
            "\n",
            "   • Prioritized Interventions:\n",
            "     – Immediate Actions:\n",
            "       1) Maintain immunosuppression with prednisone 10 mg once daily (SID) by mouth (PO) and cyclosporine 25 mg PO twice daily (BID).  \n",
            "       2) Continue anti-thrombotic prophylaxis with clopidogrel 18.75 mg PO SID.  \n",
            "       3) Monitor PCV every 3–5 days; transfusion threshold if PCV <20% or marked clinical decline.  \n",
            "\n",
            "     – Short-Term Goals (over next 1–2 weeks):\n",
            "       • Stabilize PCV ≥30%.  \n",
            "       • Achieve cessation of collapse episodes.  \n",
            "       • Ensure no major medication side effects (e.g., significant GI upset, severe polyuria/polydipsia beyond expected steroid response).  \n",
            "\n",
            "     – Long-Term Objectives:\n",
            "       • Gradual steroid taper after ~3–4 weeks if stable PCV (>35%) without relapse.  \n",
            "       • Manage cardiac disease to prevent further syncopal events; consider sildenafil (10 mg PO TID) if collapses recur.  \n",
            "\n",
            "     – Success Criteria:\n",
            "       • Maintenance of PCV >30–35% on serial CBC checks.  \n",
            "       • No new thromboembolic events or syncopal episodes.  \n",
            "       • Stable or improved cardiac parameters on follow-up exam/echocardiogram.\n",
            "\n",
            "   • Coordinated Care:\n",
            "     – Team Responsibilities:\n",
            "       • Primary veterinarian: Oversee CBC checks, adjust immunosuppressive therapy, evaluate for side effects.  \n",
            "       • Internal medicine or cardiology specialist: Reassess echocardiogram if new collapses occur or at 3–4 months for pulmonary pressures.  \n",
            "\n",
            "     – Communication Protocols:\n",
            "       • Daily phone or email updates if critical changes in gum color, appetite, or collapse signs.  \n",
            "       • Recheck visit scheduled ~02/04/25 or sooner if needed.\n",
            "\n",
            "     – Documentation Requirements:\n",
            "       • Record all PCV/TS results, including time and date (MM/DD/YY, times as applicable).  \n",
            "       • Note medication administration times, especially daily prednisone and BID cyclosporine.\n",
            "\n",
            "     – Quality Assurance:\n",
            "       • Ensure each recheck visit includes thorough physical exam (cardiac auscultation, mucous membrane assessment), lab work as indicated.  \n",
            "       • Maintain full logs of client communications regarding the dog’s status at home.\n",
            "\n",
            "----------------------------------------------------------------------------\n",
            "\n",
            "2. LONG-TERM MANAGEMENT\n",
            "\n",
            "   • Disease Trajectory:\n",
            "     – Expected Progression:\n",
            "       • IMHA often requires several months of immunosuppression; stable remission is possible if carefully tapered.  \n",
            "       • Cardiac condition (mild tricuspid regurgitation + moderate pulmonary hypertension) may slowly progress but can be stabilized with current medications.\n",
            "\n",
            "     – Monitoring Points:\n",
            "       • CBC (including reticulocyte count) every 3–5 days initially, then weekly or biweekly once stable.  \n",
            "       • Serum chemistry (ALP, ALT, BUN, creatinine) every 2 weeks to monitor for steroid/cyclosporine effects.  \n",
            "       • Echocardiogram in ~3–4 months or if new syncopal events.\n",
            "\n",
            "     – Intervention Triggers:\n",
            "       • PCV drop below 25% or evident relapse in RBC destruction.  \n",
            "       • Marked increase in respiratory rate or episodes of collapse signaling possible need to start sildenafil.  \n",
            "       • Signs of hyperadrenocorticism or severe steroid side effects (excessive PU/PD, pot-bellied appearance, abnormal liver enzymes).\n",
            "\n",
            "     – Outcome Measures:\n",
            "       • Maintenance of PCV >30–35% without transfusions.  \n",
            "       • Murmur grade stability or improvement, fewer or no syncopal episodes.  \n",
            "       • Normal or only mildly elevated ALP under immunosuppressive therapy.\n",
            "\n",
            "   • Quality of Life:\n",
            "     – Assessment Criteria:\n",
            "       • Activity level, absence of further collapse, consistent appetite, normal hydration status.  \n",
            "       • Minimal side effects from immunosuppressants.  \n",
            "\n",
            "     – Monitoring Protocol:\n",
            "       • Owner to track daily behavior, appetite, water intake, gum color.  \n",
            "       • Veterinary re-evaluations to refine dosage regimens.\n",
            "\n",
            "     – Improvement Strategies:\n",
            "       • Gradual taper of prednisone to reduce long-term side effects once disease is controlled.  \n",
            "       • Potential diet optimization to mitigate GI upset (Hill’s i/d Low Fat recommended at 1⅓ cans/day as of 01/28/25).\n",
            "\n",
            "     – Client Assessment Tools:\n",
            "       • Encouragement to keep a home log of respiration rate, appetite, medication administration times.  \n",
            "       • Written instructions on how to check mucous membrane color and watch for pale/white or jaundiced gums.\n",
            "\n",
            "----------------------------------------------------------------------------\n",
            "\n",
            "3. SUPPORT SYSTEMS\n",
            "\n",
            "   • Client Education:\n",
            "     – Understanding Assessment:\n",
            "       • Explained to Mr. Johnson on 01/27/25 that the dog’s anemia is immune-mediated (confirmed positive Coombs’, RBC destruction).  \n",
            "       • Reviewed on 01/28/25 that PCV improved to 31%, indicating partial stabilization; next steps are consistent immunosuppression.  \n",
            "\n",
            "     – Training Needs:\n",
            "       • Demonstrated how to recognize pale gums or labored breathing.  \n",
            "       • Instructed on giving oral meds at correct times (prednisone 10 mg SID, cyclosporine 25 mg BID, clopidogrel 18.75 mg SID, etc.).\n",
            "\n",
            "     – Resource Requirements:\n",
            "       • Advised client about possible future specialist (internal medicine/cardiology) follow-ups if syncopal episodes recur.  \n",
            "       • Provided prescription for sildenafil 10 mg PO TID to keep on hand, start only if new collapsing events happen.\n",
            "\n",
            "     – Support Services:\n",
            "       • Recommended weekly phone updates or scheduled rechecks every 3–5 days for CBC.  \n",
            "       • 24-hour emergency clinic contact given if acute relapse or collapse.\n",
            "\n",
            "   • Compliance Strategy:\n",
            "     – Barriers Assessment:\n",
            "       • Owner declined overnight hospitalization on 01/27/25—prefers outpatient management due to personal constraints.  \n",
            "       • No insurance on file, so cost may be a factor.\n",
            "\n",
            "     – Solution Implementation:\n",
            "       • Thorough at-home instructions (written and verbal) on medication schedules.  \n",
            "       • Encouraged timely re-evaluation if any sign of deterioration occurs.\n",
            "\n",
            "     – Monitoring Methods:\n",
            "       • Vet clinic calls to confirm medication compliance within the first week.  \n",
            "       • Recheck labs on or around 02/04/25 (1 week post-initiation of immunosuppression).\n",
            "\n",
            "     – Success Measures:\n",
            "       • Consistent improvement in PCV, resolution of clinical signs (no further collapse, improved appetite).  \n",
            "       • Full adherence to medication schedule and diet modification.\n",
            "\n",
            "============================================================================\n",
            "\n",
            "(Documented on 01/28/25 at 10:00 AM; all medications and doses verified with client. Next follow-up advised ~02/04/25 or sooner if any clinical decline occurs.)\n"
          ]
        }
      ],
      "source": [
        "result = analyze_veterinary_case([\n",
        "    \"./IMG_5188.jpeg\",\n",
        "    \"./IMG_5604.jpeg\",\n",
        "    \"./J-VSMR.pdf\",\n",
        "    \"./LabReport.pdf\",\n",
        "    \"./SP-Doc-1.pdf\",\n",
        "    \"./SP-Doc-2.pdf\",\n",
        "    \"./SP-Doc-3.pdf\",\n",
        "    \"SP-Imagyst.pdf\",\n",
        "    \"SP-Report-1.pdf\",\n",
        "    \"SP-Report-2.pdf\",\n",
        "    \"Signed-Auth-Form.pdf\",\n",
        "    \"THX - Right Lat.jpeg\"\n",
        "])\n",
        "\n",
        "print(\"\\nAnalysis Results:\")\n",
        "print(\"-\" * 50)\n",
        "\n",
        "sections = [\n",
        "    (\"Data Processing\", \"DataProcessor\"),\n",
        "    (\"History Analysis\", \"HistoryAnalyzer\"),\n",
        "    (\"Clinical Analysis\", \"ClinicalAnalyzer\"),\n",
        "    (\"Diagnostic Assessment\", \"Diagnostics\"),\n",
        "    (\"Specialist Summary\", \"SpecialistSummary\"),\n",
        "    (\"Connections Analysis\", \"Connections\")\n",
        "]\n",
        "\n",
        "for title, key in sections:\n",
        "    print(f\"\\n{title}:\")\n",
        "    print(\"-\" * 30)\n",
        "    print(result[\"results\"].get(key, \"Not available\"))\n",
        "\n",
        "if \"errors\" in result[\"results\"]:\n",
        "    print(\"\\nErrors encountered:\")\n",
        "    for error in result[\"results\"][\"errors\"]:\n",
        "        print(f\"- {error['message']} (at {error['timestamp']}\")"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyMgHaurOSGuvVRvNLzemRTb",
      "include_colab_link": true
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}